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Abstract 
Current diagnostic and therapeutic nanocarriers, including liposomes, micelles, and polymeric- and 
protein-based nanoparticles, are designed to have key functional properties such as: (i) longevity in 
the bloodstream, leading to accumulation of therapeutic cargos in neoplastic areas with leaky 
vasculatures; (ii) targeting of specific pathological sites through surface modification with targeting 
ligands; (iii) stimuli-responsive characteristics for controlled drug release under specific conditions. 
While some of these drug delivery systems have advanced into clinical stages, other nanocarriers 
remain under development to overcome issues with effective delivery such as lack of target-ability 
and fast clearance from circulation. Self-assembling peptides have recently shown great potential as 
nanocarrier materials for drug and gene delivery, owing to their safety, efficiency, and targeting 
capabilities. An amino acid pairing strategy enables us to design self/co-assembling peptides with 
multiple functionalities to fulfill drug delivery requirements.   
This thesis focuses on functionalization and characterization of self/co-assembling peptides as 
nanocarriers for hydrophobic anticancer drug delivery. Diethylene glycol (DEG) conjugation and 
protein binding are the two modification strategies used in this thesis to impart longevity and target-
ability upon the peptide-based delivery system. The studies include: (i) characterization of self-
assembling properties of the diethylene glycol (DEG)-conjugated amino acid pairing peptide AAP8, 
(ii) investigation of the self/co-assembling features of a model ionic-complementary peptide (EAR8-
II) in complex with the hydrophobic drug pirarubicin, and the anticancer activity of the complex, (iii) 
the interactions between peptide-drug complexes and serum proteins from the thermodynamic 
viewpoint, (iv) quantification of the effect of protein binding to the peptide-based delivery system on 
immune responses and biocompatibility, and (v) exploration of the targeting capability of albumin-
bound peptide-drug complexes towards lung cancer cells.  
Uncontrollable aggregation of AAP8 was the first issue to address in order to develop a promising 
platform for the peptide-based delivery system. Diethylene glycol (DEG), a short segment of 
polyethylene glycol (PEG), was conjugated to AAP8 either at one or both terminals, and then self-
assembling and drug encapsulation properties of both functionalized AAP8s were characterized to 
evaluate the effect of DEG-modification. The results illustrated a significant reduction in 
uncontrollable aggregation, and the formation of uniform fibular nanostructures. In addition, DEG 
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conjugation provided the peptide with safer features towards immune cells by reducing cellular 
toxicity to macrophages. Moreover, DEG-functionalization improved hydrophobic drug stabilization, 
as demonstrated by sustained cytotoxic efficacy against lung carcinoma cells over a relatively long 
time compared to the non-functionalized AAP8. 
Protein binding strategy was the second approach to utilize the peptide-based delivery system with 
more biocompatibility and target-ability features. EAR8-II was studied as a model ionic-
complementary peptide with high capability of pirarubicin encapsulation and anticancer activities 
against different cancer cells. Albumin as a most abundant protein in serum was selected to assess its 
binding affinity to the delivery system, and evaluate its binding effect on immune responses and 
anticancer activities.  
The results showed a central role of albumin in the in vitro delivery of peptide-drug complexes to 
target lung cancer cells based on the following characteristics: (a) Non-covalent binding of albumin to 
the complex through hydrogen bonding and Van der Waals interactions. The interaction was 
confirmed by physicochemical methods such as fluorescence quenching and isothermal titration 
calorimeter (ITC). (b) Shielding properties of albumin for the complex against macrophages and 
blood components (erythrocytes and complement protein C5b-9). In the presence of albumin, 
phagocytosis and cytokine expression level of macrophages and hemolytic activity of the peptide-
drug complex reduced significantly due to the smaller particle size of the albumin-bound complexes 
compared to unprotected ones. (c) Targeting the lung cancer cells, possibly because of the inhibition 
of the albumin-binding protein SPARC (secreted protein, acidic and rich in cysteine). SPARC is a 
glycoprotein over expressed in lung cancer cells with high affinity to albumin. The results from in 
vitro SPARC expression in A549 cells, a type of human non-small cell lung carcinoma (NSCLC), 
showed a significant drop by the albumin-bound complex at the mRNA level evaluated by qRT-PCR. 
This effect can be explained by transporting the albumin-bound complex into the cell surface, binding 
to the SPARC proteins, and so inhibiting the SPARC expressions.  
This work lays out a foundation for modification and characterization of the self/co-assembly 
peptide-based nanocarriers for hydrophobic anticancer drug delivery, especially to improve longevity 
and target-ability properties. 
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Chapter 1 
Introduction 
1.1 Overview 
Cancer is one of the most devastating diseases with more than 10 million new cases every year 
worldwide. Cancer prognosis, diagnosis, and therapy have been topical research concepts of the past 
few decades. The design and synthesis of efficient drug delivery systems that will increase the 
therapeutic efficiency of drugs while minimizing their side effects are highly important in medicine 
research. Paul Ehrlich in 1906 coined the idea of the “magic bullet” drug by introducing the targeting 
concept, in which one part of a drug should consist of a recognizing ligand to bind to the target, and 
the second part provide the therapeutic action at the disease site [1]. Material chemistry and 
nanotechnology are now revolutionizing the generation of multifunctional systems, to reach to the 
idea of the “magic bullet”. Conventional pharmaceutical agents suffer from their lack of target-ability, 
deleterious side effects, and fast clearance from circulation. Thanks to nanotechnology, the controlled 
size, shape and multi-functionality of particles, self-assembly, and controlled release of drugs are 
emerging to resolve the limitations of conventional drugs [2].  
In the past few decades, many delivery systems have made great advances in improved solubility, 
transport, safety, and targeting as nanocarriers in cancer therapy. Liposomes, polymers, and proteins 
are the pioneer devices in encapsulating therapeutic agents for safer delivery [3]. All these drug 
delivery systems are designed to possess many advantages over free drugs, such as protecting drugs 
from degradations; preventing drugs from interacting with their biological environment, enhancing 
the attraction of drugs to the pathological areas, controlling drugs release and their biodistribution, 
and improving intracellular penetration. Biodegradability, biocompatibility, environmental sensitivity, 
extended circulation half-life, and distinct uptake efficiency in the target tissues but not in normal 
ones are the main features in designing any viable drug delivery system [2,4]. 
Nanocarriers without surface modifications are usually recognized as foreign particles by the 
body’s defense system, targeted by macrophages, and readily removed from the circulation before 
reaching their targeted sites. Hence, the first step in modifying the nanocarriers is surface decoration 
for longevity [4]. Long-circulating pharmaceutical agents have the advantage of slowly accumulating 
in pathological sites with leaky vasculatures, due to their large particle size, which is known as 
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passive targeting through enhanced permeability and retention (EPR) effect [5]. Polymer-drug 
conjugates have a long history of contributing to the EPR effect by providing a prolonged circulation 
half-life, stealth properties and reduced antigenicity. Hydrophilic polymers such as poly (styrene-co-
maleic acid) (SMA) [6] and poly (ethylene glycol) (PEG) [7,8] have been shown to protect drug 
carriers from reiculoendothelial system (RES) or macrophages, and consequently impart the in vivo 
longevity. One of the main advantages of polymeric drugs is patient compliance and improved quality 
of life, as less-frequent drug administration is needed owing to their longer plasma half-life. However, 
some limitations affect the use of polymer conjugates, including their molecular weight, solubility, 
biocompatibility, biodegradability, and clearance from the body. On the other hand, many natural 
polymers such as peptides can be used as drug carriers for extra precaution [9].  
In the past two decades, albumin, as the most-abundant protein among serum proteins, has attracted 
great interest as an exogenous or endogenous carrier for long circulating drug delivery systems [10]. 
Drugs or active molecules for diagnostic applications can bind covalently or non-covalently to serum 
albumin for treating various diseases, primarily cancers, arthritis, hepatitis, and diabetes [11,12]. 
Several delivery systems have taken advantage of drug albumin-binding characteristic and have been 
advanced in clinical trials or approved as marketed products. For instance, Levemir® is an approved 
insulin detemir controlling glucose levels in diabetes patients by binding to circulating albumin [13]. 
Abraxane® is another approved albumin-based therapeutic, in which the anticancer drug Paclitaxel is 
bound to albumin forming 130 nm nanoparticles (nabTM-technology) for intravenous administration 
against solid tumors [14]. In principle, this technology relies on albumin’s major role in the delivery 
of hydrophobic drugs to target tissues, based on the following features: (i) albumin’s non-covalent 
binding affinity to many hydrophobic molecules, utilizing their transport in the body to release them 
at the cell surface; (ii) albumin’s binding to endothelial cell surface receptor called glycoprotein 
(gp60), initiating transcytosis of plasma components; (iii) albumin’s accumulation in tumor areas 
through Secreted Protein Acidic and Rich in Cysteine (SPARC) binding, increasing the  concentration 
of albumin-bound drugs inside tumors. SPARC is over expressed glycoprotein in tumor tissues 
responsible for tumor metastasis, and it has a high affinity for albumin; therefore, albumin uptake has 
shown to be higher in tumor cells than normal cells [15,16]. 
In addition to liposomes, polymers, micelles and other biomaterials applied in drug delivery, 
self/co-assembling peptides, have emerged as an important class of biomaterials with a wide range of 
applications in drug and gene delivery, vaccines, tissue engineering and regenerative medicine [17–
19]. Peptides can be rationally designed to form functional nanostructures with multiple properties 
involving controlled stable structures, incorporation with active molecules (DNA, siRNA, 
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hydrophobic molecules, etc.), enhanced cell penetration [20] and targeting ability [21], some inherited 
antimicrobial features [22], improved cell attachments [23], and many more. Therefore, these self-
assembling peptides could be major candidates for designing universal multifunctional nanocarriers 
for nanomedicine development.  
A class of self/co-assembling ionic-complementary peptides (EAK16s) has been developed as 
nanocarriers for drug delivery systems. These peptides are amphiphilic, meaning they can encapsulate 
and stabilize hydrophobic compounds in aqueous solution [24]. EAK16-II has demonstrated great 
promise in both in vitro and in vivo delivery of hydrophobic drugs by inhibiting tumor growth 
significantly compared to free drug [25]. Owing to the unique structure of amphiphilic peptides and 
their potential, a de novo design principle, amino acid pairing (AAP), has been suggested to establish 
a platform for designing functional self-assembling peptides. Amino acid pairing strategy focuses on 
the side chain complementarity and compatibility in the structural engineering point of view. The 
design principle of amino acid pairing self/co-assembling peptides is guided by three major side chain 
interactions: hydrophobic interaction, electrostatic interaction and hydrogen bonding. In addition, the 
side chain would achieve to certain physiochemical stability to maximize pair affinity and minimize 
free energy [26]. While these newly designed systems and other self/co-assembling peptides have 
shown immense potential, issues remain in optimizing the self-assembled structures and making them 
more robust for in vivo applications. Uncontrollable aggregation, enzymatic degradation, and lack of 
stability of such peptides limit their in vivo applications, therefore, in this research, two main 
strategies- diethylene glycol (DEG) conjugation and serum albumin protein binding- are applied to 
stabilize self/co-assembling peptide-based drug delivery systems in physiological conditions. The 
detailed objectives of this research project and outline of the thesis are presented next.  
1.2 Research Objectives 
The goal of this research is to develop self/co-assembling peptide-based delivery of hydrophobic 
anticancer drugs, to improve longevity, target-ability, and highly efficient therapeutic properties. To 
achieve this goal diethylene glycol (DEG) conjugation and albumin binding strategies are 
incorporated to improve the above features. The specific objectives of the thesis are listed below:  
1) Characterize the physiochemical properties of the amino acid pairing peptide (AAP8) 
functionalized with diethylene glycol (DEG) 
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•  To determine the effect of DEG-conjugation on peptide self/co-assembly properties such 
as uncontrollable aggregation, critical self-assembly concentration, secondary structure, 
and nanostructure formation.  
• To investigate the effect of DEG-conjugation on peptide and hydrophobic drug 
complexation and in vitro anticancer activity  
2) Evaluate self/co-assembly properties of an ionic-complementary peptide, EAR8-II, and its 
potential in in vitro delivery of the hydrophobic drug Pirarubicin (THP) 
• To demonstrate the advantages of EAR8-II as a model ionic-complementary peptide over 
the previously introduced EAK16-II and AAP8 
• To evaluate the optimum ratio between the peptide and the drug in order to form stable 
structures and achieve effective anticancer activity in vitro 
3) Explore the binding affinity between serum proteins (i.e., BSA and IgG) and the EAR8-II-THP 
complex 
• To determine the stability of the complex in a serum environment  
• To explore the nature of binding between serum albumin and peptide-drug complexes 
4) Study the effect of serum albumin binding to the EAR8-II-THP complex on immune responses 
• To investigate macrophage responses, including cytotoxicity, uptake and cytokine 
expression against the albumin-bound EAR8-II-THP complex  
• To examine the hemolytic activity and complement activation induced by the complex in 
the presence and absence of serum albumin 
5) Determine the target-ability of the albumin-bound peptide-based drug delivery system  
• To measure anticancer activity and cellular uptake of the complex 
• To show SPARC inhibition in non-small cell lung carcinoma (A549) 
1.3 Outline of the Thesis 
This thesis consists of five main research-based chapters preceded by the introduction and literature 
review chapters and followed by the conclusions and recommendations chapter. Chapter 1 introduces 
the overview of the thesis and points out the detailed objectives of the research. Chapter 2 provides a 
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comprehensive background on current drug delivery systems, their advantages and limitations. It also 
reviews the background of self-assembling peptides and their drug delivery applications.  
Chapter 3 focuses on the first strategy for modifying peptide-drug complexes to promote longevity. 
Diethylene glycol (DEG), a short segment of polyethylene glycol (PEG), was selected to attach to the 
short-sequence amino acid pairing peptide (AAP8). Even though this peptide has shown promise in 
the design of novel functional biomaterials, it has a propensity to initiate uncontrollable aggregations. 
DEG-functionalization showed subsequent advantages in conquering this aggregation issue. The 
physiochemical properties, such as nanostructure, secondary structure, and critical aggregation 
concentration, are analyzed by atomic force microscopy, FT-IR spectroscopy, and steady-state 
fluorescence measurements, respectively, to evaluate the effect of DEG-conjugation on peptide 
aggregation. The functionalized AAP8s are tested for their hydrophobic drug encapsulation and in 
vitro delivery characteristics.   
Chapter 4 introduces a model ionic-complementary peptide EAR8-II for hydrophobic drug 
encapsulation and in vitro delivery. EAR8-II inherits advantages from two formerly developed 
self/co-assembling peptides EAK16-II and AAP8. The effects of the peptide-to-drug ratio in the 
complexes are evaluated on the particle size, pH, charge, and stabilized THP in the solution, as well 
as in vitro anticancer activity and uptake against two cancer cell lines (A549 and HeLa).  
Chapter 5 studies the interaction between serum proteins such as albumin and immunoglobulin G 
(IgG) from a thermodynamic point of view. First, the molecular and secondary structures of the 
peptide-drug complex in the presence of albumin are analyzed by TEM, DLS, and FT-IR 
spectroscopy methods, respectively. Second, fluorescence quenching technique and isothermal 
titration calorimetery (ITC) are employed to determine the binding properties.  
Chapter 6 investigates the effect of serum albumin binding on immune responses. Macrophages, 
one of the primary immune cells, are treated with the complexes, and immune response analysis is 
conducted to evaluate the cytotoxicity, drug uptake and expression level of cytokines (e.g., iNOs, 
COX-2, TNF-α, IL-2, IL-1β). In addition, the complexes are tested on pooled human serum and red 
blood cells to examine the complement activation and hemolytic activity induced by the complexes.  
Chapter 7 evaluates the anticancer activity mechanism of the EAR8-II-THP complexes in the 
presence of BSA, by exploring the expression level of secreted protein acidic and rich in cysteine 
(SPARC) in cancer cell line (A549). SPARC is overexpressed in cancer cells with high albumin 
affinity; therefore, a drug delivery system with SPARC inhibition capability is considered to be a 
targeted delivery system.   
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Chapter 8 summarizes the overall outcomes of the thesis in respect to the objectives. It states this 
thesis’s original contribution to the research, and finally recommends the future work for this research 
and the areas for expansion.   
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Chapter 2 
Literature Review 
2.1 Current Advances in Multifunctional Nanocarriers for Anticancer Drugs 
More than fifty years ago, Richard Feynman coined the concept of nanosurgeons and nanodevices in 
his revolutionary talk “There is Plenty of Room at the Bottom”, where he encouraged researchers and 
specialists to develop devices capable of interacting with the body at the cellular level [27]. Following 
those initiations, nanoparticles have revolutionized the administration of medicines in the past few 
decades. Before 1970s, administration of pharmaceutical suspensions intravenously as well as poorly 
soluble drugs was almost impossible [28]. Recent advances in nanomedicine address these issues by 
improving solubility, and sustainability to further improve the pharmacokinetics and lower the side 
effects [29]. Table 2.1 summarizes the deficiencies of free drugs and highlights the advantages of 
drug delivery systems in pharmaceutical applications [30]. The progressive timeline of nanomedicine 
is also presented in Figure 2.1 (adapted from [31,32]) showing progress in drug delivery systems in 
the past sixty years. Technologies involved in the development of drug carriers are divided into four 
main categories: liposomes and micelles, polymer-drug conjugates, biodegradable polymeric 
nanoparticles, and peptide/protein-based materials [33].  
Smart drug delivery systems can provide a very bright future for pharmaceutical research, due to 
several reasons. Passive targeting or enhanced permeability and retention (EPR) effect of drug 
delivery systems (DDS) enhance the accumulation of the drug in pathological areas. DDS 
technologies improve therapeutic index of established drugs by controlling release profile. In 
addition, recently the therapeutic effects of nucleic acids, peptides, and plasmids are growing. 
However, without drug delivery systems, administration of these compounds is impossible. In 
general, nanocarriers improve the pharmacokinetics and pharmacodynamics properties of therapeutic 
agents by increasing plasma half-life (which improves patient compliance due to less frequent 
required dose), protecting the drug from proteolytic enzymes, reducing in immunogenicity, enhancing 
stability of proteins, improving solubility of low Mw drugs, and increasing potential for targeted 
delivery [34]. In this section, I review the current delivery systems indicating their advantages and 
limitations.   
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Table 2.1 Non-ideal properties of drugs and their therapeutic implications. Adapted from reference 
[30]. Reprinted with permission from AAAS. 
Problem Implication Effect of DDS 
Poor solubility  A convenient pharmaceutical 
format is difficult to achieve, as 
hydrophobic drugs may 
precipitate in aqueous media. 
Toxicities are associated with 
the use of excipients such as 
Cremphor® EL (the solubilizer 
for paclitaxel in Taxol). 
DDS such as lipid micelles or 
liposomes provide both 
hydrophilic and hydrophobic 
environments, enhancing drug 
solubility. 
Tissue damage on extravasation Inadvertent extravasation of 
cytotoxic drugs leads to tissue 
damage, e.g., tissue necrosis 
with free doxorubicin. 
Regulated drug release from the 
DDS can reduce or eliminate 
tissue damage on accidental 
extravasation. 
Rapid breakdown of the drug in 
vivo 
Loss of activity of the drug 
follows administration, e.g., 
loss of activity of 
Camptothecins at physiological 
pH. 
DDS protects the drug from 
premature degradation and 
functions as a sustained release 
system. Lower doses of drug 
are required. 
Unfavorable pharmacokinetics Drug is cleared too rapidly by 
the kidney. For example, 
requiring high doses or 
continuous infusion. 
DDS can substantially alter the 
PK of the drug and reduce 
clearance. Rapid renal clearance 
of small molecules is avoided. 
Poor biodistribution Drugs that have widespread 
distribution in the body can 
affect normal tissues, resulting 
in dose limiting side effects, 
such as the cardiac toxicity of 
doxorubicin. 
The particulate nature of DDS 
lowers the volume of 
distribution and helps to reduce 
side effects in sensitive, 
Non-target tissues. 
Lack of selectivity for target 
tissues 
Distribution of the drug to 
normal tissues leads to side 
effects that restrict the amount 
of drug that can be 
administered. Low 
concentrations of drugs in target 
tissues will result in suboptimal 
therapeutic effects. 
DDS can increase drug 
concentrations in diseased 
tissues such as tumors by the 
EPR effect. Ligand-mediated 
targeting of the DDS can further 
improve drug specificity. 
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Figure 2.1. Timeline of the development of nanoparticle therapeutics adapted from reference [31]. 
 
2.1.1 Liposome-based Drug Delivery Systems 
Liposomes are known as frontier nanomaterials for cancer therapy. In 1964, Bangham et.al first 
introduced liposomes and proposed their lamellae structure for bilayer phospholipids [35,36]. 
Liposomes were further improved and became more popular for drug delivery applications. Ten years 
after introduction of liposomes, G. Gregoriadis initiated the entrapment of Penicillin and Actinomycin 
D in liposomes in order to decrease their deleterious side effects on non-diseased tissues in cancer 
chemotherapy [37]. In 1980, first examples of targeted nanoparticle using ligand-conjugated 
liposomes were introduced and showed some promising preclinical and clinical results in the 
treatment of various diseases [38,39]. Doxil was the first FDA-approved liposomal-based drug 
(1995), in which doxorubicin was encapsulated into a liposome carrier to increase its half-life and 
reduce its cardiotoxicity compared with free doxorubicin [31,40]. Many liposomal delivery systems 
either Polyethylene glycol (PEG)-conjugated or non-PEG conjugated, encapsulating various drugs, 
are currently in clinical stages. So far only Doxil is approved by the FDA, and Genexol-PM is only 
approved in South Korea [41] as cancer therapeutics. There are few more liposomal-based FDA 
approved drugs for other applications such as fungi infections, lymphomatous meningitis, etc. [33]. 
Despite the progress in liposomal delivery, liposomes tend to be eliminated rapidly from the blood 
and captured by RES, primarily in the liver. Several techniques including modification by long-
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circulating polymers and antibodies, attachment of diagnostic labels and stimuli-sensitive ligands, 
incorporation of cell-penetrating peptides, viral components, and magnetic targeting components, 
have aimed to overcome the problems [42]. The trend of liposome evolution is shown in Figure 2.2. 
   
 
 
Figure 2.2. (A) Plain phospholipid with (a) water-soluble drug, and (b) water-insoluble drug, (B) 
Antibody (c) directly and (d) hydrophobically attached, (C) (e) PEG-grafted for long circulating and 
shields from the interaction with opsonizing proteins (f), (D) long circulating immunoliposome, (g) 
antibody attached to liposome, (h) or grafted to the polymeric chain, (E) new generation of liposome 
with incorporation of (i) protective protein, (j) targeting ligand, (k) diagnostic label, (l) positively 
charged lipid for (m) DNA complexation, (n) stimuli-responsive lipid, (o) stimuli-responsive 
polymer, (p) cell-penetrating peptide, (q) viral component, (r) targeting magnetic particle, (s) gold 
particles for electron microscopy. Adapted from reference [42]. Reprinted with permission from 
Rights Link. 
 
2.1.2 Polymer-based Drug Delivery Systems 
Polymeric nanoparticles are also important materials that progressed significantly during drug 
delivery evolution. Linear or branched polymer chains are mainly used as inert carriers for therapeutic 
agents. In 1976, Judah Folkman and Robert Langer published a Nature article regarding sustained 
release of proteins and other macromolecules from polymeric nanomaterials, as one of the premier 
innovations in polymeric delivery systems [43]. In 1992, a phase I clinical trial of doxorubicin carried 
by polyisohexylcyanoacrylate (PIHCA) nanoparticles was reported increasing doxorubicin 
cytotoxicity and reducing cardiotoxicity compared with unprotected doxorubicin [44]. In 1994, 
Robert Langer et al. developed PLGA-PEG, an amphiphilic copolymer composed of two 
biocompatible blocks, where exhibited considerably increase in blood circulation time and decreased 
liver accumulation [45]. The FDA approved two polymeric drug delivery systems in 1996, including 
controlled-release polymer for brain cancer (Gliadel) and biologically active polymer (Copaxone) 
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[31,40]. In 2011, peptide-conjugated PLGA-PEG encapsulating Docetaxel entered clinical trial phase 
I [32]. In general, polymeric nanocarriers can be mainly categorized into the following types 
including polymer-drug conjugates, polymer-protein conjugates, polymeric micelles, and 
multicomponent polyplexes (Figure 2.3) [34]. 
 
            
Figure 2.3. Schematic of the sub-classes of polymer therapeutics. Adapted from Reference [46]. 
 
2.1.2.1 Polymer-Drug Conjugates 
The strategy of polymer-drug conjugate, at its early development stages, had mainly focused on the 
delivery of commercialized anticancer drugs such as paclitaxel, doxorubicin, Platinates, and 
Camptothecin. Those drugs were suffering from their insolubility, deleterious side effects, 
cardiotoxicity, and poor pharmacokinetics [47]. Ringsdorf first coined the idea of polymer-anticancer 
drug conjugates in 1975 [48], followed by succeeding research by Kopecek et al., in late 1970s 
designing the first synthetic polymer-drug conjugate (HPMA-DOX) [49]. The rationale behind 
designing polymer-drug conjugates was to control the distribution of low-molecular weight anticancer 
agents throughout body and consequently lower side effects. Most of the low molecular weight drugs 
leave the circulation stream within few minutes, whereas polymer conjugates ideally produce long-
circulating compounds that circulate for several hours and further assist passive targeting through 
enhanced permeability and retention effect (EPR) [47]. Ringsdorf proposed a model for 
pharmacologically active polymers including three main compartments in polymer backbone: 1) 
Solubilizer (co-monomer or blocks of nontoxic water- or lipid soluble), 2) Pharmacon (Drug fixation 
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and release, and response to living systems), 3) Transport System (homing device for targeting and 
receptor reaction, and non-specific resorption enhancer for improving biodistribution) [48]. This 
model provides a guideline for designing a systematic polymer-drug conjugate system. The detailed 
mechanism of action of polymer-drug conjugates is presented in Figure 2.4. This mechanism shows 
the low renal elimination rate, EPR effect, biodegradability of polymer, and release of drug to 
enhance therapeutic index [47].  
It is worth noting that the only approved polymer-drug conjugate for cancer therapy is OnCaspar 
(PEGylated L-asparaginase), which was approved in 1994 and being used for acute lymphoblastic 
leukemia [33]. There are few more FDA approved polymer-cytokine / enzyme / growth factor / 
antibody conjugates available in the market for other types of therapies [50]. Polyethylene glycol is 
one of the most common polymers used for drug conjugates proving the long circulation lifetime for 
drugs. There are several chemistries involved in PEG-drug conjugation that utilize FDA approval 
including amidation, reductive amination, and Michael addition. Nonetheless, nowadays up to sixteen 
of these compounds are being tested in advanced clinical trials. The most reliable one is Opaxio (or 
also known as Xyatax CT-2013), which is a conjugation of polyglutamate-paclitaxel (PGA-PTX). 
This compound targets various cancers, particularly non-small-cell lung cancer; ovarian cancer as a 
single agent or combination chemotherapy, and so far showed gender-dependent promises in clinical 
trial phase III [47,51]. Research also showed that due to the complexity of the nature of cancer, 
combination therapy results better improvement in cancer patients. Recently, Duncan et al. 
established a combination therapy for breast cancer containing HPMA copolymer conjugating both 
aromatase inhibitor aminoglutethimide (a hormone therapy) and doxorubicin (a chemotherapy). This 
combination therapy illustrated greater activity against breast cancer cells than individual conjugates 
in vitro showing treatment of hormone-dependent cancers. The combination therapy provides 
opportunities for treating multi-drug resistant (MDR) metastatic cancers [47,52]. 
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Figure 2.4. Current understanding of the mechanism of action of polymer-drug conjugates. (A) 
Hydrophilic polymer-drug conjugates administrated intravenously can be deigned to remain in the 
circulation. (B) On arrival to the tumour interstitium, polymer-conjugated drug is internalized by 
tumour cells through either fluid-phase pinocytosis (in solution), receptor-mediated pinocytosis 
following non-specific membrane binding (due to hydrophobic or charge interactions) or ligand–
receptor docking. Adapted from Reference [47]. Reprinted with permission from Rights Link. 
 
2.1.2.2 Polymer-Protein Conjugates 
The history of polymer-protein conjugates started with the pioneer research by Frank F. Davis and 
colleagues in the late 1970s. They introduced the first PEGylation technique by covalently binding 
Polyethylene glycol (PEG) to bovine liver catalase and bovine serum albumin in order to reduce 
immunogenicity and enhance circulating life of proteins [53,54]. Since then, PEGylation has become 
the standard method for improving pharmacokinetics and pharmacodynamics properties of 
therapeutic agents due to PEG’s lack of immunogenicity, antigenicity, and toxicity. PEG is highly 
hydrophilic and protecting proteins from immune response and degradation, as well as providing 
conjugation without cross-linking to the proteins that helps the easy release [34]. In 1990, the first 
PEG-enzyme conjugate (ADAGEN) was approved by the FDA for treatment of combined 
immunodeficiency disease [50]. Regardless of the advantages associated with PEG, there are some 
drawbacks limiting its application including lack of biodegradability and reducing protein activity due 
to conjugation.  
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2.1.2.3 Polymeric Micelles 
Polymers are also used in drug delivery systems while encapsulating hydrophobic drugs either 
through micellization or microemulsification. Micelles, in general, are amphiphilic linear or branched 
polymers that spontaneously self-assemble in aqueous solution, and they can encapsulate 
hydrophobic drugs in their hydrophobic core [55]. The core/shell structure forms at above threshold 
concentration referred to as the “critical micelle concentration” (CMC). The core/shell structure 
provides the hydrophobic core as a reservoir for entrapping insoluble compounds as well as the 
hydrophilic corona for solubilizing the micelles in aqueous environment. In 1976, Peter Speiser, a 
pioneer in development of nanoparticles published the first journal article focused on polymerized 
micelles for vaccination purposes with controlled release of the antigen and consequently improved 
immune responses. He introduced new terms of “nanoparts” representing solidified micelles 
containing drugs used as immunological adjuvants [56]. There are many advantages regarding using 
micelles in drug delivery applications including easy conjugation for active targeting, high drug 
loading capacity in the hydrophobic core and rapid cellular uptake due to their nano-range size 
properties. Micelles protect drugs from degradation before reaching the target, and consequently, 
increase the plasma half-life and lower the cytotoxicity to the unaffected tissues. However, there are 
some limitations toward using surfactant-like micelles in drug delivery such as toxicity and lack of 
biocompatibility.  
Polymeric micelles are usually block copolymers consisting of hydrophilic (A) and hydrophobic 
(B) blocks arranged in di-block (AB) or tri-block (ABA). These micelles form from self-assembling 
of block- or grafted copolymers containing polymer segments of different structure and functionality 
such as ionic and nonionic block, or hydrophilic and hydrophobic block. One of the recent examples 
of polymeric micelles is functionalized PEG-poly (b-benzyl-L-aspartate) (PBLA) block copolymer 
with adriamycin facilitated with pH-cleavable hydrazone bond. Hydrazone is stable at pH 7.4, 
whereas in acidic pH is instable and let the encapsulated drug be released in tumor environment [57].  
Among many explored polymeric cases in the research stage, only five passively targeted micelle 
products have been advanced to clinical trials including NK012 (PEG-PGlu-(campothecin)), NK105 
(PEG-P(aspartate)), SP1049C (Pluronic L61-F127-(Doxorubicin)), NC-6004 (PEG-PGlu-(cisplatin)), 
and Genexol-PM (PEG-P(D,L-lactide)-(Paclitaxel)). For example, NK012 is a polymeric micelle 
containing a block copolymer of PEG and polyglutamate conjugated with anticancer drug 
campothecin (SN-28) is being tested in clinical phase II to target breast cancer [58]. Among all these 
  
  15 
polymeric micelles only Genexol received the FDA approval to be used in patients with breast cancer 
[59]. 
Dendirimers are other branch of therapeutic polymers that recently being developed for drug 
delivery application. For example, dendrimer-platinate is a conjugation of Poly(amido amine) 
PAMAM and Cisplatin, which was highly water-soluble and showed a slow release of drug in vitro 
and great anticancer activity against melanoma, where Cisplatin did not have similar activity on its 
own [60]. Vogtle et al., initially invented dendrimers in the 1970s and studied the controlled synthesis 
of dendrimers producing branched polymers with large molecular activities. Dendrimers contain 
individual “wedges” called dendrons that initiate from the core and each layer of concentric 
branching added up to form treelike architecture with a large number of surface groups. Each layer of 
branches is called by G#, starting with G0 which is the first branch after core. The higher the G level 
goes the higher branched dendrimers creates. The base of dendrimers can be polymers (e.g. 
PAMAM), amino acids (e.g. tryptophan, glutamic acid, alanine, etc.), and glycodendrimers (e.g. 
glycosides). Dendrimers either encapsulate hydrophobic drug molecules in their voids to further 
controlled release of the drugs or drug being covalently conjugated to dendrimers through pH-
sensitive ligands. Considerable advances were reported about dendrimers capabilities in both 
hydrophobic and hydrophilic drugs delivery in in vitro and in vivo [60,61]. 
2.1.3  Protein-based Drug Delivery Systems 
Naturally self-assembled proteins such as ferritin/apoferrintin protein cage [62], plant-derived viral 
capsids, the small Heat shock protein (sHsp) cage, albumin, soy, and whey protein have been used for 
drug delivery systems. Their biocompatibility, biodegradability, and low toxicity properties make 
them ideal candidates for drug delivery systems. Based on proteins’ shape in a drug delivery system 
they categorized into microspheres, nanoparticles, protein cages, nanoparticles, hydrogels, and film 
structures. Table 2.2 summarizes the protein-based drug delivery systems and their pharmaceutical 
uses [63].  
Protein cages are uniformly sized shell structures from virus or virus-like materials where the 
nucleic acids of the virus are replaced by therapeutics compounds. The uniform cage size in protein 
cages is an advantage of this type of drug delivery systems due to even drug loading and drug release, 
as well as avoidance of uncontrollable macromolecular aggregations. Protein cages can incorporate 
multifunction properties including attachment of fluorophores for imaging and diagnosis purposes, 
and attachment of carbohydrates, peptides, and nucleic acids for targeting and therapeutic objectives. 
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Figure 2.5 illustrates the schematic of folic acid conjugated protein cage loaded with doxorubicin. 
This protein cage is made of a model plant virus, Hibiscus chlorotic ringspot virus (HCRSV) 
conjugated with folic acid to impart cancer-targeting functionality and loaded with polyprotic acid 
and doxorubicin used against ovarian cancer cells. Results showed significant improvement of uptake 
and cytotoxicity of doxorubicin in the ovarian cancer cells [64]. 
                              
Figure 2.5. Schematic illustration of doxorubicin loaded viral protein cage. Step A1 and B2 are 
indicative of the removal of viral RNA from the virus. Step A2 and B3 involve the encapsulation of 
polyacid and doxorubicin during assembly of protein cage. Step B1 refers to the conjugation of folic 
acid onto the viral protein coat. Adapted from reference [64]. Reprinted with permission from Rights 
Link. 
 
Small heat shock proteins (sHsp) are another example of protein cages. These cages are composed 
of exterior, interior and interface surfaces compartments. The stability of these cages is significantly 
high in large temperature (max. 70°C) and pH (5-11) ranges [65]. The existence of unique cysteine 
residues on the interior surface of the cage provides functional thiol group binding of small molecules 
such as doxorubicin. The pH and temperature sensitivity properties of sHsp offer controlled release of 
doxorubicin in pH and temperature dependent manner.  
Soy proteins are inexpensive and accessible source used in drug delivery systems. Soy protein 
isolates (SPI) are purified from soy plant consisting dry soy globulin proteins. In a two-step process 
  
  17 
soy protein films are produced. These steps are protein denaturation by preheating and then 
crosslinking of disulfide bonds and hydrophobic attractions. Soy films have been used in delivering of 
two different drugs such as methylene blue and rifampicin for treatment of gastric intestinal tract 
[63,66].  
Table 2.2. List of protein-based drug delivery systems (DDS), the primary protein used, 
characteristics of the DDS, and the pharmaceuticals involved. Adapted from Ref [63]. Reprinted with 
permission from Rights Link. 
Protein Delivery 
system 
Description Drugs 
Albumin Nanoparticles 1. Bioconjugate hydrophilic drug 
2. Extremely robust to various conditions 
3. Bind to many drugs such as indole compound, 
penicillin benzodiazepins  
4. Non-toxicity, biodegradability and immunogenicity 
5. The most abundant plasma protein 
6-coumarin, 
DOX, Abraxane 
Casein Microsphere 1. Easy to incorporate hydrophobic drug  
2. Very tolerable to robust conditions  
3. Nontoxic of the degradable end product 
4. No disulfide bridge 
Progesterone, 
DOX, 
theophylline 
Collagen Microparticles
, minirods 
1. Low toxicity, biodegradability, and immunogenicity  
2. Structral protein with high content of glycine, 
hydroxyproline and hydroxylysine  
3. Contain carboxyl group and secondary amino groups 
with possible cross-linking function 
Glucocorticoster
oids, FITC-
dextran, all-
trans retinol  
Elastin 
polypeptide 
(ELP) 
ELPs-DOX 
nanoparticles, 
hydrogel 
1. Thermally reversible protein self- assembling into 
aggregate at phase transition for therapeutic application  
2. Elastin-like polypeptide has a pentapeptide repeatable 
unit as Val-Pro-Gly-Xaa-Gly  
3. MW of ELP can be made by recombinant technology 
as precisely as possible  
4. Genetic and chemical modification of ESP for versatile 
functionalities as well as control of biopolymer 
properties 
DOX, plasmid 
DNA 
Ferritin/apofer
ritin 
Protein cage 1. Assembled and disassembled size- container at 
different pH  
2. The first protein cage to be used  
3. Three distinct features: exterior, interface, interior for 
different functionalities  
4. Genetic and chemical modification for possible 
combination of biology and material science 
RGD4C 
peptide, FITC 
Gelatin Microsphere, 
hydrogel 
1. Low toxicity, biodregradability of end pro- ducts, and 
biocompatility  
2. Denatured form of collagen  
3. Use as ingredient in drug formulations Possess many 
carboxyl functional groups for cross-linking 
Colchicine, 
thrombocidin 
(rTC-1), 
lysozyme 
Gliadin Nanoparticles 1. Plant protein derived from wheat  
2. Non-toxicity, biocompatible and biodegradable 
3. Protect carrier from breaking down by stomach acid  
4. Easy to entrap hydrophilic drugs due to its water 
solubility  
Vitamine E, 
Linaloo and 
linalyl acetat 
(LLA), 
benzalkonium 
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chloride (BZC), 
all-trans-retinoic 
acid 
Small heat 
shock protein 
(sHsp) 
Protein cage 1. Uniform cage size with 12 nm exterior and 6.5nm 
interior  
2. Genetically, chemically modified interior and exterior 
for multifunctionalities as well as controlling of the 
protein properties  
3. Large pores (3 nm) between interior and exterior for 
easy cargo exchange  
4. Use as scaffold for chemical reactions and material 
synthesis 
Fluorescein, 
RGD 4C 
peptide, anti-
CD4 antibody, 
DOX 
Soy protein Film 1. Abundant and inexpensive plant protein  
2. Highly soluble in water and easy to incorporate 
hydrophilic drug  
3. Non-toxicity and reusable end products 
Methylene blue, 
rifampicin 
Viral capsid Protein cage 1. Modification of specific amino acid residues resulting 
in multifunctionalities  
2. Viral diversity providing different size and shape as 
well as catalyst functions  
3. Three distinct features: interior, interface and exterior 
for possible therapeutic applications  
4. Assembled and dissembled biological container at 
different conditions 
DOX, poly-
anethole-
sulphonic, 
antibody 19G2 
Whey protein Hydrogel, 
whey protein 
beads, 
microspheres 
1. Independent of pH change, easy to entrap hydrophilic 
drugs 
2. Possibly form gel, foam and emulsion Biocompatible 
and biodegradable end product 
3. Protect drugs from digestive enzymes 
Riboflavin, 
caffeine, retinol 
Zein Microspheres 1. Use to entrap hydrophobic drug,  
2. Has antibacterial activity,  
3. Protect ivermecin from photodegradation  
4. Low toxicity of degradable end products, 
biocompatible,  
5. Less expensive 
ivermectin 
   
Albumin is one of the most common proteins used in drug delivery systems. It plays an important 
role in encapsulating of hydrophobic drugs and targeting specific tissues. 130-nanometer albumin-
bound (nabTM) technology was the first new class of protein-based drug delivery technology approved 
by FDA in 2005 [67]. This technology exploits the transport properties of albumin including: (i) 
albumin binds non-covalently to many molecules including fatty acids, vitamins, bilirubin, hormones, 
and acidic and hydrophobic drugs, (ii) albumin initiates translocation of drug in cytoplasm through 
receptor binding. Gp60 is 60 kDa glycoprotein existed dominantly on the endothelial cell surface that 
can bind to albumin with high affinity, (iii) albumin accumulate in tumor sites dominantly due to the 
secretion of the albumin-binding protein SPARC (Secreted Protein, Acidic and Rich in Cysteine). It 
has been reported many cancer cells have over expression of SPARC. Albumin has high binding 
affinity with SPARC, which can cause concentrating albumin in tumor sites. Albumin is also known 
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as source of nutrition and energy for cancer cells that can be an advantage for drug delivery system 
containing albumin as a drug carrier. The detailed mechanism of albumin contained drug uptake by 
cancer cells is explained by Neil Desai et al. and illustrated in Figure 2.6 reprinted from reference 
[68]. The transport of albumin-bound drug across the endothelial cell membrane in the area of tumors 
is facilitated by Gp60 receptor and caveolin-1 mediated transcytosis. Albumin-drug molecules 
accumulation enhance significantly in tumor sites due to the presence of albumin-binding protein 
SPARC in the tumor interstitium [15,16,67–69].  
 
Figure 2.6. Mechanisms for the transport and accumulation of albumin-bound paclitaxel in tumors. 
Adapted from reference [68].  
 
2.2 Modification of Nanocarriers Enhancing Functionalities  
Application of nanocarriers in pharmaceuticals has shown enhanced the in vitro and in vivo efficiency 
of many established drugs, however many of these nanocarriers without further modifications are 
suffering from their low selectivity, low circulation life, and uncontrolled release profile. Therefore, 
over the past decades several surface modification strategies have been established in order to control 
biological properties of nanocarriers. The most common strategies comprise increasing stability and 
half-life of nanocarriers, implementing passive and active targeting moieties, incorporating 
responsiveness to the local physiological-associated stimuli such as pH and temperature, utilizing 
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with imaging/contrast ligands for therapy and diagnostic purposes [4]. The following sections 
summarize the basic surface modifications of nanocarriers and the current advances made.     
2.2.1 Longevity in Blood 
The essential property of pharmaceutical nanocarriers is longevity in blood. Since human’s immune 
system shows defense against any foreign particle, nanoparticles can be easily recognized by 
macrophages (also called opsonization) and removed from circulation before performing their 
function. Therefore, modifying nanocarriers so they cannot be recognized by macrophages is a crucial 
consideration in pharmaceuticals. The important reasons for making long-circulating drugs and 
nanocarriers are as followings: (i) maintaining a required level of a therapeutic agent in blood for 
extended time intervals; (ii) slow accumulation of drug-containing nanocarriers in pathological sites 
or enhanced permeability and retention (EPR) effect also called a ‘passive targeting’; (iii) prolonged 
circulation of nanocarrier can help to achieve a better ‘active targeting’ for targeted nanocarriers and 
more time for interaction between nanoparticles and pathological sites [5,70,71]. Polyethylene glycol 
(PEG), an FDA approved polymer for use as vehicle or base in foods, cosmetics and pharmaceuticals, 
has shown a great potential in increasing longevity of nanoparticles such as liposomes, polymers, 
peptides and proteins [8,72–76].  
2.2.1.1 Poly(ethylene glycol), PEG- modification 
Frank Davis pioneered PEGylation of a protein in 1977 at University of California, Berkeley. He 
had studied the immunogenic properties of the poly ethyleneglycol (PEG) and also developed the 
method for covalent attachment of PEG to proteins [77]. His observations show that the PEGylated 
protein has greatly reduced immunogenicities and enhanced circulation time in rabbits and mice. PEG 
is known as a candidate to be conjugated to protein/peptide for a number of reasons: (1) 
hydrophilicity, (three water molecules bond per one oxyethylene unit) that is by increasing the 
molecular mass of PEG, the solubility in water will increase, (2) linearity, (3) lack of charge (4) easy 
detection in mass spectroscopy spectrum (5) approved by the FDA for use as a vehicle or base in 
food, cosmetics, and pharmaceuticals including injectable, topical, nasal and rectal formulations [8].  
The surface functionalization of nanoparticle (NP) systems with PEG has become a standard 
strategy to increase NP circulation half-life. By reducing nonspecific interactions with proteins 
through its hydrophilicity and steric repulsion effects, PEG provides long circulating drug delivery 
systems with reduced opsonization and complement activation.  PEG was approved by the FDA for 
clinical use due to its low toxicity and lack of immunogenicity. There are numbers of clinically 
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approved therapeutics that rely on PEG properties for improved in vivo profiles, including liposomes 
(Doxil), PEG–drug conjugates (Oncaspar) and polymeric NPs (Genexol-PM) [78–80].    
PEGylation of β-sheet forming self-assembling peptides has also been studied through various 
work ever since the first report by Lynn et al. of the conjugation of PEG to the amyloid peptide (10-
35 Aβ) [81,82]. This early work showed that the PEGylation prevented lateral association of the 
fibrils inhibiting the irreversible step of fibrilogenesis. Elastin like polypeptides based on (VPGVG)4 
and (VPAVG)4 were also conjugated with PEG which enhanced their self-assembling properties [83]. 
Moreover, PEGylation of the GAGA peptide, which is based on the Bombyx mori silk, enhanced 
peptide self-assembly through formation of both parallel and anti-parallel β-sheets [84]. Collier et al. 
introduced an interesting self-assembling peptide Q11 (Ac-QQKFQFQFEQQ-Am) and elegantly 
studied the effect of PEGylation on the self-assembling procedure through conjugation of different 
PEG chains either on one side or two sides of the peptide. Their results showed that PEG conjugation 
strongly prevented lateral aggregation of the fibril-forming peptides. Further on they showed a great 
promise of Q11 as an immune adjuvant [18,85].  
PEG is formed in the process of linking more than one repeating chain of ethylene glycol to form 
linear or branched polymers. To enhance the pharmacokinetics and pharmacodynamics properties of 
peptides or proteins, a stable bond connecting PEG polymer to the peptide of choice is generated. 
Contributing factors that affect properties of PEGylated peptide are: (1) the number of PEG chains, 
(2) the molecular weight of PEG, (3) the location of the PEG conjugated to the peptide sequence, and 
(4) the chemistry applied to bind PEG to the peptide. The important characteristic of first generation 
of PEGylation was utilization of low molecular weight of linear PEGs (< 12 KDa) with side reactions 
or weak linkages upon conjugation with peptides. However, the second generation of PEGylation was 
designed to avoid the limitations present in the first generation such as restriction of low molecular 
weight, unstable linkage, and lack of selectivity in substitution [7,8,74]. The molecular weight of PEG 
plays an important role in protein activity: high molecular weight of PEG causes reduced activity in 
vitro and elevated activity in vivo by improving pharmacokinetic profile. The rapid decrease in 
systemic clearance was observed by increasing Mw of PEG from 21 to 70 kDa [86]. To couple PEG 
to peptides or proteins it is necessary to activate the functional group and one or both terminals. The 
selection of the functional group in PEG is based on the type of available reactive groups in the 
peptide/protein molecules. For peptides, typical reactive amino acids are lysine, cysteine, histidine, 
arginine, aspartic acid, glutamic acid, serine, threonine, and tyrosine, as well as N-terminal amino 
group and C-terminal carboxylic acid [7,74]. 
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2.2.1.2 Protein-Nanoparticle Interactions 
Nanomaterials and their unique properties have attracted the attention of many areas of science 
including physics, chemistry, engineering, and medicine. The interesting fact about nanomaterials is 
the very distinct mechanical, physical, and chemical properties of nanoparticles from those of their 
bulk counterparts, due to the significantly smaller particle size and high surface area. In a biological 
and medical point of view, nanoparticles are small enough to interact with physiological components 
and potentially reach the target tissues. Interaction between nanoparticles and biomolecules is an 
important subject that has been studied extensively. In the biological environments, the surface of 
nanoparticles is immediately covered by biomolecules (e.g., proteins) resulting in the formation of 
“protein corona” on the nanoparticles’ surface. The nanoparticles covered with biomolecules or 
protein corona are the surfaces can be “seen” by biological entity such as cells and tissues, which is 
dramatically different from the surface of intact nanoparticles. Therefore, a deep understanding of the 
fundamental interactions of nanomaterials with biological components plays a key role in 
nanomedicine research [87,88]. The surface properties and protein corona of nanoparticles suggested 
an important effect on their circulation time and clearance rate, which are governed by phagocytosis 
(i.e., mononuclear phagocytes uptake) [89]. The intrinsic characteristics of nanoparticles such as 
composition, size, shape, charge, coatings, surface modifications, crystallinity, hydrophobicity, and 
wettability highly affect the formation of the protein coronas [90,91].   
Albumin as the most abundant protein in plasma, which is highly soluble, and stable in the pH 
range of 4-9 and high temperature (60°C). Albumin is also known for its biodegradability, 
availability, and lack of toxicity as well as its favored uptake by tumor cells and inflamed areas. All 
these properties make albumin a potential candidate for drug delivery systems. Numerous studies 
have shown improvement in pharmacokinetics of active drugs and peptides while bound with albumin 
as well as high accumulation of albumin in inflamed joints in arthritic disease and solid tumors [92].  
Abraxane (ABI-007 or nab-paclitaxel) is a trademark name for Albumin-Paclitaxel conjugate 
utilizing nabTM technology was the first product approved by FDA for treating metastases breast 
cancer and meanwhile it has been approved in 41 countries. Compared to Paclitaxel (Taxol), 
Abraxane demonstrated 14% higher antitumor activity among breast cancer patients after failure of 
combination of chemotherapy for metastatic breast cancer. In addition, Abraxane increased the 
maximum tolerated dose (MTD) of the paclitaxel from 175 to 260 mg/m2 [67]. Previously used 
paclitaxel also known as Taxol had a drawback of containing synthetic solvent for parental 
administration (Cremophor EL) as a pre-medication that caused hypersensitivity. Abraxane overcame 
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the issues involving with Taxol, which avoided the use of cremophor and was well tolerated by the 
patients for 30 min intravenous infusion. So far, nab-paclitaxel has been applied to different types of 
cancers besides breast cancer, including lung, melanoma, and pancreatic cancers. For all the listed 
named cancer, ABI-007 is advanced up to clinical phase III and is in process of approval based on the 
latest results reported in 2012. Nab technology has been employed for various anticancer drugs such 
as nab-Docetaxel (ABI-008) against prostate cancer, nab-Rapamycin (ABI-009) mTOR inhibitor in 
solid tumors, nab-17AAG (ABI-010) Hsp90 inhibitor, nab-VDA (ABI-011) vascular disrupting 
agent, and Novel Taxane (ABI-013) that have advances in different clinical stages [11].  
Besides albumin-bound drugs, albumin has shown the great capability of binding other therapeutic 
or diagnostic molecules. B. Elsadek and F. Kratz reported a comprehensive summary of application 
of albumin in their review article in 2012 [12]. Albumin-binding pro-drug (DOXO-EMCH, or INNO-
206) for breast and lung cancer and sarcoma, albumin-modified exendin-4 conjugate for treating type 
2 diabetes, Albuferon (fusion of albumin and interferon-a-2b) for treating hepatitis C [93], 
fluorescein-labeled albumin for detecting brain tumor during surgery and diagnosis applications (e.g., 
AFL-HSA) [94,95], albumin-binding antibodies for antibody receptor-mediated cancer therapy (e.g., 
MM-111)[96], albumin conjugate antiviral C34 peptide for inhibiting HIV-1 (e.g., PC-1505) [97], and 
etc. 
Despite the functionality of the nanoparticles, depends on their size and compositions they can be 
harmful to the human body and cause protein-misfolding related diseases, and here is where 
nanotoxicology comes to play in order to design safer nanoparticles for biological applications [98]. 
The affinities of protein bindings are highly dependent on nanoparticles’ composition. For instance, 
Linse et al. focused on the potential of nanoparticles in promoting protein assembly into amyloid 
fibrils (β2-m protein) by assisting the nucleation process for potentially preventing human diseases 
such as Alzheimer’s, Creutzfeld-Jacob disease, and dialysis-related amyloidosis. They have shown 
the role of nanoparticles (e.g., copolymers, cerium oxide particles, quantum dots, and carbon 
nanotubes) in enhancing the rate of protein fibrillation by increasing the lag time of nucleation due to 
their enormous surface areas. The results showed that surface hydrophobicity of the nanoparticles 
affected the NP-induced fibrillation more than the particle sizes. In Figure 2.7, authors presented the 
artistic rendering of amyloid protein fibrillation in the presence of nanoparticles emphasizing the role 
of nanoparticles in increasing risk of amyloidosis and other protein-misfolding diseases [99–101].  
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Figure 2.7. (A) Depicted here are large NPs (blue) and an amyloid protein (green) in its monomeric 
and folded state. (B) This artistic rendering shows the association of the amyloid protein with the NP 
surfaces, perhaps with the generation of small oligomers, which are the precursors to fibrils. In 
solution, larger protein fibrils appear as the surface association of proteins enhances their growth. 
Adapted from reference[101]. Reprinted with permission from PNAS.  
 
2.2.2 Targeting 
The further development of the concept of multifunctional nanocarrier involves the attempt to add the 
specific target recognition functionality to the long-circulated nanocarrier. As noted above, most 
existing anticancer therapeutic agents do not differentiate between cancerous and normal cells, 
leading to systemic toxicity and adverse effects. Severe side effects in bone marrow suspension; 
cardiomyopathy and neurotoxicity greatly limit the maximal allowable dose of drug. Nanotechnology 
offers great-targeted approaches that can provide significant benefits for cancer therapy. There are 
two main targeting strategies for nano-scale drug delivery systems, including passive targeting and 
active targeting [2,4,102]. 
The selective targeting based on permeability of the delivery system into tumor vasculature is 
considered to be a ‘passive targeting’. When tumor cells are growing, rapid vascularization occurs 
around cancerous cells to nourish growing tumors with oxygen and nutrients. This leads to leaky, 
defective architecture and impaired lymphatic drainage, which leads to the EPR effect and results in 
accumulation of nanoparticles at the tumor site. To pursue the passive targeting, the size and surface 
properties of drug delivery system should be controlled. The optimal size should not be less than 100 
nm in diameter and the surface should be hydrophilic to avoid clearance by macrophages. EPR effect 
can exploit through surface modification of the nanocarriers. The anatomical factors responsible for 
EPR effect of macromolecules in solid tumors are extensive angiogenesis with high vascular density, 
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leaky vasculatures due to lack of smooth muscles, lymphatic clearance and slow venous return that 
promote retention and accumulation of macromolecules in the interstitium [5].  
An ‘active targeting’, achieved by conjugating nanoparticles with a targeting motif, provides a 
specific binding and subsequent accumulation of nanoparticle at the tumor site or intracellular 
organelles of cancer cells [2]. Figure 2.8 offers a schematic presentation of the combination of passive 
and active targeting.  
The active targeting agents are generally classified as proteins (mainly antibodies and their 
fragments [103–106]), nucleic acids (aptamers [107]), and other receptor ligands (peptides [21,108], 
vitamins and carbohydrates [109]). Monoclonal antibodies (mAb) are the conventional targeting 
conjugates for cancerous cells, approved by the FDA, but have two main limitations in their 
application: their large size and non-specific binding to the reticuloendothelial system (RES) [21]. 
Peptides present excellent alternatives to antibodies for cancer targeting due to their small size and 
lack of uptake by RES, high specificity to target cells, flexibility in design, synthesis and screening. 
Cell-targeting peptides (CTPs) are short sequences, usually composed of three to ten amino acids, 
which can interact and bind to a specific over-expressed receptor on the targeted cell line with high 
affinity and specificity [110,111]. This feature of CTPs enables them to be applied as a targeting 
agent in nanocarrier complexes to promote their selective uptake for therapeutic or imaging purposes. 
In addition to the cell surface targeting peptides, significant numbers of other peptides with an ability 
to target tumor vasculatures have already been identified [112,113]. It is suspected that free peptides 
are cleared very rapidly, whereas the conjugated peptides have a longer circulation lifetime. There are 
many examples using cell-targeting peptides for delivery in vitro and in vivo, including liposome 
[114,115], polymer nanoparticles [116–118], and albumin [119].  
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Figure 2.8. Schematic representation of different mechanisms by which nanocarriers can deliver to 
tumors. Polymeric nanoparticles are shown as representative nanocarriers (circles). Passive tissue 
targeting is achieved by extravasation of nanoparticles through increased permeability of the tumour 
vasculature and ineffective lymphatic drainage (EPR effect). Active cellular targeting (inset) can be 
achieved by functionalizing the surface of nanoparticles with ligands that promote cell-specific 
recognition and binding. The nanoparticles can (i) release their contents in close proximity to the 
target cells; (ii) attach to the membrane of the cell and act as an extracellular sustained-release drug 
depot; or (iii) internalize into the cell. Adapted from reference [2]. Reprinted with permission from 
Nature Nanotechnology.  
 
2.2.3 Stimuli-responsive 
The stability of a PEGylated nanocarrier does not always benefit a drug delivery system. The drug 
entrapped in a nanocarrier should be specifically released into the tumor avoiding normal cells. 
Therefore, an additional functional group, allowing detachment of PEGs when exposed to certain 
local stimuli in a pathological condition, can be utilized in a multifunctional nanocarrier. One of such 
stimuli is lower pH that has been noticed in inflamed and tumor areas. Releasable PEGylation (rPEG) 
has been developed chemically to tether drug and controls its release in low pH environments. The 
most frequently employed chemical bonds for this purpose are esters, carbonates, carbamates, 
hydrazones or amides [86]. Figure 2.9 illustrates the schematic of “smart” pH-sensitive immune-
liposome and its function in tumor site, in which in low pH area the protective PEG is “de-shielding” 
and cell-penetrating function enables carrier penetration of tumor cells [1,120]. Other stimulus 
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conditions playing role in drug or gene delivery are redox potential, temperature, magnetic fields and 
ultrasound. Change in temperature can present both internal and external stimuli factor for drug 
release. Hyperthermia, usually associated with inflammation, is considered an internal effect of 
temperature. Therefore high temperature can be locally applied on target tissue allowing nanoparticle 
to release the therapeutic agent [121–123]. Magnetic field of different gradient applied to the body 
can concentrate magneto-sensitive DDS in target area [124].   
 
                     
Figure 2.9. Schematic presentation of “smart” stimulus-sensitive long-circulating immunoliposome. 
Adapted from reference [1]. Reprinted with permission from Elsevier. 
 
2.3 Self-Assembling Peptides: Emerging Biological Nanomaterial  
Molecular self-assembly by the definition is spontaneous association of molecules under 
thermodynamic equilibrium conditions into stable and ordered structures due to the formation of non-
covalent interactions [125]. In the past two decades, self-assembling peptide nanostructures have been 
advanced tremendously in generation of new nanomaterials and nanodevices. The origin of self-
assembling peptide research is attributed to Shuguang Zhang et al. in 1992 by discovering a 16- 
residue peptide EAK16-II in a region of alternating hydrophobic and hydrophilic residues in Zuotin, a 
yeast protein [126]. EAK16 spontaneously forms to β-sheet structure due to hydrophobic alanine side 
chains on one side and ionic-complementary pairs of positively charged lysine and negatively charged 
glutamic acid side chains on the other surface. This structure is unusually stable in extreme conditions 
such as high temperatures, various pH changes, denaturation reagents such as SDS, guanidine. HCl 
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and urea [127]. A number of self-assembling peptides have been systematically designed and 
developed inspired by EAK16 self-assembly properties. So far, self-assembling peptide have been 
categorized into three distinct types applicable for various applications including scaffolding for 
tissue repair, tissue engineering, drug delivery, molecular medicine, and nanofabrication.  
2.3.1 Type I Self-assembling Peptides- Molecular Lego 
The first category of self-assembling peptides consists of the peptides with block structure and 
distinct hydrophilic and hydrophobic surfaces. Because of this amiphilicity they form β-sheet 
structures in aqueous solution and similar to Lego components the pegs and holes complement each 
other on the hydrophilic surface. The hydrophilic surface contains complementary ions in different 
patterns. For example modulus I have alternating negative and positive charge (- + - + - + - +), 
modulus II has - - + + - - + +, and modulus IV has  - - - - + + + + charge distribution pattern 
[125,128]. EAK16-II, EAK16-IV, DAR16-IV, RAD16-I, RAD16-II, etc. are examples of Type I self-
assembling peptides that have been studied and developed as matrices for mammalian cell attachment 
and drug delivery purposes [129–132].  
Zhang et al. have proposed the class of complementary ionic pairing peptides that undergo 
spontaneous assembly in physiological conditions to form microscopic and macroscopic structures 
into different geometric shapes. The alternative charge distribution play the important role in β-sheet 
self-assembling process, i.e. substituting positive charge Lys by positive charge Arg and the negative 
charge Glu with Asp does not change the self-assembly process drastically. However, if the positive 
charge residues are replaced by negative charge residue the peptide can no longer undergo self-
assembly process or form β-sheet structures in physiological solutions. In addition, if more 
hydrophobic residues such as Leu, Ile, Phe or Tyr replace the alanine residues, tendency of the 
molecules to self-associate to form matrices will enhance.   
RAD16 and EAK16 were tested extensively for cell attachment and scaffold applications. A stable 
attachment of a number of mammalian cell types such as mouse fibroblast (NIH-3T3), human 
cervical carcinoma (HeLa), rat neuronal cells (PC12), human ovary carcinoma (OVAR-5), etc., with 
the peptide materials have been observed [129,130]. The presence of 50% charged residues and β-
sheet structures of these peptides facilitates the formation of a hydrogel scaffold as a template for cell 
proliferation. RAD16-I has been commercialized with a trade name of PuraMaterixTM by 3DM Inc. 
(Cambridge, MA, USA) for tissue cells encapsulation and growth in three-dimensional peptide 
scaffold and exhibited significant cellular behaviors such as proliferation, functional differentiation, 
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active migration, and extensive production of extracellular matrices (ECM). One of the advances of 
PuraMatrixTM involved extensive neurite outgrowth and active synapse formation [130,133]. 
Advantages associated with these peptides are negligible immune response and tissue inflammation 
when introduced into animals. Exploiting their biocompatibility and self-assembly properties, 
application of these peptides in animal models for hemostasis [134], bone and cartilage regeneration 
[135], cardiovascular [136], and neurosurgical [137] are under extensive research. The Type I self-
assembling peptides also showed a great potential in drug and gene delivery systems that will be 
discussed in detail in the following sections.  
2.3.2 Type II Self-assembling Peptides- Molecular Switches 
There are several peptides that have shown drastic changes in molecular structure at different pH and 
temperature conditions. EAK12 and DAR16-IV are the examples of molecular switch peptides. At 
room temperature DAR16-IV has a β-sheet structure with 5 nm in length, however, at high 
temperature peptide goes under transition to form α-helical structure with 10 nm in length. EAK12 
can go under three distinct conformational states at various pH. β-sheet structure is the dominant 
secondary structure of EAK12 in pH 1-3, and at pH 4 the β-sheet content is reduced and backbone 
conformation is changed. At pH 5 and over the transition to α-helix is noticeable, where in pH 
between 6 and 10 a stable α-helix conformation forms [128]. 
2.3.3 Type III Self-assembling Peptides- Molecular Paint  
Type III peptides self-assemble on the surface and form monolayers for specific surface interactions 
or binding. These peptides are known for their unique features; the first feature is the functional group 
at the terminal segment for recognition by other molecules, receptors, or cells. The second feature is 
the central linker, which provides rigidity and flexibility. The third feature is the surface anchor, 
which facilitates the covalent bond between the peptide and the surface. This surface functional 
peptide series were mainly designed to study cell-to-cell communication, and cell behavior [125].  
S. Zhang et al.  have developed a biologically active surface using two oligopeptides including a 
cell adhesion segment (RADS)n (n= 2 or 3) at the N-terminus, connected to oligo(alanine) linker and 
a cysteine residue at the C-terminus as an anchor to attach the peptide covalently onto gold-coated 
surfaces and forming a monolayer. RADSC-14 and RADSC-16 with sequences of 
(RADSRADAAAAAAC, and RADSRADSRADSAAAC) are the two examples used in their study. 
They fabricated a variety of surfaces and formed patterns that areas either supporting or inhibiting cell 
  
  30 
adhesion. These engineered surfaces were mainly capable of aligning cells in a well-defined pattern, 
leading to formation of the cell array for biomedical applications [138].    
2.3.4 Type IV Self-assembling Peptides- Surfactant-like 
Surfactant-like peptides are known for the formation of either nanotube or nano-vesicle structures 
through hydrophilic head and hydrophobic tail. Developments of these structures have significant 
consequences in design of non-lipid biological surfactants to provide an enclosure for the RNA-based 
or peptide enzymes. The basic molecular structure of these surfactant-like peptides is hydrophilic 
head containing aspartic acid and hydrophobic tail containing one of the amino acids such as glycine, 
alanine, valine or leucine. Each peptide is approximately 2 nm long, similar to the biological 
phospholipids. There is a packing difference between lipids and peptides due to the intermolecular 
hydrogen bonds along the backbone among amino acids in peptide sequence. Whereas, in lipid 
structures the hydrophobic tails pack tightly to fully displace water, preventing the formation of 
hydrogen bonds. The examples of Type IV self-assembling peptides are GxD2 (x= 4 to 10), A6D, V6D, 
V6D2, and L6D2, etc. These peptides are self-assembled into a fibular dense network with several 
microns in length. In the proposed molecular models, hydrophobic tails (e.g. glycine) are hidden from 
the aqueous environment and hydrophilic heads expose to the aqueous environment in both interior 
and exterior surfaces forming the bilayer structure in the shape of nanotube or nano-vesicle 
[125,139,140].     
2.3.5 Other Self-assembling Peptides  
The other self-assembling peptides in biological applications are peptide-amphiphile nanofibers for 
resembling extracellular matrix (ECM), cell-penetrating peptides for delivering nucleic acids and 
therapeutics facilitating membrane trafficking applications.  Hartgerink et al. first introduced a self-
assembling peptide-amphiphile mineralized with five distinct regions including  (1) alkyl chain 
(hydrophobic tail), (2) four consecutive cysteine residues (disulfide bonds promote polymerization), 
(3) three glycine residues (hydrophilic head), (4) phosphorylated serine residue (calcium ion 
interaction), and (5) RGD peptide (cell adhesion ligand) [141]. Cell-penetrating peptides (CPP) and 
peptide transduction domains (PTD) are also very well known for enhancing translocation of 
therapeutics into cells. These peptides are conjugated to the delivery systems and so far they have 
shown safety features, efficient transit in vivo, no size constrains on cargo, biodegradable, and non-
immunogenicity. There are several examples of PTD and CPP motifs such as TAT, ANTp, NLS, 
RGD, and etc. [20,142,143].    
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(A) Molecular Lego 
 
(B) Molecular Switch  (C) Molecular Paint 
  
(D) Surfactant-Like  
  
Figure 2.10. (A) Molecular Lego – Ionic complementary peptide with alternating polar and non-polar 
pattern self-assemble into β-sheet structure forming scaffold hydrogel, (B) Molecular switch – 
conformational change of self-assembling peptide from β-sheets to α-helix structure exposing 
different pH or temperature, (C) Molecular paint – Endothelial cells formed a pattern assisted by self-
assembling peptide, (D) Surfactant-like - Molecular models of surfactant peptides V6D and K2V6 
forming nanotubes and nano-vesicles. Adapted from references [125,144].  
 
2.4 Self-assembling Peptides as Potential Carriers for Anticancer Drug 
Delivery 
Over the past two decades, a new class of self-assembling peptides such as ionic-complementary, 
amphiphilic peptides and recently amino acid paring peptides has been systematically studied for 
different applications including drug, gene delivery, and tissue engineering [24,126,129,145,146]. 
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Amongst many emerging drug carriers, peptides carry a great potential in overcoming many 
challenges in delivery and increasing drug biocompatibility, efficiency, and potency to conjugate with 
targeting and long circulating moieties. The natural properties of peptides, such as ability to penetrate 
cells, targeting, and therapeutic characteristics make them attractive candidates for drug delivery 
systems. Research on peptide-mediated delivery systems has shown very promising capabilities to 
deliver therapeutic agents such as hydrophobic anticancer drugs, small molecules, and 
oligonucleotides [24,147]. Self-assembling peptides can be rationally manipulated to form a variety 
of stable nanostructures, such as fibers [148,149], nanorods [150] , nanotubes [151] , nano-vesicles 
[140] and globules [152], as well as incorporate naturally binding motifs with an affinity to inorganic 
materials. Various interactions are involved in peptide formation, including hydrogen bonding, ionic 
interaction, van der Waals and hydrophobic interactions. Based on the application, in fact, millions of 
peptides with a desirable structure and function can be constructed [153].  
As discussed above, Zhang et al. and Chen et al. have extensively studied the self-assembling 
ionic-complementary peptide, EAK16-II, for various applications including drug delivery 
[25,126,146,154]. EAK16-II has sixteen amino acids creating both hydrophobic and hydrophilic side, 
the negative and positive charges also altered along the sequence (Figure 2.11). This peptide can 
spontaneously organize itself into a β-sheet structure by electrostatic interaction between ionic-
complementary residues. Fung et al. investigated the capability of the self-assembling peptide 
EAK16-II to deliver a hydrophobic anticancer drug. They discovered that the EAK16-II peptide could 
stabilize the hydrophobic compound, Ellipticine, in an aqueous solution. They also showed that the 
molecular state of Ellipticine (protonated or crystalline) in solution is EAK16-II concentration 
dependent. As a consequence, the release kinetics of ellipticine from a peptide-ellipticine complex 
into eggphosphatidylcholine (EPC) vesicles, which are used as a cell membrane mimic, depends 
significantly on concentration and as a result on molecular state of Ellipticine. In addition, the in vitro 
anticancer activity results of peptide-Ellipticine complexes towards two cancer cell lines, A549 and 
MCF-7 suggested a promising potential of EAK16-II as a carrier for a hydrophobic compounds 
[24,146]. Their study has initiated the future development of self-assembling peptide-based delivery 
of chemotherapeutics.  
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(A) 
 
(B) (C) (D) (E) 
     
Figure 2.11. Molecular structure (A) of EAK16-II (Ac-AEAEAKAKAEAEAKAK-NHs), (B) 
Ellipticine, Nanostructure of (C) EAK16-II, and (D) EAK16-II-EPT complex on mica surface 
observed by AFM. (E) Particle size distribution of EAK16-II and the EAK-EPT complex in aqueous 
solution by DLS. Adapted from reference [25].  
 
Recent advances* in EAK16-based anticancer drug delivery system illustrated a successful delivery 
of the ellipticine to the tumor site in vivo. In summary cellular uptake, toxicity, and apoptosis results 
in an A549 human lung carcinoma cell line indicate that EAK16-II-EPT complexes were significantly 
more effective than treatment with EAK16-II or ellipticine alone. This is due to the ability of EAK16-
II to stabilize ellipticine in a protonated state in well-formed nanostructures approximately 200 nm in 
size. In vivo observations in an A549 nude mouse tumor model showed a higher antitumor activity 
and lower cytotoxicity of EAK16-II-EPT complexes than in the control group treated with ellipticine 
alone after 14 days intraperitoneal (i.p) injection  (Figure 2.12). Tumor growth in animals was 
significantly inhibited after treatment with EAK16-II-EPT complexes, and without any significant 
side effects such as weight loss [25].  
                                                      
* This study was based on my collaborative research with Dr. Yong-fang Yuan at People’s Hospital 
affiliated to Shanghai Jiao Tong University and published as “Sadatmousavi, P.; Wu, Y.; Wang R.; 
Lu, S.; Yuan, Y.; Chen, P. “Self-assembly Peptide-based Nanoparticles Enhance Anticancer Effect of 
Ellipticine in vitro and in vivo”, International Journal of Nanomedicine, 2012:7 3221-3233” 
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(A) (B) 
  
(C) (D) 
 
 
Figure 2.12. (A) Size of tumors in the four groups after treatment with 11.25 mg/kg EPT and 22.5 
mg/kg EAK16-II in complex once a day for a total 14 days. (B) Mouse body weight in four groups 
during 14 days, (C) in vitro cellular uptake of EPT by A549 cells, overlap (DAPI and green) images 
for A-Untreated, B- EAK16-II control, C- EPT control, D-EAK16-II-EPT complex. High uptake of 
EPT in complex treated cells where cyan color visible for D.  (D) Representative example of tumors 
from four groups after treatment on day 14. A-D represents the same ordered treatment as (C). 
Adapted from reference [25]. 
 
2.4.1 Amino Acid Pairing Design for Self-assembling Peptides  
A novel strategy to design self-assembling peptides called “amino acid pairing” (AAP) strategy has 
been patented and developed in Dr. Chen’s research group in 2010-11 [155]. The amino acid side 
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chains of self- assembling peptide can provide major interactions with adjacent peptide molecules 
including ionic interaction, hydrogen bonding, and hydrophobic interaction. AAP-based peptide 
design provides complementary interactions that achieve certain stereo-chemical and 
physicochemical stability, resulting in pair affinity and minimum pairing free energy. Figure 2.13 
shows an AAP strategy for designing different self-assembling peptide systems. The ionic-
complementary peptides are characterized by alternating positively and negatively charged residues; 
hydrogen bonding peptides are characterized by alternating hydrogen bonding pairs consisting of 
proton donors and acceptors; and all pairing in a peptide contains all of hydrogen bonding, 
electrostatic, and hydrophobic bonding amino acid pairs [26,155] .  
 
Figure 2.13. Amino acid pairing strategy [155].  
 
The de novo all pairing peptide (APP8) was designed recently based on amino acid pairing 
strategy. This peptide contains eight amino acids including four hydrophobic phenylalanine (F) side 
chains, which are inserted among hydrogen bonding pair (QN) and an ionic pair (EK) with the side-
to-side amphiphilic design. The four (F) residues provide strong hydrophobic interactions utilized by 
aromatic ring stacking; they also impart hydrophobic region that can stabilize hydrophobic 
compounds for drug delivery purposes. The ionic pair (EK) and hydrogen bonding pair (QN) 
expected to enhance solubility and stability of self-assembly structure of the peptide. The former two 
pairs (QN) and (EK) increase overall hydrophilicity to be in balance with hydrophobic residues (F) to 
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provide good solubility in water. It has been shown previously the dominant β-sheet rich nanofibers 
by FT-IR for this peptide (Figure 2.14).       
 
       
 
Figure 2.14. De novo design of the all-pairing peptide APP8 and the self-assembly. (A) Molecular 
structure of APP8. (B) APP8 can self-assemble into nanofibers at a peptide concentration of 0.1 mg 
ml-1 (87 µM); the scale bar represents 200 nm. (C) AAP8 has a predominant secondary structure of β-
sheets by FT-IR. (D) A proposed model shows that AAP8 forms anti-parallel β-sheets with the 
assistance of amino acid pairing: red, blue and green dotted lines represent hydrophobic amino acid 
pairing (π-π stacking), ionic pairing and hydrogen bond pairing, respectively. Adapted from reference 
[26]. Reprinted with permission from Rights Link. 
 
The nano-structure assembly of APP8 peptide is concentration dependent as shown in Figure 2.15. 
Critical assembly concentration (CAC) of this peptide is 10 µM, in which the bundles of fibers form 
beyond this concentration. APP8 peptide has shown capability for encapsulating hydrophobic 
compound and stabilizing it in aqueous solution and the peptide-drug complexes exhibited good 
anticancer activity against two cancer cell lines, A549 and MCF-7, and were stable upon serial 
dilution in water [26]. 
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Figure 2.15. Nanostructure formation of APP8 in relation to the “CAC”. (A) AFM images of the self-
assembled nanostructures as a function of APP8 concentration (2.2–87 µM). The scale bar represents 
250 nm. (B) A proposed self-assembly mechanism in relation to the “CAC”. Adapted from reference 
[26]. Reprinted with permission from Rights Link. 
 
The current research is focusing on the self-assembling peptides and their modifications to improve 
their functionalities towards longevity and low immunogenicity. The details of modifications are 
discussed in the following chapters.  First, all pairing peptide (APP8) also called amino acid pairing 
peptide (AAP8) was modified with a short segment of polyethylene glycol to enhance stability, avoid 
uncontrollable aggregations and lower immune responses. Second, a short ionic-complementary 
peptide (EAR8-II) was employed as a carrier for anticancer drug, Pirarubicin, where the protein 
binding strategy was used to advance the delivery efficiency and hinder phagocytosis. 
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Chapter 3† 
Diethylene Glycol (DEG) Functionalized Self-Assembling Peptide 
Nanofibers and their Hydrophobic Drug Delivery Potential 
Abstract 
Self-assembling peptide nanofibers have emerged as important nano-biomaterials, with such 
applications as delivery of therapeutic agents and vaccines, nanofabrication and biomineralization, 
tissue engineering and regenerative medicine. Recently, a new class of self-assembling peptides has 
been introduced, which considers amino acid pairing (AAP) strategies in the peptide sequence design. 
Even though these peptides have shown promising potential in the design of novel functional 
biomaterials, they have a propensity to initiate uncontrollable aggregations and be degraded by 
proteolytic enzymes. These present the most significant challenge in advancing self-assembling 
peptides for in vitro and in vivo applications. Functionalizing biomaterials with polyethylene glycol 
(PEG) has been shown to surmount such problems. Here, the results of conjugating diethylene glycol 
(DEG), a short segment of PEG, to one of the AAP peptides, AAP8, with eight amino acids in 
sequence, are reported. The results indicate that incorporation of DEG into the peptide sequence 
modulates fiber self-assembly through creating more aligned and uniform nanostructures. This is 
associated with increasing solubility, stability, and β-sheet content in secondary structure in the 
peptide. The DEG conjugation of AAP8 also shows reduced cellular cytotoxicity. The functionalized 
AAP8 improves the peptide capability of stabilizing and delivering a hydrophobic anticancer 
compound, ellipticine, in aqueous solution, consequently inducing more cytotoxicity towards lung 
carcinoma cells over a relatively long time, compared to the non-functionalized AAP8. The presented 
functionalized peptide and its drug delivery application indicate a potentially useful design strategy 
for novel self-assembling peptide biomaterials for biotechnology and nanomedicine. 
Key Words 
                                                      
† This chapter is based on a paper “ P. Sadatmousavi, T. Mamo, P. Chen, Diethylene Glycol (DEG) 
Functionalized Self-Assembling Peptide Nanofibers and their Hydrophobic Drug Delivery Potential, 
Acta Biomaterialia 8 (2012) 3241–3250”. 
  
  39 
Drug delivery, self-assembling peptide (SAP), amino acid pairing (AAP), Diethylene glycol (DEG), 
functionalization 
3.1 Introduction 
Self-assembling peptides are a class of biomaterials showing promising results for various biomedical 
applications, including delivery of therapeutic agents and vaccines, nanofabrication, 
biomineralization, tissue engineering, and regenerative medicine [17–19]. Recently, a new class of 
self-assembling peptides based on the design principle of amino acid pairing (AAP) has been 
introduced, with the model peptide AAP8 showing great promise in creating β-sheet-rich nanofibers, 
stabilizing and delivering a hydrophobic anticancer agent [156]. The design of AAP self-assembling 
peptides is unique as it is based on the combination of several side chain interactions, including 
hydrophobic interaction, electrostatic interaction, and hydrogen bonding. While these newly designed 
systems and other self-assembling peptides have shown immense potential, issues remain in 
optimizing the self-assembled structures and making them more robust for in vivo applications [79]. 
A major issue to be addressed in improving the self-assembled fibril nanostructures is avoiding the 
uncontrollable aggregation of the β-sheet structures while improving the fibers’ capability to form 
predictable nanostructures [9,85]. The surface of the nanofibers must be modified for effective 
biomedical applications in vivo. To address these issues, conjugating the peptide units with a short 
segment of polyethylene glycol (PEG) polymer is here proposed. 
Surface functionalization of nanoparticles (NPs) with polyethylene glycol, PEG, has become a 
standard strategy for increasing the NP circulation half-life in the bloodstream, as the 
functionalization reduces protein opsonization and macrophage uptake [78,79,157]. By reducing non-
specific interactions with proteins through its hydrophilicity and steric repulsion effects, PEG results 
in long circulating drug delivery systems with reduced opsonization and complement activation [79]. 
PEG has been approved by the U.S. Food and Drug Administration (FDA) for clinical use due to its 
low toxicity and lack of immunogenicity. A number of clinically approved therapeutics rely on PEG 
for improved in vivo profiles, including liposomes (Doxil), PEG–drug conjugates (Oncaspar) and 
polymeric NPs (Genexol-PM) [80]. Various researchers have also shown the PEGylation effect on 
iron oxide nanoparticles for in vivo cancer imaging through the enhanced permeability and retention 
(EPR) effect [158]. Liu et al. reported properties of synthesized PEGylated nanoparticles with low 
cytotoxicity and high resistance to phagocytosis by macrophages in vitro, as well as low accumulation 
of them in liver and spleen in vivo biodistribution tests. These results make the nanoparticles highly 
preferable in tumor imaging. The authors claimed that these outstanding characteristics are dependent 
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on the significant shielding effect of PEG coating, providing neutral surface charge under 
physiological conditions [158]. 
The exceptional properties of PEG make this polymer a potential candidate for resolving issues 
involved in nanoparticle formation. Nanoparticles can have the problems of insolubility, toxicity, bio-
incompatibility and a low circulation half-life in the bloodstream for in vitro, in vivo, and preclinical 
applications. The PEGylation of β-sheet forming self-assembling peptides has been studied since the 
first report by Lynn et al. on conjugation of PEG to the amyloid peptide (10-35 Aβ) [81,82]. This 
early work showed that PEGylation prevented lateral association of fibrils, inhibiting irreversible 
steps of fibrillogenesis. Elastin-like polypeptides based on (VPGVG)4 and (VPAVG)4 were also 
conjugated with PEG enhancing self-assembly properties [83]. Moreover, PEGylation of the GAGA 
peptide, which is based on Bombyx mori silk, enhanced the peptide self-assembly through formation 
of both parallel and anti-parallel β-sheets [84]. Another interesting work studied the effect of 
PEGylation on the Q11 self-assembling peptide through conjugation of different PEG chains at 
various points in the backbone of the peptide [85]. The work showed that PEG conjugation strongly 
prevented lateral aggregation of fibril-forming peptide, resulting in well-ordered peptide matrices.  
In the current work, we focus on an amino acid pairing peptide, AAP8, with eight amino acids in its 
sequence. AAP8 contains four hydrophobic phenylalanine (F) side chains, a hydrogen bonding pair 
(QN), and an ionic pair (EK), in the sequence FEFQFNFK. This peptide previously showed great 
promise for various applications because of its unique self-assembly properties [156]. However, lack 
of solubility and the possibility of uncontrollable aggregation have led to formation of non-uniform 
nanostructures, making this peptide unsuitable for further applications. To overcome this issue and 
enhance nanostructure configuration, diethylene glycol (DEG), a short segment of a PEG chain, was 
conjugated to the model peptide AAP8. Since AAP8 is a short eight amino acid peptide, it is 
hypothesized that conjugating a shorter segment of a PEG molecule should be enough to obtain the 
desired effects. We believe that the longer the PEG chain, the more likely it interferes with the self-
assembly of the peptide. To investigate the various configurations of DEG conjugation, AAP8 was 
conjugated with DEG on one or both terminals of the molecule, forming AAP8-DEG and DEG-
AAP8-DEG. We utilized spectroscopy and microscopy techniques to determine the effect of DEG 
conjugation on peptide self-assembly, the β-sheet content in secondary structure, and the formation of 
peptide nanostructures. To further investigate the drug delivery potential of the modified AAP8 with 
diethylene glycol, we used an anticancer agent, ellipticine (EPT), as the model hydrophobic drug. 
Non-small cell lung carcinoma (A549) were used to evaluate anticancer activity of ellipticine 
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encapsulated with either AAP8 or modified AAP8s. In addition, the effect of DEG-conjugated on 
macrophage (RAW 264.7) cytotoxicity as one of the innate immune responses was evaluated.  
3.2 Experimental 
3.2.1  Materials 
The peptide AAP8 (Ac-FEFQFNFK-NH2) and the two diethylene glycol (DEG) (-NH-CH2-CH2-O-
CH2-CH2-O-CH2-CO-) conjugated amino acid pairing (AAP8) peptides: Ac-FEFQFNFK-DEG-NH2 
and Ac-DEG-FEFQFNFK-DEG-NH2 were purchased from CanPeptide Inc (Quebec, Canada). The 
synthesis method for all three peptides was based on solid-phase peptide synthesis (SPPS). The 
diethylene glycol was treated as one of the amino acids in the synthesis of the whole sequence. 
Matrix-assisted laser desorption ionization time-of-flight mass spectroscopy (MALDI-TOF-MS) 
showed the molecular weight of 1147.31 g/mol for AAP8, 1293 g/mol for Ac-AAP8-DEG-NH2, and 
1437 g/mol for Ac-DEG-AAP8-DEG-NH2. The purity of peptides were verified by CanPeptide as 
>95% by LC-MS characterization. The peptide aqueous solutions were prepared with pure water 
(Milli-Q: 18.2 MΩ). The anticancer agent ellipticine (99.8% pure) and fluorescence marker, 1-
anilino-8-Naphthalene Sulfonate (ANS, > 97%), were purchased from Sigma-Aldrich (Oakville, ON, 
Canada). Cell culture agents, including Dulbecco’s modified eagle medium (DMEM) low glucose, 
and phosphate buffer saline (PBS) were purchased from HyClone (Ontario, Canada). Fetal bovine 
serum (FBS) and trypsin-EDTA were purchased from Invitrogen Canada Inc. (Burlington, ON, 
Canada). A free comprehensive chemical drawing package, ACD/ ChemSketch Freeware (Toronto, 
Canada) was used to draw chemical structure of peptide molecules. This software optimizes all bond 
lengths and angles based on energy minimization.   
3.2.2 Methods 
3.2.2.1 Peptide Solution Preparation 
Solutions of the APP8 peptide and DEG-conjugated AAP8 peptides were prepared by dissolving the 
peptide powder in pure water (18.2 MΩ; Millipore, Milli-Q system) at specified concentrations 
following by 10 min bath sonication for various experiments: including nanostructure visualization 
through Atomic Force Microscopy (AFM), hydrophobicity test by fluorescence spectroscopy, 
secondary structure evaluation and anticancer activity tests in vitro when peptides are in combine 
with anticancer drug.  
  
  42 
3.2.2.2 Atomic Force Microscopy (AFM) 
The self-assembled peptide nanostructures were imaged by atomic force microscopy (AFM) 
(PicoScan, Molecular Imaging, Phoenix, AZ) on a mica substrate. The samples were prepared with 
the following procedure: a 10 µL sample of the peptide solution (15 min after preparation) was put on 
the freshly cleaved mica substrate that was fixed on an AFM sample plate. The solution was 
incubated on the mica surface for 10 min, to allow the peptide nanostructures to adhere to the surface, 
and then rinsed with water twice. The extra water (moisture) on the surface was collected with tissue 
paper. The sample plate was then covered with a petri-dish to avoid possible contamination and left to 
dry overnight. AFM images were taken at room temperature using the AFM tapping mode. All 
images were acquired using 225 µm silicon single-crystal cantilever (type NCL-16, Molecular 
Imaging, AZ) with a typical tip radius of 10 nm and frequency of 175 kHz. A scanner with a 
maximum scan size of 6×6 µm2 was used [152]. Data sets were subjected to third-order flattening. 
The AFM images underwent further dimension analysis with Gwyddion software (Free SPM data 
analysis software). 
3.2.2.3 Steady-state Fluorescence Measurements 
 The hydrophobicity of the peptide assemblies was investigated through an ANS fluorescent probe. 
ANS (1-anilino-8-Naphthalene Sulfonate) with a molecular weight of 299.3 g/mol was the 
fluorescence label used to characterize the hydrophobicity of the prepared AAP8 assemblies. ANS is 
a fluorescent dye that binds with high affinity to the hydrophobic surfaces of protein assemblies. The 
emission maximum of ANS undergoes a blue shift, and fluorescence intensity increases significantly 
upon ANS binding to low polarity regions of the protein surface. These properties make ANS well 
suited for determining the hydrophobicity of peptide nanostructures. ANS can be excited at 360 nm in 
pure water and emits light at 520 nm; whereas, in hydrophobic solution, the emission wavelength 
moves toward a lower value. A solution of 10 µM ANS was prepared in a 10 mM phosphate buffer at 
a pH of 6. The fresh peptide solution was mixed with the same volume of ANS solution on a vortex 
mixer for 10 sec. The spectrofluorometer used in this study was type LS-100 (Photon Technology 
International, London, ON, Canada). The light source used was a pulsed xenon flash lamp. For 
solution samples, spectra were obtained using a quartz cell (1 cm × 1 cm). The ANS-containing 
samples were excited at 360 nm, and emission spectra were collected from 420 nm to 670 nm. The 
excitation and emission slit widths were set at 0.5 mm and 1.25 mm, respectively [147].  
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3.2.2.4 Fourier Transform Infrared (FT-IR) Spectroscopy 
The secondary structure of the peptides was determined with Fourier transform infrared (FT-IR) 
spectroscopy (TENSOR 37, Bruker Optics Ltd, ON, Canada), with a Bio-ATR II cell. A 30 µL of 
sample solution was injected into an ATR-crystal (silicon) chamber. The scan ran wavenumber of 
1550-1700 cm-1 for the 256 runs for each measurement. The obtained spectra were analyzed using 
OPUS software (version 6.5, Bruker Optics Ltd., ON, Canada).  
3.2.2.5 Circular Dischroism (CD) Spectroscopy 
The secondary structures of the peptides were evaluated using another standard method, which 
involves a Circular Dischroism (CD) spectrometer (J-815, JACSO Inc., Easton, MD). A 150 µL of the 
sample solution at a concentration of 0.5 mg/ml was transferred to a quartz cuvette with a path length 
of 1mm for each measurement. CD spectra were collected in a continuous scanning method from 190 
to 260 nm at a scanning speed of 50 nm/min. Data were analyzed with JACSO software (J-810).  
3.2.2.6 Dynamic Light Scattering (DLS) 
The particle size distribution and zeta potential of peptide-drug complexes at different peptide-to-drug 
ratios were measured by a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). 
Appropriate settings, viscosity, refractive index, and dispersant solvent were set for each 
measurement at 25 °C. A small 50 µL volume of the sample was transferred from the vial to a 
disposable solvent resistant micro cuvette (ZEN0040, Malvern, Worcestershire, UK). The scattered 
light intensities of the samples were collected at an angle of 173°. This was known as backscatter 
detection, i.e., the relationship between the size of a particle and its scattered light intensity obtained 
with the multimodal Contin algorithm, which was provided in the Dispersion Technology Software 
5.1 package (Malvern Instruments, Worcestershire, UK). 
The zeta potential of the complexes was investigated on a Zetasizer Nano ZS (Malvern Instruments 
Worcestershire, U.K.) with suitable viscosity and refractive index setting at 25°C temperature. 
Samples were injected into a disposable cell (folded capillary DTS-1060 from Malvern, 
Worcestershire, U.K.) with a volume of ~ 1ml for zeta potential measurements. The zeta potential 
distribution was directly calculated from electrophoretic mobility distribution based on 
Smoluchowski formula. For each solution, the measurements were repeated three times. The values 
reported herein correspond to average of the peak values of the zeta potential distribution from the 
triplicates.  
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3.2.2.7 Peptide and Ellipticine Complex Preparation 
The complexes were made of ellipticine (0.1 mg/ml, 406 µM) with freshly prepared 0.5 mg/ml 
peptides: AAP8 (435 µM), AAP8-DEG (386 µM), and DEG-AAP8-DEG (347 µM). Ellipticine (1 
mg/ml) crystals were dissolved in tetrahydrofuran (THF); aliquots of ellipticine-THF were transferred 
to a 1.5 ml centrifuge tube and dried under blowing air. A fresh peptide solution was then added to 
the tube, followed by continuous probe sonication for at 6 W-power for 10 minutes. An ellipticine 
control in pure water (in absence of peptide) at the same ellipticine concentration was prepared for 
comparison.  
3.2.2.8  Cellular Toxicity of the Peptide-Drug Complexes 
 A cancer cell line, non-small lung cancer cell A549, and mouse macrophage cells RAW 264.7 were 
used for the cellular toxicity on the AAP8 peptide series and peptide-ellipticine complexes. Cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM), containing 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin in an environment controlled incubator (37 °C with 5% CO2). 
After reaching ~ 95% confluence, the cells were detached and suspended in the DMEM, followed by 
centrifuging at 500 rpm for 5 min. The cell pellets were re-suspended in a fresh DMEM at a 
concentration of 2.5 × 104 cell per ml. A volume of 200 µl of the cell suspensions was added into each 
well of a clear, flat-bottom, 96-well plate (Costar) and incubated for 24 hr. The culture medium was 
replaced with 150 µl fresh culture medium, followed by an addition of 50 µl treatment (the 
complexes, their dilutions, and control samples) into each well. Each treatment was replicated in four 
wells. The plates were incubated for 24 hr prior to performing the cell viability assay.  
MTT assay (TOX1 from Sigma–Aldrich, Oakville, ON, Canada) was used to determine the cell 
viability after each treatment. Solid MTT (5 mg) was first dissolved in PBS solution (3 mL), followed 
by a 10-time dilution in the culture medium. All the treatments were replaced by 100 µl MTT 
solution. The plates were incubated for 4 h prior to the addition of solubilization solution (100mL, 
anhydrous isopropanol with 0.1 N HCl and 10% Triton X-100). After overnight incubation, the 
absorbance at 570nm was collected on a microplate reader (BMG FLUOstar OPTIMA) and 
subtracted by the background signals at 690 nm. The absorption intensities were averaged from 4 
replicates for each treatment and normalized to that obtained from the untreated cells (negative 
control) to generate the cell viability [24].  
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3.3 Results and Discussion 
Self-assembly of short peptides into β-sheet fibril nanostructures paves the way for synthesis of novel 
biomaterials for a wide range of applications (e.g., drug delivery and tissue engineering). To develop 
peptide-based nanostructures, it is necessary to assure that the configuration of nanostructures is 
controllable and uniform (e.g., in either fibrillar or spherical shape). One of the main drawbacks of 
the β-sheet fibrillar structures is their tendency to aggregate in tangled form, which is unbearable in 
both in vitro and in vivo applications. We previously introduced the de novo design principle of amino 
acid pairing (AAP) and created a novel class of self-assembling peptides [26]. This design strategy 
focuses on amino acid pair interactions, including hydrogen bonding, ionic pairing and hydrophobic 
interactions. The current work concentrates on an AAP peptide with all three pairing interactions 
mentioned. This self-assembling peptide, AAP8, consists of eight amino acids: four Phenylalanine 
(F), hydrophobic side chains; Lysine (K) and Glutamic acid (E), an ionic pair; Glutamine (Q) and 
Asparagine (N), a hydrogen bonding pair. This peptide is phenylalanine-rich, which may generate β-
sheet-rich fibrils but possibly reduce solubility of the peptide in aqueous solution. Since the β-sheet 
formation is mainly due to intermolecular hydrogen bonding and hydrophobic interactions, it is 
hypothesized that introducing organic molecules, such as polymers via conjugation, could regulate β-
sheet formation and lead to more oriented, uniform nanostructure. This hypothesis is supported by 
earlier work of Burkoth et al. [81] and Collier et al. [85], who showed that PEG-modified Aβ and Q11 
peptides avoided lateral aggregation. In addition to improvement of peptide self-assembly provided 
by PEG-conjugation, numerous biological advantages have been drawn for drug delivery, such as 
solubility, long circulation in the bloodstream and protection of the nanoparticles from enzymatic 
degradation[82,84,85]. 
In this work, a short segment of polyethylene glycol (PEG), diethylene glycol (DEG), with a 
molecular weight of 145 Da, was selected to functionalize AAP8 and make a peptide-DEG hybrid 
molecule. Since AAP8 is a short peptide, conjugating a short ethylene glycol (EG) would be 
appropriate, so that it does not interfere with peptide self-assembly, to any larger extent. Two hybrids 
were studied here: one is a conjugation of DEG to the C-terminal of AAP8, and the other a 
conjugation to both C- and N-terminals of AAP8. The schematic of molecular formulas is presented 
in (Figure 3.1) (ACD/ChemSketch Freeware, Toronto, Canada). Hydrophilic amino acid residues 
(lysine and glutamic acid) are positioned on one side of the molecule, and hydrophobic amino acid 
residues (phenylalanine rings) are located on other side, creating an amiphiphlic side-to-side 
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configuration. Diethylene glycol with hydrophilic characteristics is shown to conjugate to AAP8, first 
on the C-terminal, then on both C- and N-terminals.  
 
 
Figure 3.1. Molecular structure of (A) Diethylene Glycol (DEG), (B) amino acid pairing peptide 
AAP8 with monomer length: 3.53 nm, (C) AAP8-DEG with monomer length: 4.52 nm, (D) DEG-
AAP8-DEG with monomer length: 5.51 nm. The width of all molecular structures are ~ 0.2-0.8 nm. 
All dimensions are estimated using ACD/ChemSketch Freeware (Toronto, Canada). 
 
3.3.1 Effect of DEG-functionalization on Self-assembly of Nanofibers 
3.3.1.1 Nanostructure Morphology  
Atomic force microscopy (AFM) images of self-assembling peptide nanostructures on a mica surface 
showed significant differences in assembly morphologies between AAP8 and functionalized AAP8 
(Figure 3.2). AFM images of AAP8 revealed that this peptide forms extremely tangled fibers with 
large aggregates (Figure 3.2(A)). In contrast, the modified AAP8 showed a greatly improved the 
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morphology, revealing more uniform fibrillar structures, with little evidence of aggregation (Figure 
3.2(B), (C)). 
Images were taken to observe the peptide assembly at two time points. AAP8 formed larger 
aggregates over time and in most cases did not attach to the mica surface (Figure 3.2(D)). This latter 
observation is due to AAP8’s hydrophobicity, which reduces the likelihood of stabilization on mica. 
However, AAP8-DEG formed more structured fibers, with bundles consisting of a few fibers of an 
increased length (Figure 3.2(E)). The most interesting morphology observed was from DEG-AAP8-
DEG, which produced highly uniform, long fibers, aligned in parallel and almost no evidence of 
aggregation or tangled fibers (Figure 3.2(F)).  
In the analysis of dimensions of the peptide assemblies, the widths were deconvoluted using the 
method reported by Hong et al., to eliminate the convolution effect arising from the finite size of the 
AFM tip [149,152]. The observed dimensions have to be corrected; for spherical shapes with a radius 
Rm, the observed width of the sample follows a relationship: Wobs=4(RtRm)0.5, where Rt is the radius of 
the AFM tip, which is 10 nm in the present case. If the sample is a sheet, the real width of the sheet 
can be calculated using this equation: W = Wobs – 2(2RtH – H2)0.5, where H is observed height. Since 
we later show the significant amount of β-sheet in the peptide secondary structure, the assumption of 
using the sheet formula for dimension analysis is acceptable.  
From the analysis of at least fifty independent fibers in each image, the corrected width and height 
were calculated and tabulated in Table 3.1 The heights of assembled nanofibers are 0.7-0.8 nm for all 
three peptides in the freshly prepared sample, a measurement is in agreement with corresponding 
molecular determinations using ACD/ChemSketch drawing software, which determined the width to 
be ~ 0.5-0.8 nm, from the topmost and bottommost atoms in the van der Waals-based structures. The 
height of AAP8 fibers increased, almost twice the initial height, over the ten-day span, which is likely 
due to aggregation progression and building of the peptide molecules to avoid attaching to a mica 
surface. The increase in height happened for AAP8-DEG to some extent, but the height of DEG-
AAP8-DEG assemblies did not show significant increase. Since, DEG-AAP8-DEG is more 
hydrophilic and stable in aqueous solution, molecules have a tendency to attach to a mica surface.  
AFM images of freshly made AAP8 demonstrated 16.86 ± 1.07 nm wide tangled short fibers, with 
aggregates of 76.08 ± 2.98 nm in diameter. The aggregates seemed to grow over ten days, to 109.4 ± 
5.6 nm in width. The ACD/ChemSketch software determined the length of an individual AAP8 
molecule to be 3.35 nm. Therefore, the fiber width observed by AFM corresponds to more than one 
peptide molecule length. 
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Figure 3.2. Nanostructure of freshly prepared (A) AAP8, (B) AAP8-DEG, (C) DEG-AAP8-DEG, and 
ten- day-old (D) AAP8, (E) AAP8-DEG, (F) DEG-AAP8-DEG taken by tapping mode of Atomic 
Force Microscopy (AFM) on mica surface. All concentrations are 0.5 mg/ml. 
 
The dimension analysis of AAP8-DEG illustrated thinner fibers, 10.2 ± 0.61 nm in width, even 
though its molecule is longer than of AAP8, 4.52 nm, as predicted by ACD/ChemSketch software. 
Each fiber consists approximately two to three DEG-conjugated AAP8 molecules stacked together 
width-wise. It was shown that over ten days, the fibers only grew to about 13.53 ± 0.87 nm in width, 
and some of the fibers associated together and created bundles, 58.95 ± 3.99 nm in width. The DEG-
AAP8-DEG presented the most uniform fibrillar structures, whether the samples were fresh or had 
aged for ten days: the initial fibers had 8.21 ± 0.79 nm width with no trace of aggregation. After ten 
days, the average fiber width was 10.97 ± 0.87 nm and the fibers were in an oriented and parallel 
pattern. The dimension of a DEG-AAP8-DEG molecule calculated by ACD/ChemSketch was about 
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5.7 nm in length, longer than those of AAP8 and DEG-AAP8, but the resulting thinner fibers indicate 
the lower possibility of aggregation. In comparison with AAP8, the DEG-conjugated AAP8s were 
shown to spread on the mica surface more expansively and assembled in a more uniform fashion. 
Conjugating DEG to the peptide changes the nanostructures significantly, which can be interpreted by 
steric shielding of the fibrils by diethylene glycol and an increase in stability in aqueous solution [85]. 
 
Table 3.1. Dimensions of AAP8, AAP8-DEG, and DEG-AAP8-DEG assemblies at two time points. 
Heights and widths are obtained by Gwyddion software (Free SPM Data analysis software), and the 
widths are corrected with the above deconvolution method [152].  *F, Fibrillar assemblies; A, 
aggregates, B, bundles. 
 Fresh   10 Day   
 Shape* Width (nm) Height (nm) Shape
* Width (nm) Height (nm) 
AAP8 
F 16.86±1.07 0.69±0.06 F 17.06±2.02 1.21±0.21 
A 76.08±2.98 0.92±0.03 A 109.4±5.65 3.15±0.45 
AAP8-DEG F 10.2±0.61 0.74±0.06 
F 13.53±0.87 1.03±0.09 
B 58.95±3.99 2.16±0.35 
DEG-AAP8-DEG F 8.21±0.79 0.81±0.081 F 10.97±0.87 0.86±0.09 
 
3.3.1.2 Secondary Structure 
To further investigate the DEG-conjugation effect on peptide assemblies, secondary structures of 
peptide-DEG hybrids were determined by Fourier Transform Infrared (FT-IR) spectroscopy and 
Circular Dischroism (CD). All results showed greater β-sheet content in their secondary structures, 
where the β-sheet content increased when DEG was conjugated to the peptide sequence. FT-IR results 
indicated a strong peak at 1614-1622 cm-1, and CD spectra represented a strong negative peak at ~ 
210-215 nm.  The three main peaks in the amide I region are for the β-sheet (1614-1622 cm-1), α-helix 
(1650-1658 cm-1) and β-turn structure (1680 cm-1). From the FT-IR spectra obtained from AAP8, 
AAP8-DEG and DEG-AAP8-DEG, the dominant peak is at 1620 cm-1, which corresponds to the β-
sheet secondary structure. There is no clear peak observed for the α-helix or β-turn. The intensity of 
these peaks increased from AAP8 to AAP8-DEG to DEG-AAP8-DEG (Figure 3.3), which showed 
that the β-sheet content increased when DEG was conjugated to AAP8. This evidence pointed out that 
functionalization of the peptide with a DEG has a significant impact on its secondary structure and 
modulates its β-sheet content due to self-association by hydrogen bonding between β-strands[159].    
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(A) (B) 
  
 
Figure 3.3. Secondary structure determination by (A) FT-IR spectra, (B) Circular Dichroism spectra, 
(⎯ ) AAP8, (….) AAP8-DEG, (---) DEG-AAP8-DEG, 0.5 mg.ml-1 in Milli-Q water. 
 
3.3.1.3 Hydrophilicity and Critical Aggregation Concentration (CAC) 
Since PEG is considered a hydrophilic polymer, we hypothesized that conjugation of a short segment 
of PEG, such as DEG, to our relatively hydrophobic peptide, AAP8 with four phenol rings, would 
reduce hydrophobicity of the peptide. In order to determine hydrophobicity, we utilized a fluorescent 
probe, which can bind to hydrophobic compounds and, as a consequence, emits light. We used the 1-
anilino-8-Naphthalene Sulfonate (ANS) fluorescence probe, which emits light at 470 nm in a 
hydrophobic environment, whereas its emission wavelength in pure water is at 520 nm. Figure 3.4(A) 
shows the fluorescence spectra of the ANS probe in three different peptide solutions compared to in 
pure water. All spectra were normalized with light scattering of air at 360 nm, to correct the lamp 
fluctuations. The normalized fluorescence intensity of the ANS shows the following trend: 
AAP8≈AAP8-DEG>>DEG-AAP8-DEG>>H2O. Meanwhile, the peak position of ANS in pure water 
(inset) is observed at ~ 520 nm, whereas it shifts to ~ 470 nm for AAP8 and its DEG-conjugates. In 
addition, the fluorescence intensity of the ANS probe decreases upon DEG functionalization of 
AAP8. Among AAP8, AAP8-DEG, and DEG-AAP8-DEG, the last one shows the lowest 
fluorescence emission intensity, and is thus the least hydrophobic. As expected, conjugation of DEG 
on both sides enhances the hydrophilicity of AAP8 compared to one-sided conjugation, which 
explains the significant reduction in aggregation likely caused by hydrophobic residues. 
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Figure 3.4. (A)Hydrophobicity of (⎯ ) AAP8, (….)AAP8-DEG, (----) DEG-AAP8-DEG, (⎯ ) pure 
water. The inset is fluorescence control of ANS probe in water with absence of the peptide. The 
peptide concentration is 0.5 mg/ml and the ANS concentration is 10 µM. (B) CAC determination by 
ANS fluorescence probe.  
 
The same method was performed to determine critical aggregation concentration (CAC). Critical 
aggregation concentration (CAC) is a parameter to evaluate self-assembly strength. CAC is defined as 
the concentration of peptides that above that concentration the peptide aggregates are spontaneously 
formed. The lower CAC, the higher tendency to self-associate the system will have. In this study, the 
CAC of these three peptides were determined by (ANS) fluorescence assay. The fluorescence 
intensity of ANS probe does not change by increasing peptide concentration at low concentrations of 
peptide in pure water, however after a certain concentration, which we call it CAC, the fluorescence 
intensity of ANS increases significantly. AAP8 showed the lowest CAC amongst the DEG-
conjugated AAP8, and DEG-AAP8-DEG showed the highest. The observed values are: ~0.015, ~ 
0.06, and ~0.15 mg/ml for AAP8, DEG-AAP8, and DEG-AAP8-DEG, respectively (Figure 3.4). 
These values show that the CAC increases with DEG conjugation. With DEG conjugation, peptide 
becomes more hydrophilic, which means that more peptide chains would be necessary to form self-
assembled nanostructures increasing the minimum peptide concentration required (i.e. higher CAC). 
DEG functionalization facilitates peptide to self-assemble in more organized ways and avoids 
aggregation at low concentrations. As we observed from AFM images, DEG-AAP8-DEG does not 
show lateral aggregation even at high concentration (0.5 mg/ml), however, both AAP8 and AAP8-
DEG showed aggregation and tangled fibers. Therefore, DEG conjugation on both sides of AAP8 
provides the more controllable and stable structure.  
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3.3.2 DEG-functionalization Effect on Encapsulation of Hydrophobic Drug and Cellular 
Toxicity 
3.3.2.1 Ellipticine Encapsulation 
In the next step, we investigated the potential use of AAP8 and its DEG-conjugates as carriers for 
hydrophobic anticancer drugs. Ellipticine (EPT), an anticancer drug, has been used as a hydrophobic 
model drug in our past drug delivery research [24,26,132,146]. Ellipticine (EPT), a cytotoxic plant 
alkaloid, is known as a polycyclic molecule that intercalates between DNA base pairs, inhibits 
Topoisomerase II, and induces G2/M phase cell cycle arrest [160]. The fluorescence properties of 
ellipticine make it easy to characterize for encapsulation and release of the drug. Despite of these 
advantages, clinical tests on ellipticine were suspended due to the drug’s lack of target-ability, and 
accumulation in undesired sites, which can be explained by insolubility of ellipticine in aqueous 
media [161]. The challenges regarding delivery of hydrophobic compounds highlight a strong need 
for more effective delivery systems. We previously showed the great potential of AAP8 to deliver 
ellipticine into cancer cells [26]. However, AAP8 without modification might be challenging for 
further in vitro and in vivo tests due to its aggregation tendency and cytotoxicity. The therapeutic 
efficiency of drug carriers may be limited by particle recognition by macrophages of the mononuclear 
phagocyte system (MPS) and possibility of rapid elimination from the bloodstream after intravenous 
injection. Therefore, the current modification of AAP8 by DEG shows means to overcome 
aggregation and may improve its drug delivery potentialities [157,162,163]. 
 
Table 3.2. Complexes characterization. 
 
Zeta Potential 
(mV) pH EPT State 
AAP8-EPT 36.6±0.41 5.0±0.1 Protonated  
AAP8-DEG-EPT 30.46±0.64 5.1±0.1 Protonated  
DEG-AAP8-DEG-EPT 30.86±0.38 5.36±0.03 Protonated  
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Figure 3.5. Nanostructure of freshly prepared ellipticine complexes with (A) AAP8, (B) AAP8-DEG, 
(C) DEG-AAP8-DEG taken by tapping mode of Atomic Force Microscopy (AFM) on mica surface. 
All concentrations are 0.5 mg/ml for peptides and 0.1 mg/ml for ellipticine. 
 
 
Preliminary characterization has been performed on the peptide and drug complexes to investigate 
the differences between complexes formed from modified and non-modified AAP8. Table 3.2 
summarizes the data for three complexes. Emission spectra of ellipticine collected with the 
spectrofluorometer showed the protonated state of ellipticine (peak at ~ 520 nm) for all AAP8-EPT, 
AAP8-DEG-EPT and DEG-AAP8-DEG-EPT complexes at 0.5mg/ml peptide and 0.1mg/ml 
ellipticine concentration. The difference between the current study and reference [26], regarding 
formation of ellipticine in solution, is due to the age of complexes in the experiments. Previously, 
AAP8 was added to EPT and mechanically stirred at 900 rpm for 24hr. However, in the current study, 
AAP8 was added to EPT and the complexes were made through the probe sonication method at a 
power of 6-8 W for 5-10 min and freshly analyzed with fluorescence spectroscopy and applied for 
cytotoxicity study. In this case, the complex product is a transparent yellow color, similar to that of 
the EAK-EPT complexes reported in Reference [24]. As it was shown in Figure 4 [24], the presence 
of protonation and crystalline states of ellipticine is time-dependent. For the freshly prepared 
complexes, protonated ellipticine is dominant, whereas after ~ 10hr, the crystalline form of ellipticine 
dominates in solution. Since in the current study the focus is not studying ellipticine state over time in 
solution and only freshly prepared samples were used in the experiments, the protonated state of 
ellipticine in AAP8-EPT complexes is reported. Note that the protonation of ellipticine usually occurs 
at higher peptide concentrations and relatively low pH (i.e. ≤ 5), lower than ellipticine pKa (6.0) 
[147]. The pH of freshly prepared AAP8 was measured as 4.3, which provides an acidic environment 
for the protonation of ellipticine. Since ellipticine is stabilized in solution in protonated form, it is 
  
  54 
expected to have positively charged species. This was confirmed with zeta potential measurements 
for complexes and no significant difference was observed from DEG-conjugated and non-conjugated 
AAP8s in complex with ellipticine. Since the zeta potential for all three complexes is more positive 
than +30 mV, they are normally considered stable particles in solution.  
 
Table 3.3. Dimensions of ellipticine complexes with AAP8, AAP8-DEG, and DEG-AAP8-DEG 
assemblies. Heights and widths are obtained by Gwyddion software (Free SPM Data analysis 
software), and the widths are corrected with the above deconvolution method [152].  Hydrodynamic 
diameter (DH) is calculated based on L and w [164]. 
  Width (nm) Length (nm) Height (nm) (DH) 
AAP8-EPT 126.11±4.94 339.36±8.57 5.398±0.325 212.91 
AAP8-DEG-EPT 98.79±3.369 283.891±1.374 1.21±0.106 - 
DEG-AAP8-DEG-EPT 74.07±2.044 472.17±27 0.819±0.103 - 
 
The interaction between hydrophobic drug, ellipticine and AAP8 peptide is based on hydrophobic 
interactions between phenylalanine side chain and ellipticine. The four F residues can provide strong 
hydrophobic interactions assisted by π-π stacking to stabilize nanostructure and consequently interact 
with ellipticine. This hydrophobic interaction between peptide and ellipticine remains constant by 
modifying AAP8 with DEG; however, DEG helps stabilizing the complex better in aqueous solution. 
Non-modified AAP8 tends to aggregate overtime when it is in complex with ellipticine in aqueous 
environment, whereas DEG-modified AAP8s provide more hydrophilic environment and assist 
stabilized fibers in complex with ellipticine in aqueous solution. AFM images illustrated the above 
hypothesis, where DEG-modified AAP8 suppress aggregation of AAP8 in complex with ellipticine 
and stabilize ellipticine more efficiently in aqueous solution. AAP8 in complex with ellipticine 
formed cylindrical shape particles with approximate hydrodynamic diameter of  ~212 nm, which is 
comparable with DLS results (Table 3.3). However, both DEG-modified AAP8s in complex with 
ellipticine formed fiber structures (Figure 3.5). The nanostructure of peptide-EPT complexes 
observed in AFM images showed wider fibers compared to those formed in the peptide nanostructure, 
as shown in Figure 3.2. The mechanism of the complexation between peptide and ellipticine is not 
fully understood. As discussed in Reference [26], a model has been proposed for AAP8 nanofibers 
via amino acid pairing, where peptide molecules are aligned in anti-parallel fashion to form 
nanofibers with a width equals to the length of a peptide chain or a multiple of the length. This may 
be seen in Figure 3.2 and Table 3.1. However, in peptide-EPT complexes, this alignment is disrupted; 
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as a result, wider nanofibers may form, perhaps because of potential multiple interactions between 
peptide and EPT molecules (e.g., ionic, hydrogen bonding and hydrophobic interactions). It is 
observed from AFM images that the height of nanofibers does not increase significantly. One may 
postulate that fiber growth in peptide-EPT complexes is not isotropic, but the reason is unclear and it 
requires more investigation. The average hydrodynamic diameter of particles was calculated based on 
the Equation 3.1 for cylindrical shape particle with length of L and diameter (width) of w observed by 
AFM images. This equation is applied for AAP8 and ellipticine complex particles, since they formed 
cylindrical shapes, whereas this equation cannot be applied for fibril structures [164]. 
 
Equation 3.1- Correlation between Hydrodynamic diameter and length and width of cylinder 
observed by AFM 
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3.3.2.2 Cytotoxicity 
Cytotoxicity of unmodified AAP8 and DEG-modified AAP8s was evaluated by MTT assay on non-
small cells lung carcinoma (NSCLC), i.e., A549 cell line, for 24 and 48 hr incubation times. Cells 
treated with AAP8 showed around 30-40% cytotoxicity. However, cells treated with both DEG 
modified AAP8 in one end and two ends showed lower cytotoxicity (0-5%). DEG-functionalization 
of AAP8 has a clear beneficial effect on the cytotoxicity of the peptide, rendering it completely 
nontoxic for all concentrations evaluated (up to 100 uM) (Figure 3.6(A)).  
Anticancer activity of ellipticine encapsulated with unmodified AAP8 and modified AAP8s were 
examined on A549 cell line for 24 hr and 48 hr incubation times by MTT assay. Results presented 
that the cytotoxicity of ellipticine in complex with modified AAP8s are lower than that of the 
corresponding unmodified AAP8, which can be understood by our two main observations: first, 
cytotoxicity of AAP8 compared to modified AAP8s is higher, which consequently may induce higher 
cytotoxicity together with ellipticine; second, the modified AAP8s, i.e., AAP8-DEG and DEG-AAP8-
DEG, can stabilize ellipticine and suspend it longer in media, resulting in the slower release of 
ellipticine from the complex and delay in drug contact with adhesive cells, as compared to AAP8-
ellipticine complexes.  This is observed for 24 hr incubation time (Figure 3.6(B)). Despite the fact 
that complexes of modified AAP8s and ellipticine showed lower cytotoxicity to cancer cells than 
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corresponding unmodified AAP8 complexes at 24 hr treatment time, the cytotoxicity of the 
complexes is higher than the ellipticine control at highest concentration (100 µM). This indicates that 
both modified and unmodified AAP8 carriers are more effective to deliver ellipticine and cause 
cytotoxicity than the drug control. This is primarily because ellipticine can be stabilized in AAP8 and 
DEG-conjugated AAP8s in aqueous media.  
(A) (B) 
  
(C) 
                         
Figure 3.6. The cytotoxicity test of (A) controls (negative control, AAP8, AAP8-DEG, and DEG-
AAP8-DEG (1.07-109 µM) for 24 hr incubation time; ellipticine in complex with above peptides and 
in pure water, (B) for 24 hr incubation time and (C) for 48 hr incubation time. The maximum 
ellipticine concentration was 100 µM diluted serially up to 1.56 µM. The peptide concentration ranges 
from (~ 1-100 µM). Note that the molar ratio between ellipticine and peptide is kept constant at 1:1. 
DMEM corresponds to non-treated cells. Error bars represent for standard error of means in 95% 
confidence interval. 
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However, the cells were treated with the complexes for 48 hr showed a reverse trend for the 
cytotoxicity results for modified and unmodified AAP8 in complex with ellipticine, up to 50-100 µM 
for both peptide and ellipticine. The cytotoxicity of the complexes showed the following trend: DEG-
AAP8-DEG-EPT>AAP8-DEG-EPT>AAP8-EPT. This can be explained by aggregation of particles 
in AAP8 and ellipticine solution overtime and settling down in the cell containing wells without 
penetrating to cell membranes, whereas in shorter incubation time, within 24 hours, the possibility of 
aggregation is lower, which allows penetration into cell membranes and cause more toxicity. On the 
other hand, the cytotoxicity of the modified AAP8s and ellipticine complexes improved overtime as 
stabilized ellipticine in the solution will eventually reach the cells, causing higher cytotoxicity (Figure 
3.6(C)). This phenomenon happened only for higher concentrations of complexes of DEG-modified 
AAP8 and ellipticine (50-100 uM of peptide and ellipticine), i.e., up to 4 times dilution, and it is 
expected, as the difference in aggregation between the modified and unmodified peptides is 
significant only at relatively high concentrations.  
The effect of DEG-conjugation was observed on cellular uptake of ellipticine through fluorescence 
microscopy. As it was mentioned previously, EPT has an intrinsic fluorescence property that can be 
detected under green light (520 nm emission). The fluorescence intensity illuminated from the A549 
cells treated with AAP8-EPT is the lowest among other DEG-conjugated AAP8 and EPT complexes, 
indicating the efficiency of the DEG delivering EPT into the cancer cells (Figure 3.7).  
 
Figure 3.7. Cellular uptake of EPT carried by (A) AAP8, (B) AAP8-DEG, and (C) DEG-AAP8-DEG 
after 2hr incubation with the complexes.  
3.3.3 Effect of DEG-conjugation on Macrophages  
So far, DEG-functionalization showed positive results on aggregation control, nanostructure 
formation, hydrophobic drug encapsulation, and anticancer activity. Here, effect of DEG-conjugation 
was studied on interaction with macrophages as one of the acute immune system components. 
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Macrophages are responsible to eliminate foreign materials from body through phagocytosis 
mechanism. If the foreign nanomaterials are recognized by macrophages innate inflammation 
responses will be observed that can be observed in vitro such as macrophage toxicity, morphology 
change and other indications such as level of induced nitric oxide synthase (iNOS). iNOS expression 
is induced by immune stimulations such as lipopolysaccharide (LPS) in mammalian macrophages 
[165,166].  
(A) 
 
(B) 
 
Figure 3.8. (A) Cellular viability of the macrophages treated by AAP8, AAP8-DEG, and DEG-AAP8-
DEG (0.001-0.1 mM) for 48 hr. (B) Morphology of the macrophage cells after exposure to the 
peptides. Arrows point at the activated feature of macrophages. Treatments: a: untreated, b: LPS, c: 
AAP8, d: AAP8-DEG, e: DEG-AAP8-DEG (peptide concentrations are 0.1 mM) 
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The cell viability of the macrophages was evaluated after treated with the AAP8 and DEG-
conjugated AAP8s peptides. First, all three peptides showed very negligible cytotoxicity towards 
macrophages after 48 hr treatment. Second, macrophage cellular toxicity decreased about ~ 10 and 
30% when treated with DEG-AAP8 and DEG-AAP8-DEG, respectively (Figure 3.8 A). This result 
indicates the stealth properties of DEG for the peptide to protect it from phagocytosis. In addition, 
morphology of the cells has been changed after treated with AAP8, whereas the morphology of the 
cells treated with DEG-conjugated AAP8 stayed almost intact for the same less phagocytosis reason. 
LPS was applied on cells as a positive control sample, which is known as one of the main stimulators 
of macrophages. The cells exposed to LPS showed the most extreme morphological change (Figure 
3.8 B). 
3.4 Conclusions 
Nanostructural characterization of the peptide AAP8 and diethylene glycol conjugated AAP8 
indicates that functionalizing the short self-assembling peptide with diethylene glycol (DEG) is an 
effective means to enhance β-sheet content in secondary structure and modulate the nanostructure to 
an aligned and uniform fibrillar configuration, minimizing random aggregation. The unmodified 
AAP8 showed significant aggregation over time, whereas DEG-conjugated AAP8s, particularly 
DEG-AAP8-DEG overcame the aggregation problem. We also observed higher hydrophilicity, in 
particular, when DEG was conjugated to both ends of AAP8. The improvement of the peptide self-
assembly upon DEG conjugation supports the hypothesis that conjugating a short chain of PEG to 
peptides helps obtain more uniform and organized nanostructure, increase β-sheet content and 
enhance solubility in aqueous solution, which all lead to low lateral aggregation. These peptides 
showed reduced cytotoxicity towards non-small cells lung carcinoma and macrophages as compared 
to unmodified AAP8, which is considered an advantage for drug carriers. Both modified and 
unmodified AAP8s showed impressive capability to stabilize the hydrophobic anticancer drug 
ellipticine in aqueous solution. All three complexes, AAP8, AAP8-DEG and DEG-AAP8-DEG with 
ellipticine, exhibited higher cytotoxicity against A549 cells than ellipticine control, indicating great 
capability of peptide-based carriers for stabilizing and delivering of ellipticine. The viability of the 
cells treated with both DEG-modified AAP8s in complex with ellipticine is higher than corresponding 
AAP8 and ellipticine complexes after 24 hr incubation time. This may be due to the delay contact of 
ellipticine, when formed complex with DEG-modified AAP8s, with adherent cells. After 48 hr 
incubation time, DEG-modified AAP8s have become more effective than unmodified AAP8 in 
complex with ellipticine, possibly due to aggregation associated with AAP8 and ellipticine in aqueous 
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solution over a relatively long time. The results reported here provide a means to overcome critical 
issues in aggregation and inherent cytotoxicity associated with the use of biomaterials, and pave the 
way to further design of functionalized biomaterials for improved drug delivery applications. 
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Chapter 4‡ 
Self/Co-Assembling Peptide, EAR8-II, as a Potential Carrier for a 
Hydrophobic Anticancer Drug Pirarubicin (THP)-Characterization 
and in vitro Delivery 
 
Abstract  
A short ionic-complementary peptide, EAR8-II, was employed to encapsulate the hydrophobic 
anticancer drug pirarubicin (THP). EAR8-II was designed to inherit advantages from two previously 
introduced peptides, AAP8 and EAK16-II, in their self/co-assembly. This peptide is short, simple, 
and inexpensive to synthesize, while possessing a low critical assembly concentration (CAC). The 
choice of alanine (A) residues in the peptide sequence provides moderate hydrophobic interactions, 
causing a minimal degree of aggregation, compared with other more hydrophobic residues. EAR8-II 
is an ionic-complementary peptide, similar to EAK16-II, can self/co-assemble with hydrophobic 
compounds such as THP, and forms a stable fibular nanostructure in aqueous solution. 
Physiochemical properties and cellular activities of the EAR8-II and THP complexes are evaluated 
and show dependency on the peptide-to-drug ratio. The complex at the peptide-to-drug mass ratio of 
5:1 provides a stable solution, uniform nanostructure, and highly effective anticancer activity against 
various cancer cell lines. This work forms the basis for detailed studies on EAR8-II and THP 
formulations in vitro and in vivo, for future development of peptide-based delivery systems for 
hydrophobic anticancer drugs.  
 
Key Words: ionic-complementary; self/co-assembly; encapsulation; stability; anticancer activity   
                                                      
‡ This chapter is based on a paper “Sadatmousavi, P.; Chen, P. Self/Co-Assembling Peptide, EAR8-II, 
as a Potential Carrier for a Hydrophobic Anticancer Drug Pirarubicin (THP)—Characterization and in 
vitro Delivery. Int. J. Mol. Sci. 2013, 14, 23315-23329.” 
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4.1 Introduction 
In the last chapter, I discussed a strategy for designing amino-acid-pairing peptides, and their 
potential for drug and gene delivery [26,167]. A short amino-acid-pairing peptide (AAP8), with a 
sequence of Ac-FEFQFNFK-NH2, was introduced and showed promise for delivering the anticancer 
drug Ellipticine. Despite its practicability in anticancer drug encapsulation, AAP8 shows 
uncontrollable aggregation, which is not favorable for many biological applications. Therefore, a 
DEG-functionalization procedure was explored as a strategy to improve the multi-functionality of the 
nanocarrier by avoiding aggregation and to enhance bioavailability of the drug delivery system [168]. 
The current work focuses on a new amino-acid-pairing peptide called EAR8-II for drug delivery.  
This peptide, like other ionic-complementary peptides, can spontaneously organize itself into a 
nano/micro structure that stabilizes hydrophobic therapeutic molecules and further facilitates passive 
targeting [3,24]. Additional advantages of using such a peptide as a carrier for drug delivery are the 
ease with which it can be synthesized and functionalized to incorporate long circulation, active 
targeting, and low immunogenic properties [23]. In particular, EAR8-II has the benefit of two well-
known amino-acid-pairing peptides, EAK16-II [24] and AAP8 [26]. The design strategy exploits the 
ionic-complementarity of EAK16-II and the short sequence of AAP8. The shorter sequence of the 
peptide is the easier and less expensive synthesis procedure, and alternative charged residues in the 
sequence provide spontaneous self/co-assembly of the peptide with hydrophobic compounds such as 
Ellipticine and Pirarubicin.  
EAR8-II (Ac-AEAEARAR-NH2) is a unique amphiphilic structure (Figure 4.1) of eight amino 
acids, including Glutamic acid (E), Alanine (A), and Arginine (R). Negatively charged Glutamic acid 
and positively charged Arginine residues are positioned in the first and second block of the sequence, 
providing ionic-complementarity. Alanine residues with hydrophobic side chains are located 
alternatively through the sequence, offering hydrophobic properties to the peptide as a whole. Self/co-
assembly characteristics of this peptide arise from its ionic pairs (E and R), and hydrophobic pairs (A) 
that both promote self-assembly in peptides as well as co-assembly with hydrophobic molecules such 
as Pirarubicin (THP).  
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(A) 
 
(B) 
 
(C) (D) 
  
Figure 4.1. Molecular structure of (A) EAK16-II (Ac-AEAEAKAKAEAEAKAK-NH2) [24]; (B) 
AAP8 (Ac-FEFQFNFK-NH2) [26]; (C) EAR8-II (Ac-AEAEARAR-NH2). The red and blue box 
regions indicate the charged and hydrophobic residues, respectively. E: Glutamic acid (Glu); A: 
Alanine (Ala); K: Lysine (Lys); R: Arginine (Arg), F: Phenylalanine (Phe); Q: Glutamine (Glu); N: 
Asparagine (Asn); and (D): Pirarubicin (THP) [169]. 
 
Pirarubicin (4-O-tetrahydropyranyladriamycin, or THP), a derivative of doxorubicin, is an 
anthracycline antibiotic, and acts against colorectal cancer [170], liver metastases [171], breast cancer 
[172], acute leukemia, and malignant lymphomas [11]. It has been reported that THP has fewer 
cardiotoxic effects than doxorubicin [173]. THP is applied as an anticancer drug model in the current 
study for the following purposes: intrinsic fluorescence property, hydrophobicity (Figure 4.1), 
promising anticancer activity, and deleterious side effects in clinical trials [174]. The fluorescence 
property of THP enables us to monitor the interaction of this drug with peptides and detect it in 
different physiological environments [169,175,176]. The low solubility of THP in aqueous 
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environments and its possible side effects in humans highlight the important role of a delivery system 
for THP. Our self/co-assembling peptide-base carriers have shown characteristics to overcome 
problems associated with THP delivery.  
The main objective of the current study is to find the effective peptide-to-drug ratio for high 
encapsulation efficiency, drug stabilization, and effective anticancer activity. The techniques applied 
are fluorescence spectroscopy, dynamic light scattering, and cellular toxicity. Emission fluorescence 
intensity is correlated proportionally to the concentration of encapsulated THP. Dynamic light 
scattering is used to determine the stability of THP in peptide solutions by measuring the average 
particle sizes and surface charge of peptide-drug complexes at different ratios. Anticancer activity and 
cellular uptake of the complexes against two cancer cells (e.g., A549 and HeLa) are also evaluated to 
determine the effect of peptide-to-drug ratio on therapeutic efficiency of the complex. This work 
provides comprehensive knowledge of the formation of peptide and drug complexes and their cellular 
toxicity at different ratios, paving the way for future cellular, immunological and animal studies in the 
development of a self/co-assembly peptide-based delivery system for hydrophobic anticancer drugs. 
Self/co-assembly peptide-based carriers have many advantages over other delivery systems including 
biocompatibility, low immunogenicity, and capability of sequence alteration based on the required 
interactions with therapeutic agents. 
 
4.2 Experimental 
4.2.1 Materials 
The EAR8-II (Ac-AEAEARAR-NH2) peptide with a molecular weight of 913.94 g/mol and  
a purity of >75% was synthesized in our laboratory by the solid-phase peptide synthesis (SPPS) 
method [177]. The N-terminus and C-terminus of the peptides were protected by acetyl (COOCH3) 
and amine (NH2) groups, respectively. The molar mass of this peptide was verified by Matrix-assisted 
laser desorption ionization time of flight mass spectroscopy (Q-TOF Ultima Global, Waters, Milford, 
MA, USA). The anticancer drug Pirarubicin (THP) (AB2000083), with the commercial name of THP 
and molecular weight of 627.63 g/mole, was purchased from ABBLIS (Houston, TX, USA).  
All cell lines, purchased from Cedarlane (Burlington, ON, Canada), were used in the current study 
and cultured in their respective culture medium as follows: Human Cervical Adenocarcinoma:  
HeLa (CCL-2) in Eagle’s Minimum Essential Medium (EMEM) (ATCC30-2003), Human lung 
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cancer: A549 (CCL-185) in F-12 medium (ATCC30-2004). All medium solutions were prepared with 
10% fetal bovine serum (FBS-F1051).  
4.2.2  Methods 
4.2.2.1 Sample Preparation 
EAR8-II peptide solutions in the concentration range of 0.05–2 mg/ml (0.0547–2.188 mM) were 
prepared by dissolving peptide lyophilized powder in Milli-Q (18.2 MΩ) water (EMD Millipore, 
Billerica, MA, USA) followed by bath sonicating for 10 min. Freshly prepared peptide solutions were 
added to THP to reach fixed [THP] concentrations at 0.1 mg/ml (0.159 mM), followed by mechanical 
stirring at 900 rpm for 24 h. 
4.2.2.2 Material Characterizations Methods 
Material characterizations techniques such as dynamic light scattering method for estimating size and 
zeta potential (3.2.2.6), Fourier transformed IR (FT-IR) spectroscopy for secondary structure analysis 
(3.2.2.4), and atomic force microscopy (AFM) for nanostructure evaluation (3.2.2.2) in this chapter 
followed the same procedures as presented in Chapter 3.  
4.2.2.3 Steady-state Fluorescence Emission  
The THP fluorescence emission spectra were acquired on a photon technology international 
spectrofluorometer (Type QM4-SE, London, ON, Canada) with a continuous xenon lamp as the light 
source. The emission spectra were collected in the wavelength range of 500–800 nm, while samples 
were excited at 480 nm. The maximum emission peak of THP is at a wavelength of 590–600 nm. The 
excitation spectrum was collected in the wavelength range of 200–500 nm. The maximum excitation 
peak of THP is at wavelength of 470–490 nm. The excitation and emission slit widths of the 
monochromators, which control the amount of light coming in and out of the sample chamber, were 
set at ½ and 2 turns to yield a spectral resolution of 1 and 4 nm, respectively. The fluorescence 
intensity at 590 and 480 nm for emission and excitation were obtained by taking the average of 
twenty points around each value, respectively. Each fluorescence spectrum was divided by lamp 
intensity to account for eventual lamp fluctuations [132]. The normalized fluorescence intensity for 
both emission and excitation spectra at 590 and 480 nm was plotted for various peptide-to-drug ratios. 
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4.2.2.4 Cellular Toxicity and Uptake  
Two human cancer cell lines (A549 and HeLa) at 104 cells per well concentrations, were seeded in 
96-well plates, followed by treatment with different peptide-drug complex ratios for 24 h. Cellular 
toxicity experiments were performed with sensitive colorimetric assay called Cell counting kit-8 
(CCK-8) (Dojindo Molecular Technologies, Inc. Burlington, ON, Canada). CCK-8 contains highly 
water-soluble tetrazolium salt (WST-8), which is reduced by dehydrogenase activities in cells to give 
the yellow color of the formazan dye, which is soluble in culture media. The amount of formazan dye 
is measured by absorption (O.D.) at 450 nm, which is directly proportional to the number of living 
cells.  
Cellular uptake of THP was also carried out by spectroscopy, exploiting the intrinsic fluorescence 
properties of THP (excitation wavelength: 480 nm, emission wavelength: 590 nm). Cells were plated in 
12-well plates, with concentrations of 2 × 105 cells per well. They were then treated with peptide-drug 
complexes for 2–4 h. For spectroscopy with the PTI system, after 6 h incubation at 37 °C, the cells 
were lysed with 1% SDS in Tris-EDTA, followed by probe sonicating to complete cell lysis. The 
lysed cell suspensions were excited at 480 nm, and emission spectra were collected from 500 to 800 
nm to quantify the THP content of the treated cells. Each spectrum was corrected by spectra of lysed 
untreated cells. The amount of drug uptake is directly proportional to the emission peak intensities. 
Higher fluorescence emission intensity indicates higher cellular uptake of THP. 
4.3 Results and Discussion 
 The details of the complexation between EAR8-II and Pirarubicin (THP), peptide concentration 
effect on the complex formation, cellular uptake, and anticancer activity of the formulation are 
reported here.  
4.3.1 Effect of Peptide to Drug Ratio on Complex Formation 
EAR8-II, similar to other ionic-complementary peptides such as EAK16-II, was observed to  
self-assemble into a dense fibular nanostructure with an average width and height of 10 and 15 nm, 
respectively. However, there was evidence of large aggregates among the fibers, which occurred due 
to the high concentration of peptide intermolecular interactions of amino acids. The hydrodynamic 
diameters of these aggregates were measured at ~500 nm resemblance to the particle size distribution 
observed by DLS, but fibers were in the range of one or two peptide monomers wide. Interestingly, 
EAR8-II combined with the hydrophobic drug THP forms a fibular bundle nanostructure with a 
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hydrodynamic diameter of 712.4 ± 17.43 nm, indicating molecular interactions between the peptide 
and the drug called “co-assembly”. The uniformly shaped fibular structure of the peptide-drug 
complex provides stability and prevents uncontrollable aggregation in an aqueous solution (Figure 
4.2).  
(A) (B) 
  
(C) (D) 
  
Figure 4.2. Nanostructure of (A) EAR8-II and (C) EAR8-II-THP complex by tapping mode atomic 
force microscopy; Intensity-based particle size distribution of (B) EAR8-II and  
(D) EAR8-II-THP complex in aqueous solution by dynamic light scattering. EAR8-II concentration is 
0.5 mg/ml, and THP concentration is 0.1 mg/ml. 
 
The absorbance peaks from the FT-IR spectrum at 1614–1622 and 1630–1637 cm−1 correspond  
to β-sheets, and peaks at 1650–1658 and 1548 cm−1 correspond to α-helical secondary structures.  
As shown in Figure 4.3, EAK16-II formed β-sheets dominantly, and AAP8 formed a mixture of β-
sheets and α-helices. However, EAR8-II showed stronger formation of α-helical structures than the 
other two self-assembling peptides, probably due to the length of peptide, because intramolecular 
interactions causing a helical structure in short sequences are stronger than the ones in longer 
sequences. The FT-IR spectrum collected from the complex containing EAR8-II and THP illustrated 
a significant increase in absorption intensity at wavenumbers corresponding to α-helical secondary 
(1654 and 1548 cm−1) structures, compared to the spectrum collected from the peptide solution. The 
higher absorption intensity in the FT-IR spectrum implies higher amounts of corresponding secondary 
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structures. The helical fibular bundle structures formed in EAR8-II-THP complexes demonstrate the 
strong interactions between the peptide and drug to form an organized nanostructure. 
 
 
 
Figure 4.3. Absorbance spectrum of (–) EAK16-II; (–) AAP8; (–) EAR8-II; and  
(–) EAR8-II-THP complex collected by FT-IR presenting secondary structures. 
 
To determine a suitable concentration of required EAR8-II for THP encapsulation, different 
concentrations of EAR8-II, in a range of 0.05–1.0 mg/ml, were prepared and combined with THP at 
0.1 mg/ml concentration in aqueous solution. Solubility of THP in water is very low, whereas it  
can be dissolved and stabilized in an EAR8-II solution at a minimum concentration of 0.2 mg/ml.  
As illustrated in Figure 4.4 (A), at lower EAR8-II concentrations (0.05–0.1 mg/ml), THP molecules 
were not fully dissolved, and crystalline THP particles floated in the solution. However, at higher  
EAR8-II concentrations (0.2–0.6 mg/ml), THP molecules were fully dissolved, and consequently,  
a clear-transparent solution of the peptide-drug complexes formed. At much higher peptide 
concentrations (above 0.6 mg/ml), THP molecules were still fully soluble, but the excess amount of 
EAR8-II produced a cloudier solution, with clearly a higher particle size distribution. Note that 
amphiphilic features of EAR8-II, including the ionic and hydrophobic residues, stimulated binding 
with hydrophobic molecules of THP through protonation of NH2 to NH3+ in THP molecules and 
hydrophobic interactions between alanine residues and aromatic rings in the THP structure. Figure 4.1 
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shows the hydrophobic and hydrophilic regions of EAR8-II peptide, as well as protonation of the 
amine group in THP. Both ionic and hydrophobic interactions are the possible main interactions of 
EAR8-II and THP, i.e., the protonation of THP in an acidic EAR8-II solution and hydrophobic 
interaction between THP and hydrophobic side chains of EAR8-II are the dominant forces in 
complexation of EAR8-II-THP. 
To evaluate the characteristics of the complex formation, the change in size, pH, surface charge, 
and the THP fluorescence of the peptide-drug complex was monitored at different peptide 
concentrations. Increasing the concentration of EAR8-II made the THP become more soluble and 
stable in the solution. The average particle size in these complexes measured by dynamic light 
scattering (DLS) presented a size increase of up to [EAR8-II] = 0.3 mg/ml, followed by stabilization 
of the particles in the smaller range of hydrodynamic diameter ~500–700 nm, where at higher [EAR8-
II] = 0.8–1 mg/ml, the solution become unstable with larger particles (Figure 4.4). At low 
concentrations of EAR8-II, non-soluble THP molecules were visible by the naked eye, and the 
solutions were cloudy. At concentrations of EAR8-II above 0.2 mg/ml, a uniformly suspended 
complex formed, where THP was fully dissolved. At a very high concentration of EAR8-II (1.0 
mg/ml), peptide fibers appeared to aggregate, and the diameter measured by DLS showed a 
significant size increase. 
The surface charge and the pH of the complex were also affected by concentration of EAR8-II. 
EAR8-II has an isoelectric point of ~6.55, in which at lower pH, the net charge of the peptide in 
aqueous solution is positive. Results showed that when the peptide concentration was increased, the 
pH of the solution decreased from pH 5.5 to 3.5 at a concentration of 0.05-1 mg/ml, owing to the 
higher [H+] at higher peptide concentrations. Since THP has a pKa of ~7.3 (pyridine-like nitrogen) it 
can be protonated in a weakly acidic environment. Consequently, acidic EAR8-II produced 
protonation of THP at higher peptide-to-drug ratios and led to more positive zeta potential values 
(Figure 4.5). Basically, an acidic environment provided higher [H+], and accordingly a higher positive 
surface charge reflected in zeta potential values. In Figure 4.5, the zeta potential values increased with 
increasing peptide concentration in the complex. Zeta potential values reached a plateau at EAR8-II 
concentrations above 0.5 mg/ml, indicating saturation of the positive charge on the surface at high 
peptide concentrations. Note, negatively charged glutamic acid residues in the peptide sequence may 
also help to stabilize the protonated THP. The high zeta potential values at very low peptide 
concentrations did not follow the above trend, due to the presence of non-stabilized protonated THP 
on the surface.  
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(A) 
 
(B) 
 
Figure 4.4. (A) Appearance of complexes formed by EAR8-II and THP and different  
EAR8-II:THP mass ratios. (From left to right: THP in water, 1:2, 1:1, 2:1, 3:1, 5:1, 6:1, 8:1, 10:1 mass 
ratios); (B) Intensity-base average hydrodynamic diameter of EAR8-II-THP complexes at fixed 
[THP] = 0.1 mg/ml. Error bars are standard deviation ( i.e. < +/- 3%) 
 
 
Figure 4.5. Zeta potential and pH of complex at fixed [THP] = 0.1 mg/ml and varied [EAR8-II]. 
0 
200 
400 
600 
800 
1000 
1200 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
Av
er
ag
e 
 S
iz
e 
(d
.n
m
) 
[EAR8-II] mg/ml 
Intensity-base Ave 
Size (d.nm) 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
14.00 
16.00 
18.00 
0.00 
1.00 
2.00 
3.00 
4.00 
5.00 
6.00 
7.00 
8.00 
0.00 0.20 0.40 0.60 0.80 1.00 
Ze
ta
 P
ot
en
tia
l (
m
V)
 
pH
 
[EAR8-II] mg/ml 
pH Zeta Potential 
  
  71 
 
The amount of protonated THP in EAR8-II is also determined by measuring the fluorescence 
intensity of the excitation and emission by THP at different EAR8-II concentrations. Protonated  
THP absorbs light at 480 nm, and emits light at 590–600 nm. Normalized fluorescence intensity for 
both the excitation and emission spectra is proportional to the concentration of protonated THP 
stabilized in the peptide solution. Although the initial concentration of THP was constant in each 
complex, the amount of protonated THP varied due to the dependency of the THP encapsulation 
efficiency on peptide concentration. As shown in Figure 4.6, when peptide concentration increased, 
the THP fluorescence intensities increased, and plateaued at peptide concentrations above 0.5 mg/ml. 
At lower peptide concentrations, substantial amounts of non-stabilized THP were present in the 
solutions, and the fluorescence intensities were significantly low, whereas at higher peptide 
concentrations where all the THP molecules were stabilized in the peptide aqueous environment, 
higher fluorescence intensities were collected. Our results showed that the minimum concentration of 
peptides required to fully encapsulate THP was ~0.5 mg/ml. 
 
Figure 4.6. Normalized fluorescence emission and excitation intensities from EAR8-II-THP 
complexes at fixed [THP] = 0.1 mg/ml and varied [EAR8-II]. 
 
4.3.2 Cytotoxicity and Cellular Uptake of the Peptide-Drug Complexes 
So far, I have illustrated that EAR8-II can stabilize THP in protonated form in aqueous solutions. It is 
expected that, due to stability and the peptide-to-drug mass ratio, different anticancer activity against 
cancer cells will be obtained [24,178]. 
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Here, a series of peptide-to-drug mass-ratio complexes at a constant THP concentration of  
0.1 mg/ml and EAR8-II at a range of concentrations of 0.05-1 mg/ml were employed to investigate 
cellular uptake and toxicity against two cancer cell lines (HeLa and A549). Cellular viability profiles 
for both HeLa and A549 cells at different ratios followed a similar trend, where the cell viability of 
A549 was relatively higher than that of HeLa, indicating more sensitivity of HeLa cells toward  
EAR8-II-THP complexes. In the absence of peptide in the complex, THP has been shown to induce 
non-significant cellular toxicity against both cell lines. Whereas, when EAR8-II stabilized THP in 
aqueous solution, cellular toxicity of both cells increased significantly. Due to the instability of the 
THP molecules in aqueous solution they do not penetrate the cell membrane effectively.  
As shown in Figure 4.7, the complexes with a peptide concentration below 0.2 mg/ml and above  
0.6 mg/ml had lower anticancer activity than the complexes with a peptide concentration between  
0.2 and 0.6 mg/ml. Cellular viability of the complexes with an EAR8-II concentration beyond  
0.2-0.6 mg/ml was significantly high, in the range of cellular viability observed in the THP control 
sample. This finding indicated effectiveness of EAR8-II in stabilizing THP in certain concentration 
ranges. As discussed above, the particle size in complexes in the 0.2-0.6 mg/ml ranges were smaller 
than those in other ratio complexes, which can be correlated to anticancer activity of the complexes.  
At lower EAR8-II concentrations, not all the THP molecules co-assembled with the peptide 
molecules, shown in the particle size distribution and in less efficiency toward cancer cells. However, 
at higher peptide concentrations, the excess presence of peptide suppressed the proficiency of THP by 
inhibiting the drug release effectively. The lower cytotoxicity at higher peptide concentration can also 
be explained by particle size effect, in which with the increased size endocytosis to the cancer cells is 
inhibited and consequently lower number of cells were killed.    
It is speculated that protonated THP molecules were inclined to interact with negatively charged 
cell membrane and promoted cellular uptake [179]. The hydrophobic properties of THP further 
stimulated molecules cross the cell membrane and localized in the cytoplasm. As shown in Figure 
4.8, cellular uptake of complexes with a peptide concentration between 0.3 and 0.6 mg/ml presented 
higher cellular uptake for both cell lines than the complexes beyond that ratio. The exception was the  
peptide-to-drug ratio 1 to 1 and the THP control, showing dramatically high uptake due to 
accumulation of free THP molecules on the cell membrane without them being fully localized in the 
cytoplasm. On the other hand, the complexes with higher EAR8-II concentrations (0.8–1.0 mg/ml) 
showed significantly lower cellular uptake due to highly bound EAR8-II to THP and inhibiting 
release of hydrophobic THP to the cell membranes. 
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Figure 4.7. Cellular viability of HeLa and A549 cells treated with the complexes for 24 h at fixed 
[THP] = 0.1 mg/ml and [EAR8-II] = 0.05–1.0 mg/ml. 
 
 
Figure 4.8. Normalized fluorescence emission intensity of THP uptake by HeLa and  
A549 cell lines treated with the complexes for 4 h at fixed [THP] = 0.1 mg/ml and  
[EAR8-II] = 0.05–1.0 mg/ml. 
 
A similar pattern was observed in the fluorescence microscopy images from the cells treated with 
EAR8-II-THP complexes at different ratios. For both cell lines, complexes with peptide 
concentrations of 0.3 and 0.5 mg/ml resulted in the highest cellular uptake of THP in cytoplasm. In 
contrast, complexes at lower and higher concentrations of the peptide showed lower localization of 
THP in cytoplasm. Note that the bright red fluorescence observed in 1:2 and 1:1 ratio complexes were 
from non-dissolved THP not localized in cytoplasm. At the ratios of 3:1 and 5:1, the localization of 
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THP in cytoplasm was very uniform, whereas other ratio complexes had THP randomly localized or 
just accumulated on the membrane (Figure 4.9). These results led us to select appropriate 
formulations to treat different cancer cells. So far, from the cumulative characterization and cellular 
uptake and toxicity results, the complex with the peptide-to-drug ratio of 5:1 has been shown to be a 
more stable and efficient solution for drug delivery, because of its high encapsulation efficiency, 
uniform nanostructure, relatively high cellular toxicity and uptake.  
Au et al. emphasized the importance of drug stability upon dilution during treatment time in 
clinical trials [180]. Since, the peptide-drug complex at a 5:1 ratio illustrated appropriate properties 
such as size, charge and toxicity against cancer cells, cytotoxicity testing was performed for this 
particular complex, and its serial dilution solutions were tested against two human cancer cell lines, 
including the non-small lung cancer cell A549, cervical adenocarcinoma HeLa. Figure 4.10 represents 
the viability of the cells treated with the 5:1 ratio complex and its serial dilution in water, where the 
final concentration of THP is between 0.3 and 38 µM. The IC50 values of the complex for the cancer 
cells were calculated, and followed the following trend; THP concentration at ~19.3 µM for A549 
>~1.8 µM for HeLa cells [181].  
Toxicity results for both serially diluted and variable peptide-to-drug ratio complexes revealed 
relatively higher cell viability of A549 compared to HeLa cells, denoting that A549 cells are highly 
resistant towards the EAR8-II-THP complex. Similar results were observed previously for EAK16-II 
and EPT complexes against MCF-7 cells and A549, in which A549 cells showed higher resistance 
than other tested cells [24]. The reason for different levels of toxicity of the same complex towards 
various cancer cells is not fully clear, but it might arise from different reactions of cancer cells to the 
EAR8-II-THP complex.  
Note that the cell viability of the THP control solution (no peptide) for both types of cell lines was 
significantly higher than for the respective THP concentrations in the presence of EAR8-II. For THP 
at 38 µM in water, the cellular viability was 64.9 ± 6.4, 29.58 ± 3.69 (%) for A549, HeLa cells, 
respectively. These findings clarify the important role of EAR8-II in stabilizing THP in an aqueous 
environment, and consequently delivering it into cells and causing cellular toxicity.  
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(A) 
 
(B) 
 
 
Figure 4.9. (A) HeLa cells; (B) A549 cells, treated with EAR8-II-THP at fixed  
[THP] = 0.1 mg/ml and varied [EAR8-II]. The ratios between EAR8-II to THP are indicated above 
each image. EAR8-II concentrations: (0:1) = 0.0 mg/ml; (1:2) = 0.05 mg/ml; (1:1) = 0.1 mg/ml; (2:1) = 
0.2 mg/ml; (3:1) = 0.3 mg/ml; (5:1) = 0.5 mg/ml; (6:1) = 0.6 mg/ml; (8:1) = 0.8 mg/ml; (10:1) = 1.0 
mg/ml. Scale bar is 100 µm. Note, all the images are taken with the same exposure time. 
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Figure 4.10. Viability of A549, HeLa cells treated with serially diluted complexes at  
5:1 EAR8-II to THP complex for 24 h. 
 
In the case of a stable complex upon dilution, the increase in cellular viability happens smoothly 
and gradually due to the lower drug concentration. Based on the observed cell viability results at  
24 h incubation time, the viability of A549 increased gradually, when the complex was diluted.  
In contrast, the viability trend for HeLa cells did not increase as smoothly as for A549 cells. The 
increase of HeLa cell viability after sixteen times dilution was sharp, indicating instability of the 
complex at high dilution factors in water, in the presence of a medium. One reason for complex 
instability is the instability of protonated THP in a highly diluted complex. As discussed, protonated 
THP is stabilized in peptide environments at low pH. Higher amounts of water lead to increased  
pH and consequently lower THP stability in solution. This effect might also arise from the stability of 
the complex in the different culture media used for different cell lines. The content of each culture 
medium varied, and THP might have distinct properties in each medium. Further experiments are 
required to confirm this phenomenon. Overall, EAR8-II-THP complexes at a peptide-to-drug ratio of 
5:1 demonstrated promising results against cancer cells and stabilized in the cell culture environment. 
 
4.4 Conclusions 
The current article introduced a new self/co-assembling ionic-complementary peptide, EAR8-II, 
stabilizing the hydrophobic drug pirarubicin (THP) in protonated form in aqueous environments, as 
shown by surface charge and fluorescence measurements. Results show the complex formation to be 
peptide-to-drug ratio dependent. Increasing EAR8-II concentration at a constant THP concentration 
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reduced the pH value of the complex and consequently caused protonation of THP stabilized in 
solution. At lower peptide-to-drug ratios, an insubstantial amount of THP molecules were solubilized 
in aqueous solution, according lower fluorescence emission intensity than in complexes with higher 
peptide-to-drug ratios, in which more THP is stabilized. The peptide-to-drug ratio affected the particle 
size distribution within a complex; where at very low and very high concentrations of EAR8-II, the 
average particle size was large, indicating the presence of long fibers and large aggregates in the 
solution. However, in complexes with peptide concentrations between 0.2 and 0.6 mg/ml, the average 
particle size observed was ~600 nm. Cytotoxicity and cellular uptake by cancer cell lines 
demonstrated peptide-to-drug ratio dependent behavior, in which, at very low and very high ratios, 
the anticancer activity was lower than that of peptide-to-drug mass ratios between 2:1 and 5:1. 
Deficiency and excess of the peptide in stabilizing THP caused not fully encapsulated and highly 
trapped THP molecules, respectively. The complex at a 5:1 peptide-to-drug mass ratio was 
recognized as an optimum peptide-to-drug ratio complex where the highest encapsulation efficiency 
was observed for the lowest peptide concentration present in the complex. This complex also offered 
the highest anticancer activity and cellular uptake against cancer cells compared to other ratio 
complexes. The anticancer activity of this complex and its serial diluted solutions were further studied 
against two cancer cells. The IC50 of THP was calculated as ~19.3 µM for A549 >~1.8 µM for HeLa 
cells, indicating sensitivity of HeLa cells compared with A549 toward EAR8-II-THP complexes. This 
study provides a platform for using self/co-assembly peptides as carriers for hydrophobic drugs in 
future for in vitro and in vivo applications by introducing a stable complex with relatively high 
therapeutic efficacy against cancer cells.   
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Chapter 5§ 
Thermodynamic Characterization of the Interaction between a 
Peptide-Drug Complex and Serum Proteins 
Abstract  
The interaction between a peptide-based drug delivery system and two serum proteins, bovine 
serum albumin (BSA) and immunoglobulin G (IgG), is investigated using fluorescence quenching 
and calorimetric techniques. An ionic-complementary self/co-assembling peptide, EAR8-II, is 
employed to encapsulate the hydrophobic anticancer drug pirarubicin (THP) and stabilize it in protein 
environments. Self/co-assembling properties of the peptide-drug complex (EAR8-II-THP) are shown 
to be different while interacting with serum proteins compared with the properties of the isolated 
complex. The results from thermodynamic studies suggest that the drug delivery system has a strong 
binding affinity (Ksv 1689 M-1), exothermic and enthalpy-driven interaction, with BSA and a 
relatively weak affinity with IgG (Ksv 295.2 M-1). In the presence of salt ions, the enthalpy and 
binding affinity remain unchanged, implying other interactions such as hydrophobic and Van der 
Waals interactions are present that are not affected by reduced polarity. This work forms the basis for 
further studies of EAR8-II-THP complexes in the presence of important proteins and for further 
evaluation of the complexes’ immune response and anticancer activity.  
Keywords: 
Self/co-assembling peptide, drug delivery, serum albumin, immunoglobulin G (IgG), complex-protein 
interaction, free energy 
  
                                                      
§ This chapter is based on a manuscript. Sadatmousavi, P.; Kavalenko, E.; Chen. P. “Thermodynamic 
Characterization of the Interaction between a Peptide-Drug Complex and Serum Proteins”. Submitted 
ACS- Langmuir, Jan  2014- under review 
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5.1 Introduction 
In the past few decades, nanotechnology has emerged as a versatile approach for different 
applications, including nanomedicine[25], cancer therapy and diagnosis, siRNA[182,183] and drug 
delivery[184]. At the same time, increasing concern about the toxicological effects of nanoparticles 
has led to an increase in toxicological studies of nanoparticles, involving interactions between 
nanoparticles and physiological biomolecules (e.g., plasma proteins). Interactions between 
nanoparticles and proteins result in the formation of a “bio-nano interface”. This interface is also 
called the protein “corona” and is significantly different from the original engineered nanoparticle’s 
surface. Therefore, what cells and tissues “see and process” are protein-nanoparticle complexes that 
are formed in the physiological environment [87,89]. The protein coronas of nanoparticles play an 
important role in determining their circulation half-life, controlled by the process of phagocytosis. 
Hence, understanding the interaction of nano-materials with plasma proteins is critical to improve the 
control of therapeutic efficiency, pharmacokinetics and pharmacodynamics [185]. 
In the current study, we focus on the characterization of serum proteins binding to the previously 
introduced peptide-drug complex, EAR8-II-THP**. EAR8-II is a simple ionic-complementary self/co-
assembling peptide that can stabilize Pirarubicin (THP) in aqueous solution [186]. High loading 
efficiency, stability, and anticancer activity of this complex against different cancer cells encouraged 
us to further study this complex for its behavior in the physiological environment. Any drug or 
delivery system applied either orally or intravenously is transported by the blood, which primarily 
encounters a large quantity of plasma proteins and various cellular components. The chemical 
composition, size, charge, and shape of nanoparticles influence the protein binding affinity and in 
consequence affect their interactions with cells and tissues [187]. On the one hand, strong binding 
between nanoparticles and serum albumin proteins is considered to be an advantage associated with a 
drug delivery system that provides long-circulating nanoparticles in the bloodstream, protected from 
immune cells, and consequently enhances drug safety [10]. On the other hand, nanoparticles that bind 
with IgG as one of the opsonin proteins [188] or fibrinogen as one of the plasma glycoproteins with 
high affinity to many nanoparticle (e.g. gold, metal oxide, single-wall carbon nanotubes) [189] are 
considered to have a disadvantage that promotes the macrophage uptake, blood coagulation, protein 
aggregation and complement activation of the nanoparticles. In addition to effect of nanoparticles 
shape and structure on protein corona composition, the temperature at which the NPs and proteins are 
                                                      
** The term nanoparticle NP and complex are used in this article interchangeably for the peptide-drug 
complex EAR8-II-THP. 
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stabilized in physiological environment is an important factor affecting the formation of protein 
corona. For instance, application of NPs in hyperthermia treatment of tumors can benefit from protein 
corona composition change at slight changes in temperature [190,191].   
In the current study, serum albumin and immunoglobulin G are the two main plasma components 
studied here to evaluate the binding affinity of the nanoparticle. Serum albumin, with a molecular 
weight of 65 kDa, is the most abundant protein in plasma, with a concentration of 35-45 mg/ml and a 
19-day half-life in humans. Albumin maintains the plasma pH, osmolality, and blood pressure and 
serves as a carrier for many drugs and small molecules [185,192]. Immunoglobulin and complement 
activation proteins such as IgG, C3, C4 and C5, on the other hand, are known as opsonin proteins and 
cause the opsonization process. The low binding affinity of nanoparticles to IgG leads to a lower 
possibility of phagocytosis followed by lower clearance and enhanced therapeutic efficiency of a drug 
delivery system [157,193,194].  
To evaluate the stability and binding properties of the peptide-drug complex (or NP) in plasma 
protein solutions, the following methodologies are applied. First, NPs were prepared at their optimal 
concentration ratios (peptide-to-drug 5:1 mass ratio), followed by incubation with serum proteins at 
different concentrations. Particle size distributions were measured to determine the effective protein 
concentrations in stabilizing NPs. Second, a fluorescence quenching technique at different 
temperatures was employed to assess the thermodynamic binding parameters by exploiting the 
intrinsic fluorescence of albumin and IgG. Third, isothermal titration calorimetry (ITC) was used to 
further estimate the binding properties of the protein-nanoparticle. The detailed theory and 
observations obtained from the above methods are discussed in the following sections.   
 
5.2 Experimental 
5.2.1 Materials 
The EAR8-II (Ac-AEAEARAR-NH2) peptide and the anticancer drug Pirarubicin with commercial 
name of THP were used from the sources presented in Chapter 4 (4.2.1). All serum proteins 
(including albumin from bovine serum (A7906) and human serum (A8763) and IgG from bovine 
serum (I5506)) were purchased from Sigma-Aldrich (Oakville, ON, Canada) with > 95% purity. The 
schematic of the molecular structures of EAR98-II, THP, and BSA are shown in Figure 5.1.  
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(A) (B) (C) 
  
 
Figure 5.1. Schematic of molecular structure of (A) EAR8-II, drawn by ACD/ChemSketch Freeware 
(Toronto, Canada), (B) pirarubicin (THP) [169], (C) BSA and Trp-212 is known as a binding site 
using protein structure prediction by the RaptorX web server. 
 
5.2.2 Methods 
5.2.2.1 Sample Preparation 
EAR8-II peptide solutions in the concentration range of 0.5 mg/ml (0.547 mM) were prepared by 
dissolving peptide lyophilized powder in Milli-Q (18.2 MΩ) water followed by bath sonication for 10 
min. Freshly prepared peptide solutions were added to Pirarubicin (THP) to reach fixed [THP] at 0.1 
mg/ml (0.159 mM) followed by mechanical stirring at 900 rpm for 24 hr. Bovine and human serum 
albumins were reconstituted in pure water at a concentration range of 4 to 224 µM. IgG from bovine 
serum was prepared at concentration of 0.1 mg/ml (0.66 µM) in saline solution (150 mM). To study 
protein and nanoparticle interactions, prepared EAR8-II-THP complexes were mixed with freshly 
made proteins in a 1:1 [v/v] ratio and was incubated for 2 hr at different temperatures according to the 
experimental requirements.  
5.2.2.2 Fluorescence Quenching of Proteins  
Serum albumin and IgG from serum have intrinsic fluorescence with emission wavelength of 350 nm 
when excited at 285 nm. This fluorescence property comes from tryptophan in binding site II of the 
albumin structure. This characteristic leads to a simple and reliable fluorescence quenching method to 
find the binding properties of proteins and the peptide-based drug delivery system. Quenching 
experiments were conducted on a steady state spectrofluorometer (QM4-SE, Photon Technology 
International (PTI), London, ON, Canada). Eighty µL of sample were transferred to quartz black 3.0 
mm followed by irradiation at 285 nm. The emission spectra were collected from 300 to 800 nm. The 
excitation and emission slit widths of the monochromators were set to be 1 and 5 nm bandpath, 
respectively, to control the amount of light coming in and out of the sample chamber. For each 
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sample, the lamp intensity of the fluorometer was monitored and used to normalize the scattering 
intensity to correct lamp fluctuations over time. Each collected spectrum from the protein-NP was 
corrected by subtracting the corresponding spectrum acquired from the peptide-drug complex in the 
absence of protein. The normalized fluorescence intensity (F0/F) is plotted against the concentration 
of the quencher for further Stern-Volmer analysis.  A drop in the fluorescence emission intensity due 
to the existence of other molecules is called fluorescence quenching. Dynamic and static quenching 
are the two main categories of fluorescence quenching [195]. Both quenching phenomena can be 
described by the Stern-Volmer equation (Equation 5.1). In this equation, F0 and F are fluorescence 
intensities in the absence and the presence of the quencher, respectively. Ksv is a Stern-Volmer 
quenching constant or association constant in the case of static quenching that can also be shown as 
KqApp τ0.  KqApp is the apparent bimolecular quenching constant; τ0 is the lifetime of the fluorophore in 
the absence of a quencher and [Q] is the quencher concentration.  
Here, the fluorophores are the serum proteins, and the quencher is the EAR8-II-THP complex. To 
fit the quenching data, the THP concentration was considered as [Q]. The fluorescence lifetime for 
BSA is ~ 5 ns [196].  
Equation 5.1. Stern-Volmer quenching equation 
 
5.2.2.3 Isothermal Titration Calorimeter (ITC) 
 Binding properties of proteins from serum and the peptide-drug complex have been 
thermodynamically characterized by an isothermal titration calorimeter technique. The EAR8-II-THP 
complex at a 5:1 mass ratio concentration was titrated into protein solutions (BSA at 640 µM and IgG 
at 6.6 µM) at 25°C. Titrations were performed in NanoITC standard volume with a Hastelloy reaction 
vessel (TA Instruments, Delaware, USA). The reference vessel was filled with the buffer solution. 
For serum albumin tests, because the solutions were made in pure water, reference cells were filled 
with water, whereas for IgG tests, because IgG was prepared in saline (150 mM) the reference cells 
were filled with saline solution. Each titration consisted of 25 injections at 200-second intervals with 
a stirring speed of 250 rpm. A 300-second baseline was collected before the first injection and after 
the last injection. Prior to starting the titration, the calorimeter was equilibrated to a baseline with a 
drift of less than 100 nW over a thirty-minute period. The data were fitted using an independent 
F0
F =1+KSV [Q]=1+Kqτ 0[Q]
  
  83 
method (1:1 binding isotherm) to estimate the thermodynamic parameters, including the binding 
constant, stoichiometry, ΔH, ΔS, and Gibbs free energy (ΔG).  
5.2.2.4 Transmission Electron Microscopy (TEM)  
The nanostructure of bovine serum albumin, self-assembled peptide-drug complexes, and the protein-
NP was observed by transmission electron microscopy (type CM20, Philips Electronics Ltd, 
Guidford, U.K.) at an accelerating voltage of 200 kV. Images were digitized using a Gatan 679 slow-
scan CCD camera and analyzed using Digital micrograph (version 2.1, Gatan Inc. Pleasanton, CA). 
Freshly prepared sample solutions were incubated on a 400-mesh carbon coated Formvar copper grid 
(Marivac Ltd., St. Laurent, QC) for 10 min. Extra moisture was taken from the edge of the grid with 
tissue paper. After air-drying for 20 min, the grid was negatively stained with 2% (w/v) uranyl acetate 
for 5 sec. Excess stains were drawn off with tissue paper and the grid was air-dried before TEM 
imaging. The TEM images underwent further dimension analysis with Gwyddion software (Free SPM 
data analysis software). Detailed experimental methods for, FT-IR spectroscopy, circular dichroism, 
and dynamic light microscopy were adapted from Chapter 3 (3.2.2.4 and 6) [25,168]. 
 
5.3 Results and Discussion 
5.3.1 Effect of Protein Binding on Peptide-Drug Complex Structure  
EAR8-II-THP nanoparticles (NPs) form a fibril bundle nanostructure in aqueous solution with helical 
secondary structures with an effective diameter of ~ 712 nm. EAR8-II is an amphiphilic ionic-
complementary peptide that stabilizes hydrophobic THP molecules. These NPs are positively charged 
(pH 3.87) due to the protonation of THP (pKa = 7.3) in the peptide environment and have a zeta 
potential of +11.5 mV. On the other hand, bovine serum albumin (BSA) is a negatively charged 
protein at pH 7 with a zeta potential of ~ -28 mV and has an effective diameter of ~ 10 nm. This 
protein forms predominantly α-helix secondary structures observed by FT-IR (1654 and 1548 cm-1). 
BSA is known for its hydrophobic functional groups that can be initial targets for its association to 
other molecules such as surfactants or hydrophobic molecules. Interestingly, we found exceptional 
stability of EAR8-II-THP nanoparticles in BSA solution in biological studies. Therefore, we 
determined that it is worth studying the detailed  binding properties of NPs and BSA using different 
methods to demonstrate the nature of binding and understand the effect of binding in biological 
applications.  
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The morphology of the EAR8-II-THP nanoparticles was changed due to binding to the BSA 
molecules (64 µM). The images obtained by TEM presented an alteration in the fibular structure of 
EAR8-II-THP nanoparticles into a more globular structure similar to the BSA nanostructure (Figure 
5.2A-C). In order to understand the behavior of NPs in BSA solution, a range of BSA concentration 
solutions were mixed with a constant concentration of NPs and characterized for self-assembling 
properties. The particle size distribution of solutions containing BSA and NP has shown a bimodal 
distribution of particles including a peak at ~ 2-20 nm and a peak at 200-1000 nm. To identify what 
each peak represents, the BSA-NP mixture was centrifuged for 1 hr at 17000 rcf, and then the size of 
supernatant was measured. The intensity of the peak around 200-1000 nm for supernatant was lower 
than the sample before centrifugation, indicating the unbound nanoparticles were precipitated. The 
population of the particles in a range of 2-20 nm, which is slightly larger than particle size for isolated 
BSA particles, remained unchanged representing stable BSA-bound NPs in the solution (Figure 
5.2D).  
Dynamic light scattering results showed the particle size dependency on the BSA concentration in 
BSA-NP complexes. By increasing BSA concentration the population of BSA-bound NPs increased, 
whereas the population of unbound-NPs decreases (Figure 5.2E). At lower BSA concentrations there 
was not enough protein to bind with all present NPs, at BSA concentration higher than 64 µM (above 
molar ratio [BSA]/[NP] = 0.4), the population of unbound EAR8-II-THP nanoparticles remained 
constant ~ 10% showing binding saturation between NPs and BSA. Therefore, increasing BSA 
concentration above 64 µM would only induce free proteins in the solution not participating in 
binding process. Therefore, for further characterization, BSA at concentration of 64 µM was selected 
to ensure free protein did not exist in the solution and the amount of unbound NPs is minimum.   
The intensity-based particle size distribution showed a significant decrease in the size of the 
complexes when it was combined with BSA. This change was more noticeable with longer incubation 
times. After two days of incubation, the majority of the particles were in the size range of 2-20 nm. 
This suggested that over time most of the unbound EAR8-II-THP particles disassemble and 
reorganize into smaller spherical structures. Stabilizing nanoparticles in serum albumin is considered 
a great advantage for future drug delivery purposes. 
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          (A) (B) (C) 
           
(D) 
 
(E) 
 
Figure 5.2. Particle size analysis of EAR8-II-THP and serum albumin. TEM images; (A) BSA (64 
µM), (B) EAR8-II-THP (NP)-BSA complex, (C) EAR8-II-THP (NP). (D) Intensity-based particle 
size distribution of the above samples measured by DLS. [BSA] = 64 µM, [EAR8-II]= 0.547 mM, 
[THP]=0.159 mM (E) Effect of BSA concentration on particle size distribution of BSA-NP 
compounds. The error bars are standard deviations (i.e., +/- 3%) 
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The secondary structures of BSA and BSA combined with the NPs were determined by collecting 
absorbance spectra by CD and FT-IR methods. Both CD and FT-IR spectra showed a dominant α-
helix structure for BSA solution, and combination of α-helix and β-sheet for the EAR8-II-THP 
complexes. The spectrum from EAR8-II-THP compound resulted in formation of a mixture of α-helix 
(1654 cm-1) and β-sheets (1620 cm-1) as secondary structures. The spectrum from the BSA solution 
showed a mainly α-helix secondary structure (two main peaks at 1654 and 1548 cm-1) with 
significantly higher intensity than the one observed with isolated nanoparticles [196–198]. When the 
NPs are combined with BSA, the results no significant change is spectrum compared to BSA in the 
absence of NPs, indicating no significant conformational change in BSA secondary structure while 
bound with EAR8-II-THP complexes. (Figure 5.3).  
(A) 
 
(B) 
 
Figure 5.3. (A) CD spectra collected from EAR8-II-THP (NP), BSA and NP-BSA complexes. All 
four spectra are baseline corrected., (B) FT-IR spectra of above complexes collected by Bio-ATR FT-
IR at [BSA] = 8 µM, [EAR8-II]= 0.547 mM, [THP]=0.159 mM 
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5.3.2 Thermodynamic Characterization of Peptide-Drug Complex Binding with Serum 
Proteins 
As discussed above, the EAR8-II-THP complex showed noticeable stability in a serum albumin 
environment without the tendency to aggregate over time. To evaluate the binding properties of the 
peptide-drug complex and serum albumin (BSA), a fluorescence quenching technique and an 
isothermal titration calorimeter (ITC) were applied in the current study.  
5.3.2.1 Fluorescence Quenching of Serum Proteins 
BSA contains a single polypeptide chain of 607 amino acids with two tryptophan residues (Trp-
134, and Trp-212) located in the first and second domains of the protein hydrophobic regions [199]. 
Exploiting the tryptophan residue’s fluorescence emission, BSA quenching experiments have been 
employed to evaluate the binding affinity of nanoparticles to BSA. A drop in the fluorescence 
emission intensity due to the existence of other molecules is called fluorescence quenching. The 
fluorescence emission of BSA at 350 nm was reduced as the complex’s concentration [THP] was 
increased due to tryptophan quenching (Figure 5.4A). The plot of F0/F vs. concentration of [THP] 
(Figure 5.4C) represents the Stern-Volmer quenching relation, in which the slope corresponds to the 
binding constant KSV. Dynamic and static quenching are the two main categories of fluorescence 
quenching that can be presented by linear Stern-Volmer plot [195]. Dynamic quenching is also known 
as collisional quenching in which the quencher diffuses to the fluorophore during its excitation 
lifetime. After contact, the fluorophore returns to the ground state without any emission. In dynamic 
quenching, there is no permanent change in the molecules, whereas in the case of static quenching, a 
complex between the fluorophore and the quencher is formed and the complex does not emit strong 
fluorescence. It is important to realize that linear Stern-Volmer plot does not prove that collisional 
quenching has certainly occurred, however, static quenching is also results in linear Stern-Volmer 
plots. Static and Dynamic quenching can be distinguished by their differing dependence on 
fluorescence lifetime measurements, and the following factors that were considered in the current 
study : (i) temperature dependence; higher temperatures result in faster diffusion and therefore more 
possibility for collisional quenching. In other words, increasing the temperature will increase the 
slope of the Stern-Volmer plot during dynamic quenching. This is due to the dissociation of weakly 
bound complexes. However, in static quenching, increasing the temperature leads to a lower Stern-
Volmer slope. Increasing temperature results in decreased stability of bound complexes, which leads 
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to lowering the quenching constant driven from the Stern-Volmer plot. In the current study, BSA was 
prepared at a 64 µM concentration and incubated with a series of EAR8-II-THP concentrations at 
4°C, 25°C, and 37°C for two hours. The fluorescence spectra of BSA were collected for all solutions 
and normalized by air light scattering (to correct for lamp fluctuation) followed by subtracting the 
corresponding EAR8-II-THP spectra. F0/F was plotted versus the THP concentration to find the 
Stern-Volmer fitting parameters at different temperatures. The association constant is decreased by 
increasing temperature, indicating a weakening of the bound complexes at higher temperatures, 
suggesting static quenching (see Figure 5.4C). 
 (ii) Absorption spectra of the fluorophore; in collisional quenching, only excited states of the 
fluorophore change and the absorption spectra are expected to remain unchanged. However, in static 
quenching, the formation of the ground-state complex results in a slight shift in the absorption 
spectra. This effect for the NP-BSA is shown in Figure 5.4 B, in which the absorption spectra of BSA 
showed a strong peak at 280 nm, where this absorption reduced significantly in BSA combined with 
EAR8-II-THP complex suggesting the static quenching of BSA by the complex.  
(iii) Bimolecular quenching constant: diffusion-controlled quenching typically shows the kqApp 
value near 1×1010 M-1.s-1. For dynamic quenching, this value is smaller than this threshold due to 
steric shielding of the fluorophore. Static quenching typically shows higher values, which indicates 
stronger binding interactions between the fluorophore and the quencher [195,200]. In the current 
study, the calculated apparent bimolecular quenching constants (KqApp) for all three temperatures have 
higher values than 1×1010 M-1 s-1, which suggests that the quenching was initiated not by collisional 
quenching but by static quenching, and a compound formed between the BSA and the EAR8-II-THP 
complex. 
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(A) (B) 
  
(C) (D) 
  
Figure 5.4. Quenching of BSA by the EAR8-II-THP complex. (A) Effect of the EAR8-THP complex 
on the intrinsic fluorescence of BSA at 298K (25°C). (Black) [BSA]: 64 µM, and (Red) EAR-THP 
complex is at [EAR]: 0.55 mM and [THP]: 0.159 mM. (A-K): [THP] in mixture is: 0, 0.016, 0.032, 
0.048, 0.064, 0.080, 0.096, 0. 2, 0.127, 0.143, 0.159 mM, respectively. (B)  Absorption spectrum of 
BSA (dotted), EAR8-II-THP complex (dashed) and the mixture of BSA and EAR8-II-THP (solid) 
(C) Stern-Volmer plot at different temperatures. (D) Van’t Hoff plot for the interaction of EAR8-II-
THP and BSA at different temperatures. ΔH = -14.35 kJ/mol, and ΔS = 12.7 J/mol.K. 
 
The interaction between the fluorophore and the quencher can occur due to various forces, 
including hydrophobic, electrostatic, hydrogen bonding, and Van der Waals interactions. To calculate 
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equation has been applied to the static quenching binding constant (KLB) at different temperatures 
[202]. When enthalpy (ΔH) does not change significantly in the range of temperatures, ΔS can be 
driven from this equation (Equation 5.2).  
Equation 5.2. Van’t Hoff thermodynamic equation 
ln(KSV ) = −
ΔH
RT +
ΔS
R  
In the BSA-NP system, the enthalpy and entropy can be driven from the slope and y-intercept of 
the ln(KSV) versus 1/T plot. The Gibbs free energy is also estimated from at each 
corresponding temperature (Table 5.1). Negative values of ΔG (~ -18 kJ/mol) and ΔH (-14.35 kJ/mol) 
convey that the interaction between BSA and the peptide-drug complex is a spontaneous and 
exothermic reaction. The small value of ΔS (12.71 J/mol.K) indicates that the reaction is more 
enthalpy driven and entropy is unfavorable showing hydrogen bonding and van der Waals forces are 
dominant forces. Notably, this protein quenching is only observed when encapsulated THP by EAR8-
II was interacting with BSA, whereas naked THP (without EAR8-II) does not show any significant 
quenching of tryptophan in serum albumin. This proves the unique capability of the self-assembling 
peptide in stabilizing a hydrophobic agent in the physiological environment. By increasing the 
temperature, the binding affinity decreased slightly, suggesting weakening the forces between BSA 
and peptide-drug complexes. Furthermore, the effect of salt is investigated in this work to confirm the 
nature of the binding. The interaction between BSA molecules and THP only occurs when THP is 
already stabilized in an EAR8-II solution; otherwise, THP molecules alone are not solubilized in a 
BSA solution and do not induce fluorescence quenching. EAR8-II as an amphiphilic peptide first 
stabilizes THP in an aqueous environment, promoting the BSA interaction.   
The fluorescence quenching results suggested a binding between BSA and the peptide-drug 
complex, however, for more confirmation on nature of quenching whether is static or dynamic 
fluorescence lifetime measurement is highly recommended.  
 
Table 5.1. Summarized data on BSA quenching by EAR8-II-THP 
Stern-Volmer 
T (°C) Ksv(M-1) Kq(M-1 s-1) R2 ΔG(kJ/mol) 
4 2259.9 3.83E+11 0.974 -17.87 
25 1688.6 2.86E+11 0.975 -18.14 
37 1123.2 1.90E+11 0.903 -18.29 
 
ΔG = ΔH −TΔS
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5.3.2.2 Isothermal Titration Calorimeter (ITC)  
Isothermal titration calorimetry (ITC) is a powerful procedure for investigating the thermodynamics 
and stoichiometry of molecular binding processes. This technique can be used in nanoparticle and 
protein assemblies to directly determine (a) binding stoichiometry, (b) nature of binding (entropy or 
enthalpy driven), (c) binding affinity between titrant and titrate [90,203,204]. In the current study, 
ITC was applied to evaluate the binding and thermodynamic parameters of the NP to BSA at 25°C to 
complement the quenching data. Titration was performed by slowly adding a peptide-drug complex 
(NP) solution into the protein solution and monitoring the heat difference that needs to be added to 
the sample and reference cells to maintain the two cell temperatures constant. The results are plotted 
as a heat rate against time plot. If the reaction is exothermic, the heat that must be added to the sample 
cell is less and a negative signal is observed (Figure 5.5). When both titrant and titrate concentrations 
are known by an isothermal fitting analysis of enthalpy vs. [NP]/[Protein] ratio curves, we estimate 
thermodynamic parameters such as binding constants Ka (M-1), enthalpy changes ΔH (kJ. mol-1), ΔS 
(kJ mol-1K-1), and binding stoichiometry n. The Gibbs free energy (ΔG) is also determined from 
common thermodynamic relations: ΔG = ΔH-TΔS or ΔG = RT ln (Ka). Table 5.2 summarizes the 
binding parameters for the NP-BSA complex and compares the corresponding values with the 
fluorescence quenching data at 25°C. Note that the concentration of titrant (NP) is ten times higher 
than the original concentration of NP used in the quenching experiment. This concentration 
adjustment is due to the need to obtain a substantial heat rate at the very first injections and low 
volumes.   
Thermodynamic values from both techniques indicate that the protein-nanoparticle interaction is a 
spontaneous reaction, with data showing a negative free energy change (ΔG < 0). The peptide-drug 
complex and protein interaction involves an unfavorable negative entropy change (ΔS < 0) that is 
compensated by a favorable highly negative enthalpy change (ΔH < 0). Negative enthalpy change is 
indicative of an exothermic process, which is comparable to the albumin bindings to NPs observed by 
ITC. The stoichiometry value acquired from ITC is at 1.87 for [NP]/[BSA], which is fairly 
comparable with the results of ratio effect on particle size analysis. At the ratio of [BSA]/[NP] ~ 0.6 
and higher, which corresponds to [NP]/[BSA] ~ 1.67, most NPs are bound to BSA and beyond that 
ratio binding saturation occurs similar to what happens in ITC thermal profile. Despite the difference 
observed between thermodynamic values from both quenching and calorimetry methods, the binding 
behavior in the NP-BSA system showed a similar trend. ITC is the method that offers thermodynamic 
values directly by measuring the heat transfer while binding, whereas the fluorescence quenching 
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method is an indirect technique using the Van’t Hoff equation; therefore, more error is associated 
with the obtained values.  
 
 
Figure 5.5. ITC result plots for (NP). EAR8-II-THP (5:1 mass ratio) complexes were titrated to BSA 
64 µM at 25°C. [EAR8-II]=5 mg/ml, [THP]=1 mg/ml.  
 
Table 5.2. Thermodynamic parameters obtained by ITC and fluorescence quenching for NP and BSA 
binding 
  Ka (M-1) 
ΔH  
(KJ/mol) 
ΔS 
(J/mol. K) 
ΔG  
(KJ/mol) n 
ITC 3.97E+04 -66.2 -134.1 -26.24 1.87 
Quenching 1.68E+03 -14.35 12.71 -18.14 - 
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5.3.3 Effect of Salt on Binding Properties  
To determine the nature of binding between tryptophan residues in BSA and EAR8-II-THP 
complexes, all of the samples were made in saline solution (150 mM) to further examine the particle 
size and thermodynamic binding parameters. Theoretically, salt molecules prefer to hydrate with 
water molecules in the solution, so they differ in binding behaviors between protein and nanoparticle 
molecules. Increasing the salt concentration reduces the polarity of the solution and decreases the 
amount of surrounding water on the surface of the protein and nanoparticles. Therefore, the presence 
of the salt molecules causes a change in the binding affinity of the protein interaction and provides 
energy for dehydration. If the main driving force in the protein-nanoparticle interaction is electrostatic 
force, increasing the salt concentration reduces the polarity of the system and lower binding affinity 
will be observed. However, when hydrophobic interaction is the main driving force in protein 
interaction, adding salt contributes to dehydration and leads to a higher binding affinity [202]. One of 
the major reasons for stronger hydrophobic interaction in the presence of salt is that decreasing the 
amount of water on the protein surface causes instability in the protein structure.  
Adding salt to the EAR8-II-THP and BSA system did not significantly affect the binding affinities. 
The Stern-Volmer parameters and thermodynamic values from calorimetry were not altered 
considerably in the presence of salt. In addition, based on the results that the binding is mainly 
enthalpy-driven and entropy in unfavorable for it, hydrogen bonds and van der Waals interactions 
played major roles in the reaction between BSA and EAR8-II-THP complexes (Figure 5.6, and Table 
5.3). 
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Table 5.3. Effect of salt in the binding properties of BSA and EAR8-II-THP. 
  Stern-Volmer ITC 
  
Ksv 
(M-1) 
Kq 
(M-1 s-1) R2 
Ka  
(M-1) 
ΔH 
(kJ/mol) 
ΔS 
(J/mol.K) 
ΔG 
(kJ/mol) n 
No Salt 1688.6 2.86E+11 0.975 3.97e4 -66.20 -134.1 -26.24 1.87 
With Salt 1734.2 2.94E+11 0.931 3.73e4 -54.97 -96.92 -26.08 1.46 
 
 
(A) 
 
(B) 
 
Figure 5.6. Effect of salt (155 mM) on the protein interaction, (A) Fluorescence quenching: Stern-
Volmer plots for BSA quenched by EAR8-II-THP, (B) ITC: integrated heats in each injection versus 
molar ratio of [NP]/[BSA]. 
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5.3.4 Immunoglobulin G Binding Properties  
The same techniques (ITC, fluorescence quenching and particle size) that were applied to 
determine albumin-binding properties were employed to characterize the immunoglobulin G binding 
parameters to the EAR8-II-THP nanoparticles. Immunoglobulin G (IgG) is a protein containing four 
peptide chains: two identical heavy chains and two identical light chains formed in a typical Y-shape 
antibody monomer. Similar to serum albumin, IgG also has a typical intrinsic fluorescence due to a 
tryptophan residue when excited at 285 nm [205,206]. The results from the fluorescence quenching of 
immunoglobulin G (IgG) by EAR8-II-THP molecules showed the Stern-Volmer constant to be 
significantly lower than what it was calculated from the quenching of BSA. The quenching constant 
is lower than the dynamic quenching threshold, suggesting collisional quenching of IgG by NPs. The 
Stern-Volmer equation fit poorly with a low fitting parameter (R2), indicating no significant binding 
between the molecules (Figure 5.7A). As discussed above, collisional quenching is due to the random 
contact of molecules and does not induce a strong binding between the quencher and the protein 
molecules. In contrast, BSA protein molecules have shown to be quenched by NPs in a static manner 
representing the formation of BSA-NP bound molecules. Similarly, the heat produced by calorimetry 
is considerably low, suggesting minimal binding of NP with IgG (Figure 5.7C). The binding profile 
from IgG and the particles did not follow a standard ITC trend to be modeled with a one-site binding 
model to derive binding parameters.  In addition, the particle size of the NP did not change noticeably 
when combined with IgG, which represented no change in the peptide-drug complex in the IgG 
environment (Figure 5.7B). All of these results suggest that IgG binding to NPs is relatively low 
compared to one observed from NP-BSA binding. It is postulated that this low binding affinity is due 
to the position of tryptophan residues and their accessibilities to the other molecules such as THP. 
Since formation of protein corona can either enhance or prevent biological responses of the 
nanoparticles, it is critical to study the molecular interactions and determine whether the nanoparticles 
have high or low affinity to certain proteins, and consequently predict the biological responses. It has 
been suggested that tightly bound proteins are the main components in nanoparticles fate in vivo and 
control the biodistribution of nanoparticles. At the same time, surface modifications of nanoparticles 
to avoid undesirable protein bindings provide the safer therapeutic nanoparticles for drug delivery 
[189,207]. 
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(A) (B) 
  
(C) 
                      
Figure 5.7. Binding properties of EAR8-II-THP and IgG. (A) Stern-Volmer plot from the 
fluorescence quenching method, (B) Particle size distribution (DLS), (C) ITC: integrated heats in 
each injection versus injection number.   
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experiments illustrate spontaneous, exothermic, and enthalpy-driven binding (negative ΔG and ΔH) 
between the complex and BSA, with a reasonably high binding affinity (Ksv 1867 M-1). Results from 
thermodynamic analysis showed that the main interaction between BSA and NPs is mainly hydrogen 
bonds and van der Waals forces (e.g. π-π stacking).  
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Chapter 6 
Effect of Protein Binding to Peptide-Drug Complex on Immune 
Response 
Abstract 
Interactions between therapeutic agents and immune systems are critical in the development of drug 
delivery systems. Macrophages are immune cells that recognize and clear foreign materials from the 
body through phagocytosis. The ability to evade phagocytosis, and thus enable both extended 
circulation and site-specific targeting, is a key in designing effective drug delivery systems. For this 
purpose, serum albumin was used as a co-carrier for our peptide-based drug delivery system. The 
EAR8-II-pirarubicin (THP) complex, a peptide-anticancer drug assembly, had shown strong binding 
(exothermic and spontaneous) with serum albumin and relatively weak binding with immunoglobulin 
G (IgG). Here, we demonstrate the role of serum albumin in safe delivery of the peptide-drug 
complex, presenting reduced macrophage uptake and toxicity, inflammatory response, hemolytic 
activity (both in vitro and in vivo), and complement activation. Cellular toxicity and uptake results 
revealed that more than half of the cells survived in the complex solution with albumin, and that the 
phagocytosis rate of THP was three-fold lower compared to that in the complex solution without 
albumin. Cellular toxicity and uptake of the drug by macrophages was highest in the presence of IgG, 
possibly due to the IgG opsonin effect. The cytokine expression level by macrophages, as measured 
by qPCR, was also found to be much lower in the presence of albumin. Hemolytic activity was at 
minimum when albumin was used. However, the level of the final complement product, C5b-9, did 
not differ significantly between the albumin-associated complex and the complex alone; in both 
cases, complement product levels were biologically irrelevant (10-60% increase). These outcomes 
illustrate a promising role of serum albumin in enabling safer peptide-based delivery systems, which 
will help further development into clinical applications.  
Keywords 
Macrophages, cytokine, biocompatibility, hemolysis, cytotoxicity 
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6.1 Introduction 
We previously introduced a newly designed self/co-assembling peptide, EAR8-II, and its unique 
capabilities to encapsulate the hydrophobic anticancer drug, Pirarubicin, and to remain stable in a 
physiological environment [186]. For the first time in peptide-based drug delivery research, 
thermodynamic interactions between peptide-drug complexes and serum proteins were investigated, 
and we presented a spontaneous and exothermic interaction between the peptide-drug complex and 
serum albumin. This effective binding of the EAR8-II-THP complex to serum albumin protein 
encouraged us to further investigate the effect of protein binding on in vitro immune response and 
biocompatibility. One of the main challenges of using such complexes is their rapid elimination by 
macrophages. Therefore, in this current study we focus on macrophages’ reaction to the complex in 
the presence and the absence of bovine serum albumin (BSA) and immunoglobulin G (IgG). The fact 
that macrophages are widely located in many tissues of the body, invading and eliminating foreign 
particles, has provided an opportunity to design effective therapeutic compounds to evade 
macrophage recognition. Surface modifications, size, and shape of the particles have important roles 
in developing delivery systems capable of extended circulation and target specificity [208]. 
It has been demonstrated that plasma protein binding is a successful approach for improving the 
pharmacokinetic properties of short-lived molecules [185]. Drugs tend to bind to plasma proteins 
such as albumin [209], lipoproteins, immunoglobulin [194,210], transferrin [211], fibrinogen [89,98], 
and α1-acid glycoprotein [212], but due to the large amount and small size of albumin in the 
bloodstream, most particles bind to albumin [192]. It has been reported that many drugs, peptides 
[185], and fatty acid molecules [213] have the affinity to bind to serum albumin. This binding is 
usually through covalent or non-covalent interactions between albumin and other molecules [12]. For 
example the albumin-paclitaxel nanoparticle formulation, Abraxane, is a well-known compound for 
treating solid tumors. Paclitaxel comprised of lipophilic molecules, is encapsulated with human serum 
albumin in a solvent-free and high-pressure condition to form 130 nm nanoparticles. Abraxane has 
been approved by the FDA, and was administrated intravenously first in 2005 by Niel Dasai [67]. His 
trial revealed a significant improvement in therapeutic efficiency of Abraxane compared to standard 
paclitaxel, indicating the positive impact of albumin binding for both therapeutic and safety concerns. 
We speculate that serum albumin covers the nanoparticles and renders them invisible to macrophages, 
resulting in the observed improvement in nanoparticle longevity.   
Immunoglobulin and complement proteins play an important role in modulating inflammation by 
clearing foreign materials from the body. Lin et al. showed that immunoglobulin G proteins bind to 
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antigens and facilitate Fc receptor mediated-phagocytosis that consequently activates the complement 
system [214]. This effect is crucial in preventing inflammation against pathogens, although the 
objective of the current study is protecting the nanoparticles from being recognized as pathogens by 
macrophages of the immune system. As observed in the previous studies, the affinity of peptide-drug 
complex binding to IgG was significantly lower than to serum albumin. It is hypothesized that high 
affinity to BSA and low binding to IgG offers low macrophage uptake and accordingly low 
inflammation responses.  
Following physiochemical characterization analysis of binding presented in an earlier study, we 
evaluate in vitro the effect of protein binding to the peptide-drug complex. Macrophage cellular 
toxicity, uptake, cytokine expression, hemolysis, and complement activation were assessed by CCK-
8, fluorescence, real-time RT-PCR, and ELISA assays, respectively. First, the cytotoxicity of the 
macrophages (RAW 264.7) treated with the complex in the presence and absence of BSA and IgG 
suggested higher cell viability with BSA bound to NPs††. Second, cellular uptake results of 
macrophages showed the lowest uptake in the presence of BSA, followed by the complexes with both 
BSA and IgG. Third, albumin-bound NPs showed significantly lower cytokine expression levels than 
naked NPs. Finally, hemolysis experiments were performed, and C5b-9 complement protein 
consumption was evaluated through ELISA, demonstrating protein binding effect on enhancement of 
the biocompatibility features of peptide-based delivery systems.  
Overall, serum albumin binding to nanoparticles plays an important role in nanoparticle 
stabilization in a physiological environment and cellular responses. Therefore, a comprehensive study 
of protein interaction with nanoparticles provides useful guidelines for designing appropriate 
nanoparticles for drug delivery systems that are less susceptible to rapid removal by the human 
immune system. 
6.2 Experimental  
6.2.1 Materials 
The EAR8-II (Ac-AEAEARAR-NH2) peptide and the anticancer drug Pirarubicin with commercial 
name of THP were used from the sources presented in Chapter 4 (4.2.1). The supplies for BSA and 
IgG were similar to the ones presented in Chapter 5 (5.2.1). The mouse macrophage cell line 
                                                      
†† Note that in this chapter EAR8-II-THP complex is presented as NP. NP only: NP - -, NP with BSA: 
NP + -, NP with IgG: NP - +, NP with BSA-IgG: NP + + 
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(RAW264.7) was purchased from Cedarlane (Burlington, ON, Canada). Cells were grown in 
Dulbecco’s modified medium (DMEM) with high glucose including 10% fetal bovine serum and 1% 
penicillin-streptomycin (Sigma P4333).   
TRI reagent (T9424), Chloroform (C2423), isopropyl alcohol (I9516) for RNA purification, and 
designed primers for real-time RT-PCR were purchased from Sigma-Aldrich (Oakville, ON). The 
qScript cDNA SuperMix (95048), and Perfecta SYBR Green Fast Mix, Low ROX (95074) for real 
time RT-PCR experiments were purchased from Quanta Biosciences (Gaithersburg, MD). Human 
C5b-9 ELISA kit (558315) for complement activation assay was purchased from BD Biosciences 
(Mississauga, ON). Lipopolysaccharides (LPS) from Escherichia coli 0111:B4, γ-irradiated (L4391) 
was purchased from Sigma-Aldrich (Oakville, ON) as a positive control for macrophage activation.  
6.2.2 Methods 
6.2.2.1 Cellular Toxicity and Uptake 
Macrophage cells (RAW 264.7) were cultured in Dulbecco’s Modified Eagle Medium (DMEM), 
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in an environment 
controlled incubator (37°C with 5% CO2). After 95% confluence, cells were detached and then 
seeded at concentration of 1.5×104 cells per well in 96-well plate, followed by treating with NPs for 
different incubation times for cellular toxicity assay (Cell counting kit CCK-8). For cellular uptake 
experiments cells were seeded at concentration of 2×105 cells per well in 12-well plates. THP cellular 
uptake tests were conducted by cell lysis after treatment with 1% SDS in Tris-EDTA and pipetting 
up-and-down to complete cell lysis. The fluorescence emission intensity was measured by 
spectrofluorometer at 590 nm indicating amount of THP uptake by the cells (Refer to 4.2.2.4). Note 
that cells were treated in serum free medium to isolate the effects of BSA and IgG.  
6.2.2.2 RNA Extraction 
RAW 264.7 cells were seeded in 12-well plate at concentration of 2.5×105 cells per well. After 6 hr 
incubation time with NPs the total RNA was extracted from the cells using the TRI reagent protocol 
(Sigma-Aldrich). RNA concentration was determined by measuring absorbance at 260 nm (OD260) 
using NanoDrop system. The quality of purified RNA was assessed by absorbance ratio of 260/230 
and 260/280. Note that nucleic acid and proteins have absorbance at 260 and 280 nm, respectively. A 
ratio of ~ 2.0 is generally accepted for pure RNA for 260/280. And the absorbance at 230 nm is 
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indication of other contaminants including phenol. The ratio of ~ 2.0-2.2 is acceptable for 260/230 for 
pure RNA.  
6.2.2.3 Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Single stranded cDNA was synthesized from 100 ng of total RNA using MMLV (Moloney–Murine 
leukemia virus) reverse transcriptase. The cDNA for β-actin as a housekeeping gene and other 
cytokines were amplified by RT-PCR using Agilent Technologies (Paq5000). Briefly, 2 µl of each 
cDNA samples was amplified in a 20 µl PCR reaction containing 10 µl of PerfeCta SYBER Green 
Fast Mix, Low ROX and 0.75 µl of 10 µM primers (reverse and forward). The list of primers used for 
each cytokine is presented in Table 6.2. Samples were amplified under the following temperature 
profile: Initial denaturation for 1 min at 95°C, 45 cycles of 10 sec at 95°C and 30 sec in 60°C. Data 
are collected at the end of melt curve. Relative transcript levels were calculated using relative 
standard curve method [215,216].  
6.2.2.4 Hemolytic Activity Test 
To evaluate in vivo toxicity of the NP-BSA complexes, 0.4 ml of three THP dosages (5, 10, 20 
mg/kg) was injected into 12-weeks-old male C57BL/6 mice (30-32 g) via intraperitoneal injection 
(i.p.). Subjects were monitored for their acute responses; 1 hr after injection, their blood, urine, and 
four tissue samples (heart, spleen, liver, and kidney) were collected for testing potential hemolysis 
and off-target effects. Collected blood was processed for hemolysis activity and red blood cell 
aggregation tests. All animal studies followed the protocols approved by the University of Waterloo 
Office of Research Ethics and the Animal Care Committee.  
In addition to in vivo hemolysis testing, the hemolytic activity of the EAR8-II-THP complexes in 
the presence and absence of BSA was studied ex vivo using fresh blood from 2 year-old rabbits 
(White New Zealand female rabbit- 4.5 kg). In order to separate red-blood cells (RBCs), blood was 
washed 3 times with 3 ml PBS and centrifuged at 1500 rpm for 15 min followed by collecting the 
RBC and diluting in PBS at 5% (volume). The test samples were diluted in PBS and added to RBC 
with final RBC concentration of 1%. For each sample 5 different dilutions were tested in triplicate 
and each dilution was triplicated. Pure water and PBS were used as positive and negative controls, 
respectively. The mixtures were incubated at 37°C for two hours, then centrifuged at 1500 rpm for 5 
minutes; the supernatant was transferred to 96-well plate for absorbance (Abs) reading at 570 nm. 
The sample absorbance was compared with positive control (PC) and negative control (NC) samples 
and hemolysis percentage was calculated using the following formula:  
  
  103 
  
The hemolysis activity of the blood samples collected from mice was also analyzed using the above 
method. At the same time, 2 µl of RBCs isolated after centrifugation was transferred to a glass slide 
monitoring possible RBC aggregation.  
Three groups of samples were evaluated for hemolysis activity. The original complex was made at 
[THP] = 0.5 mg/ml or 0.8 mM, and [EAR8-II] = 2.5 mg/ml or 2.73 mM. Since in hemolytic activity 
test samples were diluted 5-fold in PBS, samples were made at concentrations 5 times higher than our 
working concentrations to keep the sample conditions consistent through out the current study. The 
first group contained serially diluted EAR8-II-THP complexes in water, with a final THP 
concentration range of 10 –160 µM. In the second group, EAR8-II-THP complexes were diluted in 
BSA (320 µM). The third group included samples with fixed complex concentration ([THP] = 80 µM) 
with varying BSA concentration (64 –512 µM). In addition, solutions containing only BSA at 
different concentrations were also tested as controls for hemolytic activity.   
6.2.2.5 In vitro Complement Activation Test (C5b-9) 
An enzyme-linked immunosorbent assay (ELISA) was used to quantify NP-induced formation of a 
complement cascade endpoint, the C5b-9 complex, in human serum. C5b-9 formation in the presence 
of NPs was measured using the Human C5b-9 ELISA Set (BD Biosciences, Mississauga, ON, 
Canada). 96-well micro-plates were prepared overnight with capture antibody, washed, and blocked 
using assay diluent, as provided in the kit. 
NP treatments were prepared with the same conditions as for the hemolysis assay and added (60 
µL) to a separate 96-well micro-plate, followed by the addition of 40 µL of freshly thawed pooled 
human serum (Innovative Research, Novi, MI, USA). NP-serum samples were then incubated at 37 
°C for 60 minutes with periodic mixing. Following incubation, all sample wells were diluted 2500x in 
assay diluent, and 100 uL of each well was transferred to the washed ELISA plate for a 120 minute 
incubation at room temperature. 
Separate washing and incubation steps followed for the working detector mixture (detection 
antibody and enzyme; 60 minutes) and substrate (3,3’,5,5’-Tetramethylbenzidine, TMB; 30 minutes 
in dark environment). After adding the stop solution, absorbance values were measured using a 
BioTek Epoch spectrophotometer at 450 (signal) and 570 (background) nm. 
Hemolysis%= Abs(samples)− Abs(NC)Abs(PC)− Abs(NC) ×100%
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% C5b-9 formation was calculated relative to a 100% baseline, containing only serum and buffer, 
and a positive control, containing serum and Zymosan microparticles (utilized for well-known 
complement activating properties). Estimated C5b-9 concentrations were established using log-log 
regression of the standard curve also obtained during the experiment and accounting for the large 
dilution factor. 
  
6.3   Results and Discussion 
Previously, EAR8-II was introduced as a potential nanocarrier for the hydrophobic anticancer drug 
Pirarubicin (THP). The EAR8-II-THP complex demonstrated efficient anticancer activity at different 
peptide-to-drug ratios. However, macrophages were able to rapidly recognize and capture the free and 
unbound complexes [186]. As macrophage uptake remains a key disadvantage of such drug delivery 
systems [217], designs or strategies to evade this uptake are necessary for advancement in this field. 
Polyethylene glycol modification of nanoparticles is an established strategy whereby stealth 
nanocarriers avoid phagocytosis [31]. In this present study, a protein-binding strategy is introduced to 
further mitigate macrophage uptake and cellular responses. Thus far, EAR8-II-THP complexes have 
illustrated exclusive binding to serum albumin proteins (spontaneous and exothermic interaction). It 
has been reported that in the presence of serum, the size and charge of nanocarriers play important 
roles in opsonin adsorption and subsequent phagocytosis [218]. We hypothesize that protein binding 
can decrease interactions with macrophages and other immune components. Here, the effect of 
protein binding to peptide-drug complexes on cellular responses is presented through macrophage 
cytotoxicity, uptake, cytokine expression level, hemolysis, and complement activation. 
6.3.1 Macrophage Cellular Toxicity and Uptake 
Phagocytosis by mononuclear phagocytes and macrophages is the first interaction of particles in the 
bloodstream with the immune system [219].  Macrophages are among the main cells involved in both 
innate and adaptive immune systems, and are used in this study to evaluate immune recognition of 
our peptide-based drug delivery system. Mouse macrophages, RAW 264.7 cells, were treated with 
different concentrations of EAR8-II-THP (NP) complexes in the presence and the absence of serum 
proteins, including BSA and IgG, for various incubation times.  
The viability of the cells treated with NPs in the presence and the absence of proteins at 2 and 4 hr 
incubation times did not differ significantly, where only about 20% of the cells died when IgG was 
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present. However, cell viability dropped considerably after a 6 hr incubation period as the effect of 
protein binding became more noticeable. Among the various treatments, the cytotoxicity of NPs in 
the presence of IgG was the lowest, due to the opsonization effect of IgG. However, when both IgG 
and BSA were present in a culture environment, strong BSA binding to the NPs compensated for the 
opsonized particles and led to a higher viability of cells treated with NP and IgG. The highest cell 
viability was observed among cells treated with NPs and only BSA, indicating protection of NPs from 
macrophages while bound to BSA (Figure 6.1A). In addition, as is expected, increasing concentration 
of THP reduced the cell viability with all four treatments. Corresponding IC50 values for the 
treatments at a 6 hr incubation time in the presence of proteins, were in increasing order: NP -+ 
(NP+IgG) < NP -- (NP only) < NP ++ (NP+ BSA and IgG) < NP +- (NP+ BSA) (Table 6.1). Note 
that IC50 values were calculated through interpolation and extrapolation of data from cell toxicity 
values (100 – % cell viability) for evaluating the concentration of a drug required for 50% 
cytotoxicity in vitro. Similar trends were observed for cellular uptake observed by fluorescence 
microscopy. NPs in the presence of IgG showed the highest uptake, followed by unprotected NPs, 
NPs with BSA and IgG, and NPs with only BSA (Figure 6.1B).  
Figure 6.1. (A) Cellular viability of RAW 264.7 cells treated with EAR8-II-THP (NP), in the 
presence of BSA and IgG at 6 hr treatment time. (B) Cellular uptake of EAR8-II-THP by 
macrophages (a-d) fluorescence microscopy images. NP -- : EAR8-II-THP complex (no protein), NP 
+-: complex with BSA, NP - +: complex with IgG, NP ++ : complex with BSA and IgG. 
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A study was also conducted using different concentrations of the complex, in the presence and in 
the absence of BSA, to verify the above results. Macrophages treated with multiple combinations of 
NPs and proteins were lysed after a 2 hr incubation time. The lysed cells were collected for 
fluorescence studies, utilizing the intrinsic fluorescence properties of THP. Cellular uptake of THP by 
macrophages was measured using excitation and emission wavelengths of 480 nm and 590 nm, 
respectively [220]. Higher intensities of emitted light corresponded to higher cellular uptake of THP. 
Figure 6.1D displays the normalized fluorescence intensity of emitted light at 590 nm with respect to 
light fluctuation, representing the THP content of cells after a 6hr incubation period [221]. By 
increasing the complex concentration, the emission fluorescence intensity of THP was increased for 
NPs alone, more than for the NPs in the presence of BSA. As shown in Figure 6.2C, the slope of 
fluorescence intensity against THP concentration was more than double that measured with NPs and 
BSA, indicating protection of NPs by BSA and subsequent reduction of cellular uptake. Localization 
of red fluorescence represented THP uptake, yielding higher intensities when NPs were delivered in 
the absence of serum albumin (Figure 6.2A-B).    
 
 
Figure 6.2. Cellular uptake of EAR8-II-THP (A) 5:1 ratio complex without BSA, (B) with BSA, (C) 
normalized emission fluorescence intensity of THP at different complex concentration monitored by 
fluorescence spectroscopy (Excitation: 480 nm, emission 590 nm)- 2 hr incubation time. 
 
One of the main explanations of macrophage uptake and toxicity is particle size-dependent 
phagocytosis. Larger sizes and surface areas of particles increase in the attachment of opsonin 
  
  107 
proteins, leading to higher macrophage uptake and elimination from the circulatory system [222]. 
Uptake results presented here follow the trend of particle sizes observed from NPs in their specified 
combinations with IgG and BSA proteins (Table 6.1). NPs with IgG and unprotected NPs showed 
distinctly larger particle sizes and thus appeared to be more visible to macrophages. However, when 
NPs were bound to BSA, particle sizes decreased significantly and the chance of macrophage uptake 
reduced by 50%. When both proteins were in the culture environment, BSA binding was a dominant 
force and particle size distribution was mainly in a small range of ~10 nm; as a result, cellular uptake 
behavior was similar between NPs with BSA and NPs with both proteins. We postulate that BSA can 
act as a carrier for the NP by reorganizing the NP structure within BSA molecules, thus helping the 
NPs to evade macrophage recognition.  
Another key factor in uptake is particle surface charge-dependent phagocytosis. It has been 
previously reported that mammalian macrophages have negatively charged plasma membranes, based 
on electrophoresis and cell membrane staining (TEM) results in which cationic markers attached to 
cell membranes strongly in comparison to neutral and anionic markers [223,224]. As such, measuring 
the surface charge of NPs aids in a more thorough understanding of uptake behavior. The zeta 
potential of the complex in different protein environments was measured and presented in Table 6.1. 
Unprotected NPs exhibit positive surface charge due to protonated THP in the EAR8-II solution. 
When combined with BSA, the zeta potential dropped significantly, to negative values, while with 
IgG, zeta potential values decreased but still remained positive. Strong ionic attraction between 
positively charged particles and cell membranes resulted in high measured values of cellular uptake. 
However, for negatively charged particles stabilized with BSA, repulsion forces between particles 
and cell membranes resulted in significant reductions of cellular uptake and toxicity.  
Table 6.1. Zeta potential, average diameter, and macrophages IC50 of the EAR8-II-THP complexes 
(NP) in the presence of BSA or IgG. NP - -: NP only, NP+ -: NP with BSA (64µM), NP -+: NP with 
IgG (0.66 µM), NP++: NP with BSA and IgG 
 Zeta Potential (mV) Size (d.nm) PdI IC50  
THP(µM) 
NP - - 11.205 ± 0.28 566.55 ± 44.15 0.44 ~ 0.3 
NP + - -11.33 ± 0.57 15.07 ± 0.82 0.48 6.5 
NP - + 1.71 ± 0.12 244.03 ± 66.19 0.47 << 0.3 
NP + + -11.51 ± 0.89 19.46 ± 3.79 0.48 1.25 
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6.3.2 Macrophages Cytokine Expression  
The innate immune response is one of the primary defense mechanisms against microbial infection 
and cellular damage. Macrophages are crucial components of the innate immune system that produce 
cytokines to mediate inflammatory responses. Foreign particles that cannot be destroyed by 
macrophages after producing some therapeutic effect in the body can cause prolonged chronic 
inflammatory responses initiated by macrophage activity [225,226]. The aim of the current study was 
to establish a model system to examine the effect of our peptide-drug complex (NP) and its 
combination with IgG and BSA proteins on cytokine expression in mouse macrophage cells. 
Expressions of different cytokine mRNA levels were examined here, including inducible nitric oxide 
synthase (iNOS), cyclooxygenase-II (COX-2), tumor necrosis factor (TNF-α), interleukin-1 Beta (IL-
1β), interleukin-2 (IL-2), and interleukin-6 (IL-6). These pro-inflammatory cytokines are important 
regulators of both innate and adaptive immunity. When a stimulator such as LPS activates 
macrophages, a large amount of nitric oxide (NO) is produced by iNOS through the conversion of L-
arginine to L-citrulline, which results in inflammatory disorders [225,226]. Production of iNOS 
provides macrophages with cytotoxic efficacy against viruses, bacteria, fungi, and tumor cells 
[166,227]. COX-2, an inducible enzyme with functional significance in many organs and diseases, is 
responsible for catalyzing the rate-limiting step in prostaglandin (PG) and leukotriene synthesis 
[228,229]. COX-2 is expressed by growth factors and pro-inflammatory stimuli, including LPS and 
activated oncogene in macrophages [230]. Induction of tumor necrosis factor- α (TNF-α) by 
macrophages leads to the development of chronic inflammatory diseases such as rheumatoid arthritis; 
therefore, down-regulating this gene is an established medical method to prevent and treat the disease 
[231]. LPS-stimulated macrophages also tend to overexpress interleukins, such as IL-1β, IL-2, and 
IL-6, that can promote differentiation of T and B cells [232].  
The immune response of macrophages towards our peptide-based drug delivery system was studied 
at the mRNA level through quantitative RT-PCR. The expression levels of cytokines, including 
iNOS, COX-2, IL-1β, TNF-α, and IL-2, were measured for the cells treated with NP only and NP 
with BSA and IgG. The quality of the RT-PCR results, reflected in the % efficiency values and the R2 
value of standard curves, is presented in Table 6.2. Similar to cytotoxicity and uptake results, 
cytokine expression levels were significantly higher for cells treated with unprotected NPs than for 
cells in the presence of NPs with BSA and IgG (Figure 6.3). Cytokine expression levels of all the 
treatments, including unprotected NPs, were still considerably lower than those treated with LPS (100 
ng/ml) as a positive control for macrophage activation, indicating the relative non-immunogenicity of 
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our peptide-drug complex, especially in the presence of serum proteins. The cytokine expression 
values of LPS-treated cells are reported in Table 6.2. An exception in cytokine expression was 
observed in COX-2, where the expression level was higher for cells treated with NP than those treated 
with LPS. Likewise, TNF-α expression in macrophages appeared to be down-regulated by our NP 
treatment. According to recent advances in anti-inflammatory treatment, secretion of TNF-α by 
macrophages plays a predominant role in reducing both local and systemic inflammation [231]. Since 
the peptide-based drug delivery system showed secretion of this gene in macrophages, it presents an 
opportunity for further investigating and developing similar systems for synergetic anticancer and 
anti-inflammatory effects. 
 
Table 6.2. List of murine primers for Quantitative Real-time RT-PCR, and Standard curve 
parameters. * Relative Normalized quantities for cells treated with LPS (100 ng/ml) 
Cytokines Primers 
qRT-PCR values 
LPS*  Reference 
R2 % Efficiency 
Β-Actin F: AGAGGGAAATCGTGCGTGAC 0.999 97.8 180.03± 32.15 [233] R: CAATAGTGATGACCTGGCCGT 
iNOS F: CAGCTGGGCTGTACAAACCTT 0.949 85.1 114.72± 21.65 [233] R: CATTGGAAGTGAAGCGTTTCG 
COX-2 F: AGAAGGAAATGGCTGCAGAA 0.542 258 25.57± 4.96 [234] R: CTCAATACTGGAAGCCGAGC 
IL-1β F: CCCAAGCAATACCCAAAGAA 0.993 98.2 7271± 1821 [235] R: GCTTGTGCTCTGCTTGTGAG 
TNF-α F:AGACCCTCACACTCAGATCATCTTC 0.997 97 43.76± 10.04 [236] R: TTGCTACGACGTGGGCTACA 
IL-2 F: CCTGAGCAGGATGGAGAATTACA 0.965 76.1 1937± 414 [233] R: TCCAGAACATGCCGCAGAG 
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(C) (D) 
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Figure 6.3. Relative normalized cytokine expression at the mRNA level of RAW 264.7 macrophage 
cells treated by EAR8-II-THP (NP) only, NP with BSA (NP + -), NP with IgG (NP - +), and NP with 
BSA and IgG (NP + +). (A) Inducible nitric oxide synthase (iNOS), (B) Cyclooxygenase-II (COX-2), 
(C) Interleukin-1Beta (IL-1β), (D) Tumor necrosis factor (TNF-α), (E) Interleukin-2 (IL-2) 
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6.3.3 Hemolytic Activity 
Hemolytic activity is one of the most important criteria in the development of therapeutic agents 
destined for circulation in the bloodstream. The hemolysis assay evaluates the compatibility of 
nanomaterials with red blood cells, providing a measure of the acute response to foreign materials 
[154,237]. This phenomenon is quantified by reading and comparing the absorbance at 570 nm with 
negative and positive controls. In more severe cases, hemolytic activity can be visually assessed in 
whole blood after centrifugation, since the supernatant color tends to become red if RBCs are lysed 
and hemoglobin is released. Here, EAR8-II-THP complexes were tested in a hemolysis assay and 
found to be more compatible with red blood cells when pre-incubated with BSA. Fresh rabbit blood 
cells were treated with serially diluted EAR8-II-THP at a final THP concentration range from 10 – 
160 µM, either in water or BSA. Table 6.3 summarizes the hemolysis results for different treatments. 
Note that materials inducing hemolysis values below 5% are generally considered safe and blood 
compatible [238].  
EAR8-II-THP complexes at the highest THP concentration were highly hemolytic; however, when 
these complexes were serially diluted, hemolytic activity reduced significantly. This reduction was 
more noticeable when the complex was pre-incubated in BSA, indicating the positive effect of BSA 
binding on blood compatibility of the peptide-based anticancer drug delivery system. As shown in 
Figure 6.4, plasma collected from samples treated with only NPs is redder than plasma from samples 
treated with NPs pre-incubated with BSA (at the same THP concentrations). Also, decreasing THP 
concentrations corresponded to lower hemolysis values. These results were confirmed with 
absorbance readings (Figure 6.4D), verifying that at each concentration of NP, pre-incubated with 
BSA, resulted in hemolysis reductions of 37-56%. Moreover, results showed that the hemolytic 
activity of NP-BSA complexes at a fixed NP concentration and varied BSA concentrations is 
independent of BSA concentration. Increasing BSA concentration did not affect the hemolysis 
significantly, suggesting that BSA binding to NPs is effective even at low BSA concentrations. 
To move forward with hemolytic activity, three selected dosages of THP pre-incubated with BSA 
were tested in vivo. Mice were injected with EAR8-II-THP complexes containing 4% BSA at 5, 10, 
and 20 mg/kg and monitored for one hour; selected mice were treated with saline as a control. Blood 
was then collected and tested for hemolytic activity. While a high dosage of THP (20 mg/kg) in the 
presence of EAR8-II and BSA was shown to be slightly hemolytic, with a hemolytic activity of 7.16 
± 2.22 % (Figure 6.5), lower dosages of THP (10 mg/kg and 5 mg/kg) caused lower hemolysis (< 
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5%), showing their blood compatibility. Red blood cells after centrifugation were observed by 
microscope to rule out aggregation. 
 
 
Figure 6.4. Images from plasma collected from the blood samples treated with EAR8-II-THP 
complexes; (A) Complexes without BSA (-), (B) complexes with BSA (+), (C) direct comparison 
between with and without BSA complexes at 80 µM of THP. NC: negative control (normal saline), 
PC: positive control (pure water) (D) Hemolytic activity of EAR8-II-THP complexes (NP). NP--: NP 
diluted in water, NP +-: NP diluted in BSA. Error bars represents standard error of the means for 95% 
confidence interval. 
 
 
Figure 6.5. in vivo hemolytic activity of EAR8-II-THP and 4% BSA. 
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6.3.4 In vitro Complement Activation 
We evaluated complement activation in human serum containing peptide-drug complexes in the 
presence and absence of BSA, by using ELISA to measure the generation of C5b-9 complexes, as a 
final product of the complement cascade. All EAR8-II-THP complexes with or without BSA induced 
the formation of C5b-9 to some extent in pooled human serum. The results suggested that the 
presence of BSA in the complex solution did not have a direct effect on C5b-9 formation. Most of the 
complexes are considered to cause complement activation that is likely inconsequential in a biological 
context, since the C5b-9 concentrations were only 10-60% higher than control serum samples (as a 
baseline) without NP incubation [239]. It is worth noting that the serum samples treated with 
Zymosan (i.e., positive control) showed more than 1000% increase in C5b-9 concentrations which is 
substantially higher than in any of the NP treated trials. However, samples with very high 
concentrations of THP (160 µM) and lower concentrations (10-20 µM) showed statistically 
significant difference from the baseline (p < 0.05). One reason may be differences in the size and 
nanostructures with diluted NPs. Even though particle size distribution results did not show a clear 
difference between various concentrations of the NPs, the nanostructure of the particles may undergo 
changes upon dilution.  
In addition, similar to hemolysis results, it was observed that C5b-9 formation is independent of NP 
pre-incubation with BSA. The relative change in C5b-9 concentration to the baseline is about 30-
60%, which is biologically insignificant. Table 6.3, presents the concentrations (µg/ml) of C5b-9 
formed by serum due to NPs incubation, and Figure 6.6 illustrates the relative percentage of C5b-9 
formation in respect to untreated serum control. These observations suggested that THP concentration 
in the complex played an important role in complement activation, as moderate THP concentration in 
NPs, either with or without BSA showed the least-significant activation of the complement. 
Consequently, we can claim that BSA existence in NP formation does not trigger immune response in 
the form of C5b-9 complement formation.   
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Figure 6.6. Effect of BSA binding on complement activation. Final BSA concentration was 64µM in 
serum, and results are expressed as percentage of respective control baseline. * = Significant rise of 
C5b-9 formation compared to the untreated serum control (p < 0.05). Zymosan (10 mg/ml) was used 
as positive control, and the relative percentage of C5b-9 formation by Zymosan was observed as 
1230% (not shown).  
 
6.4 Conclusions 
The effect of protein binding was shown to be significant in the biological and immunological 
interactions of peptide-drug complexes, including macrophage toxicity and uptake as well as cytokine 
expression at the mRNA level, hemolysis, and complement activation. Strong protein binding 
between our unique amphiphilic peptide-drug (NP) complex is hypothesized to be through 
hydrophobic interactions between tryptophan residues in BSA and hydrophobic THP molecules, and 
EAR8-II. Macrophages are more sensitive to larger sizes and cationic particles due to their negatively 
charged plasma membrane. When the peptide-drug complexes were bound to serum albumin, their 
particle sizes decreased considerably, thus circumventing possible aggregation and avoiding 
macrophage uptake. In addition, the negative surface charge of the particles in the presence of 
albumin provided repulsion between the particles and macrophages to further decrease uptake. 
However, unprotected NPs and NPs combined with IgG had significantly larger particle sizes and 
positively charged surfaces, facilitating their uptake by macrophages. Cytokine expression results also 
suggested a considerably lower induction of cytokines by the cells treated with protected NPs 
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compared to those treated with peptide-drug complexes alone. Further biocompatibility studies 
revealed the positive effect of BSA binding to the complex in reducing hemolytic activities and 
producing insignificant amounts of complement complex C5b-9. All these results verified the 
significant effect of albumin binding on reducing the side effects of the peptide-based drug delivery 
system, especially towards macrophages and red blood cells, without causing other incompatibilities. 
The albumin binding strategy shows promising potential as a basis for peptide-based drug delivery 
formulations with clinical application in cancer therapy.   
 
Table 6.3. Effect of BSA in haemolytic activity of the EAR8-II-THP complex 
Samples (uM) Hemolysis % C5b-9 (µg/ml) 
THP BSA Mean± 
Margin Error+ 
Evaluation
<15% 
%Hemolysis 
Reduction++ 
Mean± 
Margin Error+ 
160 0 38.46 ± 0.42 Fail - 7.12 ± 0.05* 
0 64 2.08 ± 0.75 Pass - 6.13 ± 0.70* 
80 0 8.19 ± 0.46 Fail - 5.51 ± 0.43 
40 0 6.40 ± 0.34 Fail - 5.18 ± 0.49 
20 0 4.74 ± 0.17 Pass - 7.31 ± 0.92* 
10 0 3.88 ± 0.08 Pass - 6.48 ± 0.11* 
80 64 5.16 ± 0.33 Fail 37.08 5.39 ± 0.42 
40 64 2.86 ± 0.16 Pass 55.25 5.38 ± 0.78 
20 64 2.44 ± 0.09 Pass 48.55 6.22 ± 0.79* 
10 64 1.70 ± 0.13 Pass 56.09 6.24 ± 1.21 
80 12.8 3.55 ± 1.05 Pass 56.63 7.16 ± 0.51* 
80 25.6 3.25 ± 0.99 Pass 60.29 6.50 ± 0.64* 
80 51.2 4.82 ± 0.40 Pass 41.12 6.21 ± 0.64* 
80 102.4 4.39 ± 0.19 Pass 46.29 6.24 ± 0.60* 
Zymosan - - - - 56.28 ± 2.30* 
+Margin error was calculated with critical value for 95% confidence interval.  
++Hemolysis reduction percentage was calculated relative to the corresponding THP concentration treatment in 
the absence of BSA. 
*Baseline C5b-9 level (Control) was 4.57±0.79 µg/ml. Significant differences with respect to the baseline: *p < 
0.05 
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Chapter 7 
Albumin-Bound Peptide-based Drug Delivery System Promotes 
Target-ability through SPARC Inhibition 
7.1 Introduction 
One of the most important functionalities of albumin is the transcytosis of bound ligands such as 
hormones, peptides, and fatty acids through receptor-mediated processes. Transcytosis is the process 
of delivering molecules across the vascular endothelial cells for nutritional purposes [240]. Schnitzer 
et al., demonstrated specific binding between albumin and 60-kDa microvascular endothelial 
glycoprotein (gp60) and secreted protein, acidic and rich in cysteine (SPARC), that initiates the 
endothelial transcytosis [241,242]. SPARC is an extracellular matrix glycoprotein that has been 
shown to bind albumin with high affinity. SPARC is overexpressed in a number of tumors, including 
breast, lung, melanoma, prostate, and plays a key role in tumor metastasis through de-adhesion, 
migration and angiogenesis [15]. SPARC expression is suggested to facilitate drug distribution in 
tumors and enhance clinical effectiveness of albumin-associated nanoparticles because of SPARC-
albumin binding affinity [243]. To exploit albumin transcytosis’ properties and its high affinity to 
SPARC receptors, many albumin-based drug delivery systems (e.g., nab technology) have been 
developed and have shown greater drug accumulation in tumor cells than in normal tissues [16].  
Previously, I focused on the effect of albumin in delivering peptide-drug complexes with low 
immunogenicity and increased biocompatibility. The results suggested that albumin has a key role in 
safe delivery of the peptide-based hydrophobic anticancer drug delivery system in vitro because of 
the following properties: the high affinity of albumin to the hydrophobic drug pirarubicin through 
hydrophobic interactions and shielding of the peptide-drug complex against macrophages and red 
blood cells leading to lower phagocytosis, cytokine expression, and hemolytic activities. The third 
feature of albumin, which is tumor accumulation through SPARC binding affinity, is explored in the 
current study.  
EAR8-II, a model amino acid pairing ionic-complementary peptide, has so far shown great promise 
for encapsulating the hydrophobic drug Pirarubicin (THP) and inducing excellent anticancer activities 
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against various cancer cells in vitro [186]. In addition, binding affinity with serum albumin utilized 
the drug delivery system with the properties that induce less inflammatory responses. Since albumin 
binding has shown positive effects on enhancing the biocompatibility of the complex, this study 
focuses on the anticancer activity of the albumin-bound peptide-drug complexes. A549, is a type of 
human non-small cell lung carcinoma (NSCLC), is used here to evaluate the anticancer activity of the 
complex. Cell viability, uptake tests have been conducted to evaluate the therapeutic activity of the 
THP at the cellular level. qRT-PCR technique is employed to determine SPARC expression level at 
the mRNA level. A549 cells have shown overexpression of SPARC protein, which is responsible for 
tumor metastasis. Therefore, developing a delivery system with capability to inhibit the SPARC 
expression in lung cancer cells is an ultimate goal of the current research.  
 
7.2 Experimental 
7.2.1 Materials 
The peptide EAR8-II, Pirarubicin (THP), and bovine serum albumin (BSA) are the main components 
used here and the sources are similar to those reported in previous chapters. qRT-PCR reagents are 
also the same materials presented in Chapter 6 (6.2.2.3).  
7.2.2 Methods 
7.2.2.1 Cellular-based Methods 
A549 cells were cultured in 96-well plates with 104 cells/well for cytotoxicity and cellular uptake 
experiments, in 24-well plates with 4.5 104 cells/well for RNA extraction, and in 6-well plates with 
2.4 105 cells/well for protein extraction. Cells were incubated in F-12 medium containing 10% FBS, 
overnight at 37°C, until the cell confluence reached ~ 60%. 24 hr later, the medium was replaced with 
serum-free F-12 containing peptide-drug complexes at various concentrations (final [THP]: 0.3-38 
µM). The first group of sample treatments was the complex without pre-incubation with BSA, and the 
second group of treatments was the same complexes pre-incubated with BSA at a 64 uM final 
concentration. The third group was considered for fixed THP concentration in the complex, and BSA 
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concentration was varied from 0-64 uM in solution. Cells were incubated with the treatments for 6 
and 24 hours to be further tested for cellular uptake and cytotoxicity. Also, a 6 hours treatment was 
considered for RNA extraction experiment. The cell-counting kit (CCK-8) was used for cell toxicity 
assay using a micro-plate reader (absorbance 450 nm). THP cellular uptake tests were conducted on 
treated cells by complete cell lysis with 1% SDS in Tris-EDTA and pipetting up-and-down. BioTeK 
Monochromator-based Multi-mode Microplate reader measured the emission fluorescence intensity 
of the cells. The amount of THP uptake is directly proportional to the emission intensity at 590 nm. 
Normalized fluorescence intensities were obtained by subtracting the values from the intensities of 
untreated cells.  
7.2.2.2 SPARC Inhibition Analysis by Quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR) 
The total RNA was extracted from A549 cell samples with Trizol reagent (Sigma-Aldrich, Canada), 
and the single stranded complementary DNA was synthesized from 500 ng of total RNA using 
qScript SuperMix from Quanta Biosciences (Gaithersburg, MD, USA). The cDNA for human β-actin 
as a housekeeping gene and human SPARC were amplified by PCR using Agilent Technologies 
(Paq5000). Briefly, 2 µl of each cDNA sample after 10-times dilution was amplified in a 20 µl PCR 
reaction containing 10 µl of PerfeCta SYBER Green Fast Mix, Low ROX from Quanta Biosciences 
and 0.75 µl of 10 µM primers (reverse and forward). The primers were synthesized by Sigma-Aldrich 
(Oakville, ON, Canada). The forward and reverse primers for human β-actin are: 5' 
GGCGACGAGGCCCAGA 3', and 5' CGATTTCCCGCTCGGC 3' [244], and for human SPARC 
primers are 5′ AAGATCCATGAGAATGAGAAG 3' and 5′ AAAAGCGGGTGGTGCAATG 3' 
[243], respectively. Samples were amplified under the following temperature profile: initial 
denaturation 1 min at 95°C, 45 cycles of 10 sec at 95°C and 30 sec in 60°C. Data are collected at the 
end of melt curve. Relative transcript levels were calculated using relative standard curve method 
[215,216].  
7.3 Results and Discussion 
In this study the effect of albumin binding on anticancer activity of the peptide-drug complex (EAR8-
II-THP) was assessed.  
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7.3.1 Cellular Toxicity and Uptake 
EAR8-II-THP complexes have shown a significant anticancer activity against the A549 cell line. 
A549 cells after 24 hr incubation with the 5-to-1 mass ratio peptide-drug complexes at various 
concentrations of THP (0.3 -37 µM) was tested for cellular toxicity assay (CCK8). The results 
revealed high cellular toxicity particularly at higher THP concentration in the absence of serum. The 
IC50 was calculated at ~ 3.6 µM of THP, which is significantly lower than the previous results in 
chapter 4, where the complexes were applied to the A549 cells in the F-12 medium containing 10% 
FBS having IC50 of ~ 19.3 µM [186]. Already this result indicates the presence of serum proteins 
affecting the toxicity of the complex. Here, complexes were pre-incubated with only serum albumin 
before being introduced to the A549 cells in order to isolate the effect of BSA. The IC50 for albumin-
bound complexes was calculated at [THP]~ 5 µM, which is slightly higher that the one calculated for 
unbound complexes. This effect can be explained by delaying the THP release in the presence of BSA 
and cause cell death at higher THP concentrations showing stealth property of BSA for NPs (Figure 
7.1A). 
(A) (B) 
 
 
Figure 7.1. Percentage viability of the A549 cells when treated with (A) the EAR8-II-THP complexes 
at various THP concentrations with and without BSA (64µM) pre-incubation. Incubation duration 
was 24 hr, (B) the fixed complex concentration and varied BSA concentration for 6hr and 24 hr 
incubation time.  
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In order to find the influence of BSA concentration in A549 cellular toxicity, a fixed complex 
concentration at [THP] of 19.38 µM was incubated with varied BSA concentrations (0-64 µM). As 
shown in Figure 7.1B, the percentage of cell toxicity is independent of BSA concentration, indicating 
the passive property of BSA in the complex’s cytotoxicity effect on A549 cells.   
In addition to cytotoxicity testing, uptake of THP by A549 cells was evaluated by exploiting the 
intrinsic fluorescence property of THP through a microplate reader. When the THP concentration in 
the complex was increased, the emission intensity observed in lysed cells increased proportionally. 
Longer incubation times also led to higher THP uptake, illustrating the higher efficiency of the 
complex over time (Figure 7.2A).  
 
Figure 7.2. Normalized fluorescence emission intensity of THP uptake by the A549 cells treated by 
the various concentration of EA8-II-THP complexes  
 
7.3.2 Inhibition of Endogenous SPARC Expression at the mRNA Level 
First, the endogenous expression of SPARC in non-small cell lung carcinoma (A549 cell line) was 
evaluated by qRT-PCR method showing prevalent SPARC expression at mRNA and protein level 
normalized by β-actin as a housekeeping gene. To study the respond of A549 cells toward albumin-
bound complexes, the SPARC expression level was evaluated for cells treated with the EAR8-II-THP 
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treatments for 6 hr. This step was done because the cell viability results showed relative high cell 
viability in a 6 hr incubation time. However, if the cells were tested for 24 hr, the cell viability would 
be too low to be able to extract enough RNA for qRT-PCR experiments.  
A literature review suggested that if the SPARC expression in a specimen is 75% or more relative 
to the expression of the housekeeping gene (i.e., β-actin), the specimen should be considered SPARC 
positive. Specimens are considered SPARC negative when SPARC expression is less than 25% to the 
expression of β-actin. A level between 25-75% is considered a moderate SPARC level [243]. In the 
current study, SPARC expression levels reduced significantly when the cells were treated with the 
complex, and this drop was more significant when the complex was bound with albumin. The 
normalized SPARC level in respect to β-actin expression levels for untreated cells and cells treated 
solely with the peptide-drug complex were more than 100%, indicating the SPARC positive cells, in 
which the expression of SPARC is even higher than of the housekeeping gene. However, specimens 
treated with albumin-bound complexes showed a significantly lower SPARC level of 52-65%, which 
is considered SPARC intermediate. In addition, normalized SPARC expression levels were also 
present relative to the expression level from untreated cells, revealing that increasing the 
concentration of BSA led to SPARC expression levels from up 65% (Figure 7.3). The pair t-test 
results between each treatment and untreated specimen represented a statistically significant reduction 
of SPARC expression for BSA-containing complex treatments (p < 0.05). SPARC proteins facilitate 
the uptake of albumin-bound molecules to the tumor cells. In the current study, endogenous SPARC 
expression was inhibited at the mRNA level by albumin-bound peptide-drug complex that can be 
further considered as one of the action mechanism of this system against cancer cells.  
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Figure 7.3. Relative SPARC expression in A549 cell line treated with EAR8-II-THP complexes (at 
THP final concentration of 19.38 µM and EAR8-II at 68.4 µM) and BSA concentration varied from 
16 -512 µM. Error bars are relative standard deviations. * p < 0.05 compared with untreated cells.  
 
7.4 Conclusions 
The current study focused on albumin-bound peptide-drug complexes and their effect on non-small 
cell lung carcinoma (A549 cell line) through inhibition of SPARC expression at the mRNA level. It 
has been shown that SPARC expression facilitates the transport of albumin-bound delivery systems. 
The EAR8-II-THP complex was used as a drug delivery model for showing the binding affinity to 
albumin molecules. The effect of the presence of BSA in the complex solution on the cytotoxicity of 
the complex did not differ significantly to the absence of BSA. However, the target-ability of the 
complex increased considerably with SPARC inhibition through albumin’s binding affinity to 
SPARC specifically. SPARC suppression is suggested as one of the uptake mechanisms by the 
albumin-bound peptide-based delivery system that can be further explored for more comprehensive 
conclusion.   
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Chapter 8 
Conclusions and Recommendations 
8.1 Original Contribution to Research 
This thesis represents new findings in the inter-disciplinary fields of nanotechnology, biochemistry, 
thermodynamics, molecular biology, immunology, and chemical engineering. Amino acid pairing 
peptides present a great potential to encapsulate hydrophobic anticancer drugs and induce high in 
vitro anticancer activities. However, they have a tendency to aggregate in physiological 
environments, which limits their in vivo applications. Therefore, this research has mainly focused on 
overcoming the delivery limitations. Polymer conjugation and protein-binding strategies were 
originally investigated in this thesis to modify the self/co-assembling peptide-based drug delivery 
systems for longevity and target-ability applications. The major objectives and their respective 
outcomes of the research are summarized in the following section.  
8.2 Principle Objectives and their Respective Outcomes 
Characterize the physiochemical properties of amino acids pairing peptide (AAP8) 
functionalized with diethylene glycol (DEG) 
The first objective of this research was to avoid uncontrollable aggregation of amino acid pairing 
peptide (AAP8) by diethylene glycol conjugation in either one or both terminals. These modifications 
contributed to modulating the fiber self-assembly through creating more aligned and uniform 
nanostructures due to increasing solubility, stability, and β-sheet content in secondary structure in the 
peptide. In addition, the DEG-modification led to lower toxicity of the AAP8 towards macrophages, 
indicating shielding properties of diethylene glycol for the peptide. The DEG modification also had 
advantages in hydrophobic drug stabilization in aqueous solution, consequently inducing more 
cytotoxicity towards lung carcinoma cells over a relatively long time, compared to the non-
functionalized AAP8. As a conclusion, these DEG modifications can potentially be useful in the 
design and development of long circulating self-assembling peptide biomaterials for advanced drug 
delivery systems. 
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Evaluate self/co-assembly properties of an ionic-complementary peptide EAR8-II and its 
potential in in vitro delivery of the hydrophobic drug Pirarubicin (THP) 
The second goal of this research project was to present a model self/co-assembling peptide EAR8-II 
that inherits advantages over EAK16-II and AAP8 in hydrophobic anticancer drug delivery. EAR8-II 
showed lower aggregation properties than AAP8 due to the replacement of phenylalanine with 
alanine residues providing moderate hydrophobic interactions between peptide molecules. EAR8-II 
showed a great potential in encapsulating the hydrophobic drug Pirarubicin (THP) in a peptide-to-
drug ratio dependent manner. The complex at the peptide-to-drug mass ratio of 5:1 provided a stable 
solution, uniform nanostructure, and highly effective anticancer activity against various cancer cell 
lines. 
Explore the binding affinity between serum proteins (i.e., BSA and IgG) and the EAR8-II-THP 
complex 
Evaluating the binding affinity with serum proteins and the drug delivery system was the third 
objective of the current research. Results illustrate the high affinity with serum albumin, whereas the 
IgG showed relatively weak interaction with the EAR8-II-THP complex. EAR8-II-THP complexes 
form spherical and more uniform nanostructures (~ 20 nm) when bound with BSA and form larger 
aggregates when in contact with IgG, indicating more stability of the complex in an albumin solution. 
In addition, the binding affinity in the presence of salt showed no significant change compared to in a 
salt-free environment showing that ionic interaction is not the major driving force between serum 
albumin and the complex. Since the thermodynamic values showed spontaneous, exothermic, and 
enthalpy driven binding between BSA and the peptide-drug complex, it is determined that this 
binding is through hydrogen bonding and Van der Waals forces.  
Study the effect of serum albumin binding to the EAR8-II-THP complex on immune responses 
The main goal of the albumin binding strategy was making the peptide-based delivery system 
invisible to the immune system during long circulation. To show the positive effect of albumin 
binding on the delivery system, a series of immune response experiments were performed and 
resulted the significant reduction in immunogenicity of the complexes in the absence of serum 
albumin. The THP uptake rate and cytotoxicity of macrophages dropped considerably when the 
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complexes were pre-incubated with BSA. The cytokines responsible for inflammatory responses 
expressed relatively lower when the cells were treated with albumin-bound EAR8-II-THP complexes. 
Furthermore, the percentage of hemolytic activity also reduced more than half in the existence of 
serum albumin. All these findings indicate the shielding feature of serum albumin for the 
nanoparticles in physiological conditions.  
Determine target-ability of the albumin-bound peptide-based drug delivery system  
The last objective of the current research was exploring the target-ability of the albumin-bound 
peptide-based drug delivery system. Albumin has a high affinity to SPARC (secreted protein acidic 
and rich in cysteine), which is overexpressed in many cancer cells. When the peptide-based drug 
delivery system (EAR8-II-THP) was pre-incubated with serum albumin, the cellular toxicity and the 
uptake of THP showed no a significant difference to when the complex was applied to the cells 
without BSA pre-incubation. However, the SPARC expression level showed significantly lower 
values when the BSA concentration was increased.  
8.3 Recommendations 
Based on the outcomes of this thesis, the following recommendations are suggested: 
1. Confirm DEG-conjugation advantages in inflammatory responses by performing more 
detailed in vitro and in vivo studies; 
2. Find the optimize molecular weight of conjugated polymer in order to control the particle size 
of suitable for in vivo studies; 
3. Develop a robust method to evaluate the encapsulation efficiency and loading capacity of the 
peptide-based delivery systems; 
4. Replace the short sequence based peptides with longer sequences (e.g., 16-20 amino acids) to 
enhance encapsulation efficiency of the hydrophobic drug; 
5. Study the binding affinity with other key circulating proteins (transferrin, fibrinogen,...); 
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6. Combine the polymer-conjugation and albumin binding strategies in order to evaluate the 
synergetic effect of the modifications on therapeutic efficiency and reduced inflammatory 
responses; 
7. Establish the in vivo animal model, optimize the drug concentration (below maximum 
toxicity dose MTD), and perform systematic in vivo studies to evaluate immune responses, 
biodistribution, and tumor inhibition rates; 
8. Self/co-assembling peptides have potential to conjugate with targeting ligands (peptides, 
mAb...) for targeted therapy. 
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